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Duchenne muscular dystrophy (DMD) and the milder Becker muscular dystrophy 
(BMD) are both caused by mutations in the DMD gene, which encodes the protein 
dystrophin.  Its regulation is of therapeutic interest as even small changes in expression of 
functional dystrophin can significantly impact disease severity in humans.  While tissue 
specific distribution and transcriptional regulation of dystrophin has been characterized, 
the posttranscriptional regulation of dystrophin is not well understood.  3’ UTRs have 
been shown to regulate gene expression posttranscriptionally by altering mRNA stability, 
localizing mRNA, or directly affecting translation, and the DMD 3’ UTR is particularly 
interesting in that it contains very large, highly conserved regions that are more 
conserved than the coding region of the gene. 
In this dissertation, we take advantage of C2C12 mouse muscle cells and the 
pHRL Renilla reporter construct to dissect the regions of the DMD 3’ UTR responsible 
for regulating expression during myogenesis.  We identify highly conserved regions in 
the 3’ UTR that alter mRNA stability and translation of a reporter construct during 
differentiation.  We characterize the DMD 3’ UTR variants in a population of 1,222 
humans that include DMD and BMD patients.  We conclude that if disease causing 
mutations exist in the DMD 3’ UTR they are either extremely rare or cause a disease 
phenotype in nonmuscular tissues, but that variation in the 3’ UTR could alter disease 




treatments in human patients.   
Canine models of DMD are important tools for developing treatments for human 
DMD patients because they better recapitulate the disease phenotype and have an 
immune system more similar to humans’ than other model organisms.  In this 
dissertation, we characterize three canine models of DMD, each containing different 
classes of mutations that can be used to facilitate preclinical studies directed toward these 
specific mutation classes in developing therapeutic approaches. 
This dissertation adds to the understanding of how dystrophin is regulated, the 
role the DMD 3’ UTR has in dystrophin regulation and pathogenesis of disease, and 
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 Muscular dystrophies are a group of disorders characterized by progressive 
muscle degeneration.  The most common and most severe form is the X-linked, recessive 
Duchenne muscular dystrophy (DMD).  DMD was first described in 1851 by Edward 
Meryon and published the following year (Emery, 2002; Meryon, 1852), but became 
associated with the French neurologist Guillaume Duchenne who published the clinical 
and histological features of the disease several years later (Duchenne, 1867; Emery, 
2002).  Although patients afflicted with DMD are asymptomatic at birth, the effects of 
progressive muscle degeneration begin to manifest in early childhood.  Patients often 
show difficulty walking, running, and climbing stairs by five years of age (Blake et al., 
2002; Emery, 2002; Sussman, 2002).  Weakness of the pelvic girdle and lower limb 
muscles results in the Gower’s maneuver, where a child must climb up his thighs to stand 
up from a lying down position.  As the degenerative process continues, muscle tissue is 
replaced by a fibrous connective tissue and the muscles become enlarged, an observation 
often seen in patients at three to four years old that present with enlarged calf muscles.  
As the lower limb muscles continue to weaken, the patient loses the ability to walk and 
becomes wheelchair bound, typically by 12 years of age.  Ultimately, the intercostals and 
cardiac muscles begin to be affected and death occurs as early as the late teens or early 
20s.  However, with proper management and modern techniques, such as assisted 





Simonds et al.,1998; Wagner et al., 2007). 
 The milder Becker muscular dystrophy (BMD) was first described in the 1950s 
(Becker, 1962; Becker and Kiener, 1955) and was found to cause muscle degeneration 
and weakness similar to Duchenne muscular dystrophy but at a much slower rate.  In 
BMD patients, onset of clinical symptoms can begin around 12 years of age, but some 
patients do not show symptoms until much later in life.  Loss of ambulation in BMD 
patients is highly variable and can occur as early as adolescence or well into late 
adulthood.  BMD patients typically survive into the fourth or fifth decades of life. 
 Cognitive defects are seen in both DMD and BMD patients.  Approximately one 
third of DMD patients have cognitive impairments with the DMD population having a 
mean full scale intelligence quotient (IQ) score one standard deviation lower than the 
population average (Cotton et al., 2005).  Neurological disorders, such as autism 
spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), also occur 
at an increased frequency in DMD and BMD patients (Hendriksen and Vles, 2008; Wu et 
al., 2005).   
 Both DMD and BMD are caused by mutations in the DMD gene (Koenig et al., 
1987; Muntoni et al., 2003).  The DMD gene is the largest known human gene, spanning 
more than 2 megabases and comprising 79 exons on the X chromosome.  Tissue specific 
promoters within the DMD gene drive the expression of several isoforms of the protein 
dystrophin (Hoffman et al., 1987; Muntoni et al., 2003).  Three full length isoforms exist, 
each having a unique first exon spliced to the remaining 78 exons of the DMD gene and 
include the isoforms Dp427m, a muscle specific isoform (Koenig et al., 1987; Monaco et 
al., 1986); Dp427c, expressed primarily in cortical neurons in the brain (Nudel et al., 
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1989); and Dp427p, expressed primarily in cerebellar purkinje cells (Gorecki et al., 1992; 
Holder et al., 1996).  The expression of several truncated dystrophin isoforms is driven 
by promoters that lie within the introns of the DMD gene and are coded by the exons 
downstream of the promoter.  These include Dp260, a truncated dystrophin isoform 
expressed in the retina (D'Souza et al., 1995); Dp140, expressed in the central nervous 
system and kidneys (Lidov and Kunkel, 1997; Lidov et al., 1995); Dp116, expressed in 
Schwann cells (Byers et al., 1993); and Dp71, which is ubiquitously expressed (Austin et 
al., 1995; Lederfein et al., 1992).  All of these DMD mRNA isoforms encode the C-
terminal domain of dystrophin and are thought to share the same 3’ UTR. 
 The most extensively studied dystrophin isoform is the muscle specific isoform, 
Dp427m.  It is a large, 427 kDa protein that localizes to the sarcolemma and acts as a 
scaffold for a complex of proteins including the dystroglycans, sarcospan, syntrophin, 
and dystrobrevin to form the dystrophin associated glycoprotein complex (DGC).  The 
DGC anchors the cytoskeleton of muscle fibers to the extracellular matrix and has been 
shown to play an important structural role in maintaining muscle fiber integrity.  The 
dystrophin protein can be organized into three distinct domains; the N-terminal domain 
that contains actin binding domains that bind to the cytoskeleton inside the cell, a C-
terminal domain that interacts with proteins of the DGC at the subsarcolemmal space, and 
a large rod domain found in the middle of the protein that connects the N- and C-terminal 
domains and is thought to provide dystrophin with the flexibility it needs to function 
during muscle contractions.  In addition to the structural role, dystrophin has also been 
shown to mediate signal transduction cascades through the C-terminal domain (Blake et 
al., 2002; Cohn and Campbell, 2000), and to regulate miRNAs in muscle cells 
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(Cacchiarelli et al., 2010; Marrone and Shcherbata, 2011).  
 Other dystrophin isoforms have important functions in nonmuscular tissues.  In 
the brain, the dystrophin glycoprotein complex is involved in several cellular processes in 
brain development and function (Waite et al., 2012; Waite et al., 2009).  In addition to the 
full length brain isoforms (Dp427c and Dp427p), the shorter isoforms Dp71 and Dp140 
are also expressed in the brain.  Dp71 has been shown to form dystrophin associated 
protein complexes at the plasma membrane and nucleus and is the most abundant isoform 
in the brain (Tadayoni et al., 2012).  Dp140 is developmentally regulated in the brain 
with higher expression during fetal development compared to adults (Lidov et al., 1995).  
There is a correlation with mutations at the distal end of the DMD gene and cognitive 
impairment in human patients, and mutations affecting these dystrophin isoforms could 
explain the neurological disorders seen in DMD and BMD patients.  The dystrophin 
isoform expressed in the retina, Dp260, is involved in synaptic maturation and attachment 
of the retina to the vitreous (Rodius et al., 1997; Schmitz and Drenckhahn, 1997), and 
ophthalmological defects, such as red green vision impairments, have been observed at a 
higher frequency in DMD and BMD patients with mutations downstream of exon 30 that 
lie within this isoform (Costa et al., 2007). 
 Whether a patient develops DMD or BMD is largely dependent on the type of 
mutation found in the DMD gene.  The more severe DMD phenotype is typically caused 
by mutations that severely reduce or eliminate synthesis of functional dystrophin protein, 
such as those that disrupt the reading frame (Flanigan et al., 2009; Flanigan et al., 2011; 
Monaco et al., 1988; Muntoni et al., 2003), whereas the less severe BMD is caused by 
mutations that maintain the open reading frame and allow for residual expression of 
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functional dystrophin protein (Flanigan et al., 2009; Flanigan et al., 2011; Monaco et al., 
1988; Muntoni et al., 2003).  This observation has been described as the reading frame 
rule (Monaco et al., 1988), and holds true even in some very drastic cases.  For example, 
one BMD patient was found to have a very large in frame deletion in the rod domain that 
deleted 46% of the coding region of the DMD gene (England et al., 1990).  Yet this 
patient had very mild muscular dystrophy and was still ambulant at age 61 (England et 
al., 1990).  Observations like this inspired the theory that DMD patients could be treated 
if partially functional dystrophin expression could be restored, and led to the 
development of several therapeutic approaches to treat DMD patients (Fairclough et al., 
2013; Muir and Chamberlain, 2009; Pichavant et al., 2011).   
One such approach uses antisense oligonucleotides that bind to exon splicing 
junctions to skip exons in the final mRNA product.  When out-of-frame mutations are 
present, the reading frame of the DMD transcript can be restored by skipping the exons 
containing and/or surrounding the mutation.  This could potentially lead to the expression 
of a partially functional dystrophin protein and result in a BMD-like phenotype.  It is 
estimated that 83% of all DMD mutations could be corrected by skipping specific exons 
(Aartsma-Rus et al., 2009; Muntoni and Wood, 2011).  This technique has been 
successful in ameliorating the DMD phenotype in both animal models and human clinical 
trials product (Cirak et al., 2011; Goemans et al., 2011; Gurvich et al., 2008; Kinali et al., 
2009; Lu et al., 2005; Mendell et al., 2013; van Deutekom et al., 2007). 
Read through of premature stop codons is another approach to treating DMD 
patients (Barton-Davis et al., 1999; Finkel, 2010; Howard et al., 2004; Malik et al., 2010).  
Mutations that cause premature stop codons occur in ~15% of DMD patients (Aartsma-
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Rus et al., 2006), and could be treated with drugs that promote readthrough.  Initial 
human trials of one such drug, Ataluran, was shown to increase dystrophin expression in 
most patients and treated patients could walk further in a six-minute walk test compared 
to untreated patients (Finkel, 2010; McDonald et al., 2010).  However, there was no 
correlation between dystrophin levels and the patients that could walk the furthest in this 
study.  Other drugs with greater effectiveness have shown success in animal models 
(Kayali et al., 2012), but have yet to be tested in humans. 
Delivery and expression of functional dystrophin using viral gene therapy in 
DMD patients is also being pursued (Fabb et al., 2002; Foster et al., 2012; Foster et al., 
2008; Koo et al., 2011a; Koo et al., 2011b; Rodino-Klapac et al., 2010; Wang et al., 
2000; Wang et al., 2007; Wang et al., 2012).  However, the large 14 kilobase (kb) DMD 
mRNA cannot fit in the viral vectors which has been a major challenge with this 
approach.  To overcome this, minidystrophin gene constructs (~3-6 kb) lacking the most 
nonessential DMD coding exons that express functional dystrophin protein have been 
designed, and have been successful in animal models of DMD (Fabb et al., 2002; Foster 
et al., 2012; Foster et al., 2008; Koo et al., 2011a; Koo et al., 2011b; Rodino-Klapac et 
al., 2010; Wang et al., 2000; Wang et al., 2007; Wang et al., 2012). 
The fourth approach to treating DMD patients is by overexpressing utrophin.  
Utrophin is a dystrophin related protein with structural and functional similarities that has 
been shown to functionally compensate for the lack of dystrophin (Khurana and Davies, 
2003; Miura and Jasmin, 2006).  Utrophin levels have been increased by several methods 
and have shown success in animal models lacking dystrophin (Chakkalakal et al., 2008; 
Moorwood et al., 2013; Sonnemann et al., 2009; Tinsley et al., 2011).  However, utrophin 
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is overexpressed in DMD patients (Mizuno et al., 1993) and the benefit of further 
increasing utrophin levels in humans has yet to be shown. 
DMD homologues have been identified in several animal species from mammals 
(Bulfield et al., 1984; Carpenter et al., 1989; Cooper et al., 1988; Valentine et al., 1988), 
to fish (Bassett and Currie, 2004) and nematodes (Bessou et al., 1998), and have been 
very useful tools in understanding DMD pathogenesis and developing treatments for 
human patients.  The best characterized animal model of DMD is the mdx mouse 
(C57BL/10ScSn-Dmdmdx/J) that contains a nonsense mutation in exon 23 of the DMD 
gene and does not express dystrophin (Bulfield et al., 1984; Sicinski et al., 1989).  
However, the severe muscle degeneration and early death seen in human DMD patients is 
not seen in these mice (Collins and Morgan, 2003; Dangain and Vrbova, 1984).  Instead, 
a relatively mild skeletal phenotype is observed.  This is partly due to compensation for 
the lack of dystrophin by the functionally related protein utrophin, and although a 
dystrophin/utrophin double knockout mouse (mdx/utrp-/-) better mimics human DMD 
pathology (Janssen et al., 2005), it is not a perfect genetic model for DMD. 
Larger mammals, such as the dog, better recapitulate the phenotype of human 
DMD.  Canine X-linked muscular dystrophy (CXMD) dogs have an  absence of 
dystrophin expression, and similar clinical features and disease progression as human 
DMD patients (Valentine et al., 1988).  In addition, dogs have an immune system very 
similar to humans’ (Wang et al., 2007), making the cxmd dog important for testing side 
effects of therapies, such as viral gene delivery, where the immune response in humans 
has been problematic (Cavazzana-Calvo et al., 2005; Mendell et al., 2012).  The best 
characterized dog model to date is the Golden Retriever Muscular Dystrophy (GRMD) 
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dog (Cooper et al., 1988; Kornegay et al., 1988; Valentine et al., 1988).  The GRMD dog 
has a point mutation in the splice acceptor site of intron 6, causing exon 7 to be skipped 
during splicing and results in a premature stop codon (Sharp et al., 1992).   
Studies in the mdx mouse have shown that expression of even small amounts of 
dystrophin can lessen disease severity (van Putten et al., 2012; van Putten et al., 2013).  
Human clinical trials using developing therapies, such as exon skipping, have shown that 
these strategies can restore dystrophin expression in the majority of muscle fibers in 
treated muscle (Goemans et al., 2011; Kinali et al., 2009; Mendell et al., 2013; van 
Deutekom et al., 2007).  However, dystrophin expression is highly variable between 
patients and typically results in less than 20% dystrophin levels compared to normal 
controls (Cirak et al., 2011; Goemans et al., 2011; Kinali et al., 2009; van Deutekom et 
al., 2007).  Regulatory factors that affect dystrophin expression could account for some of 
the variability seen, and these factors could impact disease pathogenesis and effectiveness 
of developing therapies.  While tissue specific distribution and transcriptional regulation 
of DMD have been well characterized, the posttranscriptional regulation of dystrophin 
synthesis is not well understood.  The untranslated regions of genes, such as the 3’ UTR, 
have been shown to regulate gene expression posttranscriptionally by altering mRNA 
stability, localizing mRNA, or directly affecting translation (Andreassi and Riccio, 2009; 
Chatterjee and Pal, 2009; Gramolini et al., 2001; Matoulkova et al., 2012; Mazumder et 
al., 2003; Pickering and Willis, 2005), and mutations in these regions can be pathogenic 
(Chatterjee and Pal, 2009).  In one study, it was shown that DMD transcript stability was 
a bigger determinant of dystrophin protein levels in BMD patients than transcription rate, 
and increasing stability could improve the outcome of therapies such as exon skipping 
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(Spitali et al., 2013).   
The DMD 3’ UTR contains some particularly interesting characteristics that 
suggest it could be involved in posttranscriptional regulation of dystrophin.  The 2.7 kb 
DMD 3’ UTR is larger than the average 3’ UTR length of ~1020 nt (Mignone et al., 
2002) in human transcripts, and contains several large, highly conserved regions that 
could be regulating expression.  The high amount of conservation in the DMD 3’ UTR 
was first described over two decades ago comparing human and chicken sequences 
(Lemaire et al., 1988).  Two large, conserved regions were identified, named Lemaire A 
and Lemaire D, both of which are more highly conserved than the protein coding region 
(Greener et al., 2002; Lemaire et al., 1988).  Evidence for two potential regulatory 
elements within these regions of the DMD 3’ UTR have been previously reported.  
miRNA-31 is predicted to bind to a site within Lemaire A, and is thought to suppress 
dystrophin synthesis in myoblasts prior to differentiation and in dystrophic muscle 
(Cacchiarelli et al., 2011).  In vitro experimental evidence has also been presented for 
binding of the RNA binding protein vigilin to the Lemaire D region of the DMD 3’ UTR 
(Kanamori et al., 1998).  However, the biological significance of this binding with regard 
to dystrophin expression has not been explored. 
To date, no well defined, disease causing mutations have been identified in the 
DMD 3’ UTR in human DMD or BMD patients.  There are two examples of BMD 
patients (Greener et al., 2002; McCabe et al., 1989) and two examples of DMD patients 
(Pillers et al., 1990; Todorova et al., 2008) with deletions that span the DMD 3’ UTR.  
However, these deletions extend into the coding region of the DMD gene, delete other 
neighboring genes, or have not been fully analyzed to determine the extent of the 
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deletion, and disease causing mutations shown to be contained solely within the 3’ UTR 
have yet to be identified.  However, there is a small group of human patients (0.2% in one 
large study) (Flanigan et al., 2009) where dystrophin expression is absent, but they have 
no mutations in the coding region of the DMD gene, suggesting the possibility of disease 
causing mutations outside of the coding region, such as the DMD 3’ UTR, that may have 
been overlooked by standard mutation screens. 
The experiments discussed in this dissertation explore the role the DMD 3’ UTR 
has in dystrophin expression in muscle tissue.  The results presented here demonstrate 
that a highly conserved region overlapping Lemaire A at the beginning of the 3’ UTR 
increases both mRNA stability and translation efficiency, whereas a highly conserved 
region overlapping Lemaire D at the distal end of the 3’ UTR primarily affects mRNA 
abundance.  We show evidence that the highly conserved element contains multiple 
regulatory elements and interacts with RNA binding proteins.  We characterize the 
variants seen in DMD 3’ UTRs from a population of 1,222 humans that include DMD 
and BMD patients, and conclude that a disease causing 3’ UTR mutation is unlikely to 
exist in this group of patients.  However, we could not rule out the possibility that 
variants in the 3’ UTR could modify the disease phenotype when a second mutation is 
present or cause a disease phenotype in nonmuscular tissues.  This dissertation concludes 
with a characterization of four canine models of DMD who presented in clinical 
veterinary practice with symptoms of weakness along with altered or absent dystrophin 
expression on muscle biopsy, and identify the mutations responsible in three such dogs.  
We developed genotyping assays for each mutation to aid in establishing research 
colonies of these dogs.  Identification of these novel mutations adds to the catalog of 
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available dog models, and may facilitate developing therapeutic approaches directed 
toward these specific mutation classes in an animal model that more faithfully 
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CONSERVED REGIONS OF THE DMD 3’ UTR REGULATE  
 
TRANSLATION AND MRNA ABUNDANCE  
 





Duchenne muscular dystrophy (DMD), a severe muscle wasting disease, is caused 
by mutations in the DMD gene, which encodes for the protein dystrophin.  Its regulation 
is of therapeutic interest as even small changes in expression of functional dystrophin can 
significantly impact the severity of DMD. While tissue specific distribution and 
transcriptional regulation of several DMD mRNA isoforms have been well characterized, 
the posttranscriptional regulation of dystrophin synthesis is not well understood.  Here, 
we utilize qRTPCR and a quantitative dual luciferase reporter assay to examine the 
effects of isoform specific DMD 5’ UTRs and the highly conserved DMD 3’ UTR on 
mRNA abundance and translational control of gene expression in C2C12 cells. The 5’ 
UTRs were shown to initiate translation with low efficiency in both myoblasts and 
myotubes, whereas two large highly conserved elements in the 3’ UTR, which overlap 
the previously described Lemaire A and D regions, increase mRNA levels and enhance 
translation upon differentiation of myoblasts into myotubes.  The results presented here 
implicate an important role for DMD UTRs in dystrophin expression and delineate the cis 










The DMD gene is the largest known human gene, spanning more than 2 
megabases and comprising 79 exons.  Tissue specific promoters drive the expression of 
several isoforms of dystrophin, including those expressed in brain and muscle tissue, 
which differ only in their first exon, and several truncated isoforms that are derived from 
promoters found within the DMD gene (Hoffman et al., 1987; Muntoni et al., 2003).  The 
predominant muscle isoform, Dp427m, has been shown to play a structural role in 
maintaining muscle fiber integrity by connecting the cytoskeleton of muscle fibers to the 
extracellular matrix via the dystrophin associated glycoprotein complex (DGC), and to 
mediate signal transduction cascades through the C-terminal domain of dystrophin (Blake 
et al., 2002; Cohn and Campbell, 2000). Mutations in the DMD gene cause the 
dystrophinopathies, Duchenne Muscular Dystrophy (DMD) and Becker Muscular 
Dystrophy (BMD) (Koenig et al., 1987; Muntoni et al., 2003). Patients with DMD exhibit 
severe muscle degeneration, development of cardiac hypertrophy, an association with 
neurological disorders, and a life expectancy into the second decade of life.  BMD 
patients exhibit muscle degeneration that occurs at a much slower rate and typically 
survive into late adulthood.  The more severe DMD phenotype is typically caused by 
mutations that severely reduce or eliminate synthesis of functional dystrophin protein, 
such as those that disrupt the reading frame (Flanigan et al., 2009; Flanigan et al., 2011; 
Monaco et al., 1988; Muntoni et al., 2003), whereas the less severe BMD is caused by 
mutations that maintain the open reading frame and allow for residual expression of 





1988; Muntoni et al., 2003).  This observation and the finding that expression of even 
small amounts of dystrophin can lessen disease severity (van Putten et al., 2012; van 
Putten et al., 2013) has increased interest in the mechanisms that control DMD expression 
and has also led to the development of several therapeutic approaches to treat DMD 
patients (Fairclough et al., 2013; Muir and Chamberlain, 2009; Pichavant et al., 2011).  
Examples of the latter include delivery of antisense molecules designed to induce 
skipping of mutated exons (Cirak et al., 2011; Goemans et al., 2011; Gurvich et al., 2008; 
Kinali et al., 2009; Lu et al., 2005; Mendell et al., 2013; van Deutekom et al., 2007); 
premature stop codon suppression therapies (Barton-Davis et al., 1999; Finkel, 2010; 
Howard et al., 2004; Malik et al., 2010); and the delivery and expression of 
minidystrophin gene constructs lacking nonessential DMD coding exons (Fabb et al., 
2002; Foster et al., 2012; Foster et al., 2008; Koo et al., 2011a; Koo et al., 2011b; 
Rodino-Klapac et al., 2010; Wang et al., 2000; Wang et al., 2007; Wang et al., 2012). 
  5’ UTRs have been shown to be important for determining translation efficiency, 
and mutations in this region can be pathogenic (Chatterjee and Pal, 2009; Pickering and 
Willis, 2005).  The length, GC content and secondary structures of a 5’ UTR all have an 
impact on translation.  mRNAs with high translation rates often contain 5’ UTRs that are 
short, with low GC content, and little secondary structure, whereas mRNAs with a low 
translation rate, or those that are regulated in a tissue specific manner or involved in 
developmental processes, often contain 5’ UTRs that are longer, more GC rich, and 
contain more secondary structure (Kochetov et al., 1998; Pickering and Willis, 2005). 
Most of the DMD 5’ UTRs are longer and have a lower GC content compared to the 










Note:  The 5’ UTR length, percent GC content, and Kozak sequence is shown for 5’ 
UTRs of several dystrophin isoforms along with the primary tissues expressing each 
isoform.  The average 5’ UTR length of 210 bp (Mignone et al., 2002) and percent GC 
content of 58.4% (Waterston et al., 2002) are shown for human 5’ UTRs along with the 
consensus Kozak sequence (Kozak, 1987).  The lengths of most DMD 5’ UTRs are 
longer than average and have a GC content that is less than the average human 5’ UTR.  
The Kozak sequence for each 5’ UTR isoform and exon 1 is shown with the high impact 
-3 and +4 positions underlined.  The DMD 5’ UTRs have several changes compared to 
the consensus sequence. 
 
 
ribosome entry sites (IRES) contained within 5’ UTRs have also been shown to regulate 
gene expression.  The 5’ UTR of utrophin, a homologue of dystrophin encoding a 
functionally related protein, was shown to regulate translation during muscle regeneration 
through an IRES (Miura et al., 2010; Miura et al., 2005).  Likewise, the retinal dystrophin 
5’ UTR (Dp260) was shown to contain a cryptic intron with IRES elements that regulates 
translation of the R-dystrophin transcript (Kubokawa et al., 2010).  The functions of the 
5’ UTRs for the remaining dystrophin isoforms are unknown, and may be involved in the 
posttranscriptional regulation of dystrophin synthesis in other tissues. 
With the exception of the Dp40 isoform, all identified DMD mRNA isoforms 





UTRs have been shown to regulate gene expression posttranscriptionally by altering 
mRNA stability, localizing mRNA, or directly affecting translation (Andreassi and 
Riccio, 2009; Gramolini et al., 2001; Matoulkova et al., 2012; Mazumder et al., 2003). 
The 2.7 kb DMD 3’ UTR is longer than the average 3’ UTR length of ~1020 nt (Mignone 
et al., 2002), and contains several large, highly conserved regions that may be regulating 
the dystrophin expression through these mechanisms (Figure 1.1).  The high amount of 
conservation found within the DMD 3’ UTR was first described over two decades ago 
(Lemaire et al., 1988).  Two large, conserved regions were identified, named Lemaire A 
and Lemaire D, both of which are more highly conserved than the protein coding region 
(Figure 1.1) (Greener et al., 2002; Lemaire et al., 1988).  The unusually high amount of 
conservation extends beyond the Lemaire sequences.  For example, a sequence 
overlapping and extending past the Lemaire A region spans 429 nucleotides with 97.4% 
sequence identity between human and mouse sequences (Figure 1.1).  The high 
conservation of these regions in the DMD 3’ UTR is similar to the large, hyper or highly 
conserved elements (HCEs) identified in other 3’ UTRs (Dassi et al., 2013; Siepel et al., 
2005).  HCEs are involved in transcriptional and posttranscriptional gene regulation 
(Dassi et al., 2013; Ho and Gunderson, 2011; Sathirapongsasuti et al., 2011; Siepel et al., 
2005).  However the mechanism of how HCEs regulate gene expression is still not 
understood. The extensive length and high conservation of these regions is unusual, and 
greater than what would be expected to retain a single binding site for RNA binding 
proteins or miRNAs.  Nevertheless, evidence for two potential regulatory elements within 
these regions of the DMD 3’ UTR has been previously reported.  These include a 













Figure 1.1.  Conservation of the DMD 3’ UTR.   
 
The conservation and regions of interest are shown for the DMD 3’ UTR.  The 2.7 kb 
DMD 3’ UTR contains several large regions of high conservation.  Conservation among 
vertebrates is shown using the PhastCons measurement of 100 vertebrate species 
(PhastCons track, UCSC Genome Browser).  Regions of interest in the 3’ UTR include 
the highly conserved Lemaire A and Lemaire D regions, a previously described miRNA-
31 and vigilin binding sites, a variable CA repeat region, and an AU rich region.  The 
percent sequence identity between human and mouse sequences are shown for the full 3’ 
UTR (78%), and the regions overlapping Lemaire A (97%) or Lemaire D (90%) (See 
Materials and methods).  The percent sequence identity in these regions are higher than 
the average human 3’ UTR (74.7%) and the coding region (84.7%) of a gene (Waterston 









































dystrophin synthesis in myoblasts prior to differentiation and in dystrophic muscle 
(Cacchiarelli et al., 2011), and a binding site for the RNA binding protein vigilin within 
Lemaire D (Kanamori et al., 1998).  Each of these elements spans only a small portion of 
the respective conserved domains and is consequently unlikely to explain the high degree 
of sequence conservation observed across hundreds of nucleotides in the DMD 3’ UTR 
(Figure 1.1).  
The results presented here demonstrate that the 5’ UTRs for the full length muscle 
and brain isoforms initiate translation with low efficiency in C2C12 cells and that, in 
differentiated myotubes, the highly conserved region overlapping Lemaire A increases 
both mRNA levels and translation efficiency, whereas the region overlapping Lemaire D 
primarily affects mRNA abundance.  Directed mutagenesis further demonstrates that the 
elements responsible for increasing dystrophin expression during differentiation span the 
entire Lemaire A and D domains, and that the predicted binding of vigilin and miRNA-31 
does not appear to be involved in this function of the DMD 3’ UTR in differentiated 
C2C12 myotubes.   
 
Results 
The DMD 3’ UTR regulates expression during myogenesis 
To investigate whether the DMD 3’ UTR regulates gene expression, we designed 
a Renilla reporter construct containing the DMD 3’ UTR downstream of the Renilla 
coding sequence in pHRL-CMV (3’ UTR) (Figure 1.2A). This reporter construct along 
with controls containing either an SV40 derived 3’ UTR (pHRL) or the DMD 3’ UTR 
inserted in the reverse orientation (3’ UTR Rev) were transfected into mouse muscle 













Figure 1.2.  The DMD 3’UTR regulates expression in C2C12 and HEK 293 cells.   
A.  Diagram of the control pHRL-CMV Renilla vector (pHRL) with the SV40 PolyA 
region, and the pHRL-CMV vector with the DMD 3’UTR replacing the SV40 polyA 
region in either the forward (3’UTR) or reverse orientation (3’UTR Rev).   
B.  Relative expression levels in C2C12 and HEK 293 cells are shown.  Relative 
expression levels are normalized to the ratio of the control Renilla pHRL vector.  The 
average of four biological transfection replicates is shown for each construct.  Error bars 











































firefly luciferase vector to normalize for variation in transfection efficiency.  The 
undifferentiated C2C12 myoblasts and HEK 293 cells were subsequently lysed and the 
relative amounts of Renilla and Firefly protein were measured using a Renilla/Firefly 
dual luciferase assay (see Materials and methods). Changes in gene expression were 
determined by comparing the Renilla luciferase activities expressed by each experimental 
construct normalized to the cotransfected Firefly luciferase control (Figure 1.2B, C2C12 
Myoblasts). To determine whether the 3’ UTR regulates expression during myogenesis, 
transfected C2C12 cells were induced to differentiate for 6 days and relative expression 
levels were determined as described above (Figure 1.2B, C2C12 Myotubes). The DMD 
3’ UTR increased  expression by 350% and 200% compared to pHRL in C2C12 
myotubes and HEK 293 cells, respectively, whereas in C2C12 myoblasts, relative 
expression levels decreased by 50% (Figure 1.2B). To monitor changes in expression of 
the pHRL-CMV (pHRL) control construct and the DMD 3’ UTR (3’ UTR) construct 
during differentiation, Renilla and firefly activity levels were measured every 24 hours 
for 7 days as the cells differentiated (Appendix C).  The observed increase in expression 
of the 3’ UTR construct (3’ UTR) began 2 days after C2C12 cells were grown in 
differentiation media and continued to increase until the 5th day of differentiation 
(Appendix C).    This increase in expression of the 3’ UTR construct correlates with the 
morphology of the differentiating C2C12 cells with elongation of the myoblasts first 
being observed at Day 2 and large, mature myotubes being formed by Day 5 (data not 
shown).  As a control, the DMD 3’ UTR was inserted in the reverse orientation with an 
intact DMD polyadenylation signal (3’ UTR Rev), and transfected into C2C12 cells or 





(Figure 1.2B).  These experiments show that the DMD 3’ UTR increases expression of 
the reporter gene in differentiating C2C12 cells and correlates with the expected increase 
in the muscle isoform of dystrophin in differentiated myotubes. 
 
Conserved domains in the DMD 3’ UTR regulate gene expression 
Having shown that the DMD 3’ UTR can regulate gene expression during 
myogenesis, we were interested in determining which regions of the DMD 3’ UTR were 
important for this regulation.  We hypothesized that the domains responsible for gene 
regulation are most likely contained in one of the highly conserved regions of the DMD 
3’ UTR.  For this reason, we split the DMD 3’ UTR into three segments – the first 
segment (A) consisting of the first 626 nucleotides of the DMD 3’ UTR that includes 
Lemaire A, a CA-repeat domain, and surrounding highly conserved regions; a middle 
section (M) consisting of 1,542 nucleotides found in the middle of the DMD 3’ UTR that 
contains a few regions of high conservation but consists mostly of unconserved 
sequences; and a third segment (D) consisting of the last 431 nucleotides of the DMD 3’ 
UTR that contains Lemaire D and the surrounding highly conserved sequences (Figure 
1.3A).  We made three deletions in our DMD 3’ UTR construct corresponding to each of 
the major sections of the DMD 3’ UTR (dl-A, dl-M, and dl-D, Figure 1.3A) while 
maintaining an intact polyadenylation site and transfected these constructs into C2C12 
cells.  After 48 hours, the media was replaced with differentiation media and the relative 
expression levels for each construct were measured each day for 7 days (Figure 1.3B).  
As we saw before, the expression of the full length 3’ UTR construct had a 6-7-fold 
increase in expression as the cells completed differentiation, but the constructs with the 













Figure 1.3.  The conserved Lemaire A and Lemaire D regions are necessary for the 
increase in expression during C2C12 myogenesis.   
 
A.  Diagram showing the conservation of the DMD 3’UTR and the regions deleted in 
each 3’UTR construct.  Conservation of the DMD 3’UTR across vertebrates is shown 
using the PhastCons score across the 3’UTR (100 Vertebrate Phastcons track, UCSC 
genome browser).  Three deletion constructs were made in the DMD 3’UTR that included 
Lemaire A (dl-A), the middle portion of the 3’UTR (dl-M), and Lemaire D (dl-D).   
B.  Relative expression levels were measured in C2C12 cells transfected with the full 
length DMD 3’UTR Renilla construct (3’UTR) or a deletion construct (dl-A, dl-M, or dl-
D) during differentiation from myoblasts to myotubes.  Expression levels were 
normalized to the expression of the control pHRL Renilla construct (pHRL) at each day 
of differentiation.  The average of four biological transfection replicates is shown for 








































in expression.  This experiment shows that the large increase in expression seen during 
C2C12 differentiation is dependent on the presence of both the Lemaire A and Lemaire D 
regions, whereas deleting the middle region of the 3’ UTR (dl-M) had a smaller impact 
on expression (Figure 1.3B). 
To determine whether the Lemaire A and Lemaire D regions were regulating 
expression by directly altering translation or steady state mRNA levels, we measured 
mRNA and protein levels for each transfection in both C2C12 myoblasts and myotubes 
(Figure 1.4).  We measured Renilla steady state mRNA levels using qPCR relative to a 
cotransfected pHRL control vector, and measured Renilla protein levels for each 
construct using the Firefly/Renilla dual luciferase assay described above. Consistent with 
our previous experiment, deleting Lemaire A or Lemaire D did not have a significant 
effect on mRNA or protein levels in C2C12 myoblasts (Figure 1.4). Surprisingly, 
deleting the middle section (dl-M) resulted in a ~40-50% increase in mRNA and protein 
levels in myoblasts compared to the full length 3’ UTR construct (3’ UTR) (Figure 1.3B, 
Figure 1.4).  In myotubes, deleting any region of the 3’ UTR resulted in a significant 
decrease in protein expression compared to the full length 3’ UTR construct, with the 
largest effect on expression observed when the conserved Lemaire A or Lemaire D 
regions were deleted.  When the Lemaire A region was deleted (dl-A), steady state 
mRNA levels decreased by ~50% whereas luciferase activity decreased by ~75% 
showing that this region is critical for the increased expression seen in C2C12 myotubes 
by affecting both translation and steady state mRNA levels of the reporter mRNA (Figure 
1.4).  Deleting the Lemaire D region (dl-D) resulted in a ~50% decrease in steady state 








Figure 1.4.  The conserved regions in the DMD 3 ’UTR increase translation in C2C12 
myotubes. 
 
A.  Renilla mRNA and protein levels for C2C12 myoblasts transfected with the full 
length 3’ UTR construct (3’UTR) or deletion constructs (dl-A, dl-M, dl-D) are shown.    
RNA levels were measured using qPCR relative to the cotransfected pHRL control.  
Protein levels were measured using a Renilla/Firefly dual luciferase assay.  RNA and 
protein levels were normalized to the amount of mRNA and protein levels of the full-
length 3’UTR.  The average of at least three biological transfection replicates is shown 
for each construct.  Error bars equal +/- 1 standard deviation. 
B.  Renilla mRNA and protein levels for C2C12 myotubes transfected with the full length 
3’ UTR construct (3’UTR) or deletion constructs (dl-A, dl-M, dl-D) are shown.  The 
average of at least three biological transfection replicates is shown for each construct.  








this region has a larger impact on maintaining mRNA steady state levels in C2C12 
myotubes than on translation.  To directly measure the effect these regions have on 
mRNA stability, we used the transcription inhibitor, Actinomycin D, to measure the half-
life of our reporter constructs and found that the Lemaire A and D regions increase 
mRNA stability in C2C12 myotubes (Appendix A). 
There is evidence that the length of a 3’ UTR can affect translational efficiency 
and mRNA stability (Hogg and Goff, 2010; Tanguay and Gallie, 1996).  To determine 
whether the effect of deleting regions of the DMD 3’ UTR was due to changing the 
length of the 3’ UTR or the absence of the region deleted, we made DMD 3’ UTR 
constructs with the Lemaire A section (A) or middle section (M) of the 3’ UTR reversed 
and transfected these constructs into C2C12 cells.  Expression decreased by the same 
amount in C2C12 myotubes whether these regions were deleted or reversed in our 
constructs (Appendix C). 
 
Lemaire A and Lemaire D regions of the DMD 3’ UTR are  
necessary for increasing expression during myogenesis 
 It was shown previously that Lemaire A contains a predicted miRNA-31 binding 
site and that overexpression of miRNA-31 can inhibit dystrophin expression in cultured 
cells (Cacchiarelli et al., 2011).  An unrelated analysis of the conserved regions in the 
DMD 3’ UTR predicted the formation of a conserved 27-bp stem-loop structure within 
the Lemaire A region (Greener et al., 2002).  To experimentally address the presence of 
discrete regulatory elements within the 626 nucleotide Lemaire A region, the entire 
region was divided into four parts of ~150 base pairs each (Aa, Ab, Ac and Ad)  


















Figure 1.5.  Lemaire A is necessary for high expression in C2C12 myotubes. 
   
A.  Diagram of the pHRL 3’UTR constructs with ~ 150 nucleotide portions of the 
Lemaire A region deleted (dl-Aa, dl-Ab, dl Ac, and dl-Ad).  Lemaire A overlaps the 
sequences deleted in the dl-Aa, dl-Ab, and dl-Ac constructs.  The miRNA-31 binding site 
lies within the Ac region. 
B.  Renilla protein expression in day six C2C12 myotubes transfected with the Lemaire A 
deletion constructs is shown.  Relative expression levels for each construct were 
measured using a dual luciferase assay as previously described.  The average of four 












Lemaire A, with the predicted miRNA-31 binding site lying within the Ac region (Figure 
1.5A).  The last region (Ad) contains the CA repeat and conserved sequences 
downstream of Lemaire A.  Each of these smaller regions was deleted from the DMD 3’ 
UTR to create the reporter constructs dl-Aa, dl-Ab, dl-Ac, dl-Ad (Figure 1.5A), and 
transfected into C2C12 cells.  After 2 days in growth media (myoblasts) or 6 days in 
differentiation media (myotubes), relative expression levels were measured using the 
luciferase assay as previously described.  In myotubes, we found that deleting any portion 
of Lemaire A (dl-Aa, dl-Ab, and dl-Ac) decreased expression as much as deleting the 
entire Lemaire A region (dl-A) (Figure 1.5B), showing that all sections of the conserved 
Lemaire A region must be present to increase expression in myotubes.  Deleting the 
portion of the 3’ UTR containing the CA repeat and downstream conserved sequences 
(dl-Ad) decreased expression by ~50% (Figure 1.5B).  Consistent with our previous 
experiment, deleting any portion of the Lemaire A region had little impact on expression 
in C2C12 myoblasts compared to the full length 3’ UTR construct (Figure 1.6). 
 To determine if the entire Lemaire D region was required for its effects on 
expression,  we used deletion mutagenesis to make DMD 3’ UTR constructs with ~150 
bp sections of the Lemaire D region deleted (dl-Da, dl-Db, dl-Dc) (Figure 1.7A), and 
transfected these constructs into C2C12 cells.  Deleting the entire Lemaire D region (dl-
D) resulted in 65% decrease in expression compared to the full length 3’ UTR construct 
in differentiated myotubes (Figure 1.7B).  Deleting any portion of the conserved Lemaire 
D region (dl-Da, dl-Db, dl-Dc) resulted in a similar decrease in expression compared to 
deleting the entire Lemaire D region (50%, 57%, and 43% respectively) (Figure 1.7B) 



















Figure 1.6.  Expression of DMD 3’ UTR constructs in C2C12 myoblasts.   
 
Relative expression levels for the control pHRL reporter construct (pHRL), the DMD 
3’UTR construct (3’UTR), several deletion constructs within the Lemaire A and D 
regions, and the vigilin mutant construct (Vm) are shown (See figure 1.5 and 1.7 for 
deleted regions).  C2C12 myoblast cells transfected with the DMD 3’ UTR construct (3’ 
UTR) had a decrease in Renilla expression by 50% compared to the control pHRL 
reporter construct (pHRL).  Deleting the Lemaire A or D regions (dl-A, dl-D) had no 
significant effect on expression compared to the DMD 3’ UTR construct (3’ UTR).  
Deleting any portion of the Lemaire A region (dl-Aa, dl-Ab, dl-Ac, and dl-Ad) or the 
Lemaire D region (dl-Da, dl-Db, and dl-Dc) or mutating the vigilin binding site (Vm) did 
not have a large impact on expression compared to the full length DMD 3’ UTR construct 
(3’ UTR) in C2C12 myoblasts.  The average of four biological transfection replicates is 
















Figure 1.7.  The Lemaire D region is necessary for high expression in C2C12 myotubes.  
  
A. Diagram of the pHRL 3’UTR constructs with portions of the Lemaire D region 
deleted (dl-D, dl-Da, dl-Db, dl-Dc).   Lemaire D and the vigilin binding site overlap the 
Db and Dc regions.  A construct containing six point mutations in the vigilin binding site 
was made (Vm).   
B.  Relative expression levels from day 6 C2C12 myotubes transfected with the pHRL 
Renilla construct (pHRL), the full length 3’UTR construct (3’UTR), or Lemaire D mutant 
constructs (dl-Da, dl-Db, dl-Dc, and Vm containing 6 point mutations in the vigilin 
binding site) is shown.  Relative expression levels for each construct were measured 
using a dual luciferase assay as previously described.  The average of four biological 
transfection replicates is shown for each construct.  Error bars equal +/- 1 standard 
deviation. 
 
expression in myotubes.  Previously, it was shown that the RNA binding protein vigilin 
can bind in vitro to a predicted binding site found within Lemaire D of the DMD 3’ UTR 
(overlapping the Dc region) (Figure 1.7A).  This binding did not occur when six point 
mutations were introduced into the DMD 3’ UTR transcript that disrupted the predicted 
secondary structure of the vigilin binding site (Kanamori et al., 1998).  To determine 
whether vigilin may be regulating dystrophin expression in muscle cells, we recreated the 
previously described DMD 3’ UTR mutant construct containing these six point mutations 
and transfected this construct into C2C12 cells.  We found that mutating the vigilin 





1.7B), suggesting that vigilin is not regulating dystrophin expression in cultured muscle 
cells through binding to this site. 
 
Expression is not suppressed by miRNA-31 in C2C12 myotubes 
 
 It was shown previously that miRNA-31 could inhibit dystrophin expression by 
binding to a predicted miRNA-31 binding site in the DMD 3’ UTR (Cacchiarelli et al., 
2011).  Undifferentiated myoblasts express miRNA-31 at high levels where this miRNA 
inhibits proteins involved in myogenesis and decreases in expression as the cells 
differentiate into myotubes (Cacchiarelli et al., 2011; Daubas et al., 2009).  When we 
delete the Ac region overlapping the predicted miRNA-31 binding site, we see a decrease 
in both C2C12 myoblasts and myotubes (Figure 1.5, Figure 1.6).  To determine whether 
miRNA-31 has an effect on our reporter construct in differentiating C2C12 cells, we 
made a 3’ UTR construct with the 21 bp miRNA-31 binding site deleted (dl-M31), and 
transfected this construct into C2C12 myoblasts or myotubes (Figure 1.8).  We saw no 
significant change in expression when the miRNA-31 binding site was deleted in our 
construct (dl- M31) compared to the full length 3’ UTR construct (3’ UTR) in C2C12 
myoblasts but saw an ~40% decrease when the miRNA-31 binding site was deleted in 
myotubes (Figure 1.8).  This result suggests that miRNA-31 is not suppressing expression 
in C2C12 myotubes and that there are other regulatory elements in this region increasing 
expression in differentiated myotubes.   
 
An AU rich region increases expression in myotubes 
The middle portion of the DMD 3’ UTR contains only limited regions of 

















Figure 1.8.  Deleting the miRNA-31 binding site decreases expression in C2C12 
myotubes. 
 
Renilla expression levels for the full length DMD 3’ UTR construct (3’UTR) or the 
construct with the miRNA-31 binding site deleted (dl-M31) in transfected C2C12 
myoblasts and myotubes are shown.  The result of three biological replicates is shown 
with expression levels normalized to expression of the full length 3’ UTR construct 
(3’UTR) in myoblasts or myotubes using a Renilla/Firefly dual luciferase assay.  Error 
bars equal +/- 1 standard deviation. 
 
 
when this region was removed, suggesting that this region may inhibit expression in 
myoblasts (Figure 1.4).  In contrast, protein expression decreased by ~25% in myotubes 
when the middle region of the 3’ UTR was removed (Figure 1.4).  After analyzing the 
sequence in the middle region of the 3’ UTR, we discovered a highly conserved AU rich 
region at the distal end of the middle section (Figure 1.1).  AU rich elements in 3’ UTRs 
have been shown to regulate mRNA stability and translation of mRNA transcripts 





whether this sequence contained a functional AU rich element, C2C12 cells were 
transfected with a 3’ UTR construct that contained a 262 base pair deletion spanning the 
conserved AU rich sequence in the middle section of the 3’ UTR (dl-ARE).  Deleting the 
AU rich sequence had no effect on protein expression of the Renilla reporter construct in 
myoblasts, but, in myotubes, protein expression decreased to 64% compared to the full 
length 3’ UTR construct, similar to the protein levels seen when the entire middle region 
is deleted (Figure 1.9).  The increase in mRNA and protein levels seen in myoblasts when 
the entire middle region is deleted does not appear to be due to an effect of the conserved  
AU rich sequence. 
 
DMD 5’ UTRs initiate translation with low efficiency 
To determine the effect the Dp427m 5’ UTR has on expression in muscle cells, 
we inserted the 5’ UTR sequence from the muscle isoform of dystrophin immediately 
upstream of the Renilla coding sequence in our 3’ UTR construct to create a Renilla  
construct with both the DMD 5’ and 3’ UTR (5’ UTRM) (Figure 1.10A).  To maintain 
the initiation codon sequence context for the muscle isoform of dystrophin, we also added 
the three amino acids of the Dp427m exon 1 transcript to the beginning of the Renilla 
sequence.  We transfected this construct into C2C12 cells and analyzed relative 
expression levels in myoblasts and myotubes that were differentiated for 6 days in low 
serum media.  We saw a significant decrease in expression when the Dp427m 5’ UTR 
was added to the Renilla construct with 2.2% protein expression in myoblasts and 11.4% 
protein expression in myotubes compared to the control pHRL-CMV reporter (pHRL) 
(Figure 1.10B).  The relative increase in expression between transfected myoblasts and 


















Figure 1.9.  An AU rich region in the DMD 3’UTR decreases expression in myotubes.   
 
Relative expression levels for C2C12 cells transfected with either the Renilla reporter 
construct containing the full length DMD 3’UTR (3’UTR), a deletion construct deleting 
the middle region of the DMD 3’UTR (dl-M), or a construct with a 262 base pair region 
containing an AU rich sequence found in the middle region of the 3’UTR deleted (dl-
ARE) are shown for 7 days of C2C12 cell differentiation.  Expression is normalized to 
the expression of a control Renilla construct (pHRL) at each time point.  The average of 
four biological transfection replicates is shown for each construct at each time point.  


















Figure 1.10.  The DMD 5’UTRs cause suboptimal translation initiation.   
 
A. Diagram of pHRL Renilla vectors containing the DMD 3’UTR and the Dp427m 
muscle 5’UTR (5’UTRM), the Dp427p brain 5’UTR (5’UTRP), or the Dp427c brain 
5’UTR (5’UTRC) inserted immediately upstream of the hRluc Renilla coding sequence 
in the pHRL-CMV vector. 
B.  Relative expression levels for C2C12 myoblasts or myotubes transfected with either 
the control Renilla reporter construct (pHRL) or a Renilla reporter construct containing 
the Dp427m 5’UTR and the full length DMD 3’UTR (5’UTRM) are shown.   
C.  Relative expression levels in C2C12 myoblasts or myotubes transfected with a 
reporter construct containing either the Dp427m muscle 5’UTR (5’UTRM) or the 
5’UTRs of the full length Dp427p and Dp427c brain isoforms (5’UTRP, 5’UTRC) are 
shown.  The average of four biological transfection replicates is shown for each construct 


























(5’ UTRM) compared to the 3’ UTR construct lacking the 5’ UTR (3’ UTR).  Thus the 
difference between myoblasts and myotube expression levels appears to be solely due to  
the presence of the 3’ UTR.  To determine if there were any differences between the 
different 5’ UTR isoforms, we also made constructs containing the 5’ UTRs from the two 
full length brain dystrophin isoforms (Dp427p, Dp427c) (Figure 1.10A).  Similar to the 
results obtained for the Dp427m 5’ UTR, we found a large reduction in expression in 
both C2C12 myoblasts and myotubes with the brain Dp427p 5’ UTR (8% in myoblasts 
and 28% in myotubes) and Dp427c 5’ UTR (5% in myoblasts and 13% in myotubes) 
compared to the control pHRL-CMV vector (Figure 1.10C).  To determine whether the 
Lemaire A and Lemaire D regions had similar effects on expression in the presence of the 
muscle DMD 5’ UTR, we used deletion mutagenesis to delete the Lemaire A and 
Lemaire D regions (dl-A and dl-D) in a construct containing the Dp427m 5’ UTR, and 
transfected these constructs into C2C12 cells.  The relative changes in expression when 
these regions were deleted was independent of whether the 5’ UTR was present or absent 
in C2C12 myoblasts and myotubes (Figure 1.11). 
 
Discussion 
 5’ and 3’ UTRs regulate gene expression, and mutations in these regions have 
been linked to a number of genetic disorders (Barrett et al., 2012; Chatterjee and Pal, 
2009), including several DMD patients with mutations in the 5’ and 3’ UTR of the DMD 
gene.  An L1 insertion in the Dp427m 5’ UTR was identified in a patient with X-Linked 
Dilated Cardiomyopathy (XLDC) with no apparent muscular atrophy or weakness 
(Yoshida et al., 1998).  Because no mRNA was detected in these patients,  it is speculated 


















Figure 1.11.  3’ UTR deletions in the Dp427m 5’ UTR construct.   
 
Relative expression levels for the Dp427m 5’ UTR construct with the full length DMD 3’ 
UTR (5’ UTRM) or with the Lemaire A or Lemaire D regions deleted in the 3’ UTR (5’ 
UTRM dl-A and 5’ UTRM dl-D, respectively) are shown for C2C12 myoblasts and 
myotubes (See Figure 1.3A for deletion boundaries).  Deleting the Lemaire A or Lemaire 
D region of the 3’ UTR resulted in a slight decrease in expression in C2C12 myoblasts.  
This is similar to the effect seen when deleting these regions when the 5’ UTR is not 
present (Figure 1.4).  In C2C12 myotubes, deleting the Lemaire A or Lemaire D regions 
(5’ UTRM dl-A, and 5’ UTRM dl-D) resulted in a significant decrease in protein 
expression compared to the 5’ UTR construct containing the full length 3’ UTR (5’ 
UTRM).  The decrease when the Lemaire A region is deleted (72%) or Lemaire D region 
is deleted (61%) is similar to the decrease seen in expression when the 5’ UTR is not 
present (Figure 1.4).  The effect of the highly conserved Lemaire A and D regions of the 
DMD 3’ UTR on expression does not appear to be dependent on the presence of the 
Dp427m 5’ UTR.  The expression shown for each construct is relative to the amount of 
the 5’ UTRM construct observed in myoblasts and myotubes.  The average of four 







(Yoshida et al., 1998) and that alternate isoforms may rescue dystrophin expression and 
function in skeletal but not cardiac muscle.  There are two examples of BMD patients 
with mutations in the DMD 3’ UTR (Greener et al., 2002; McCabe et al., 1989).  
However, these deletions extend into the coding region of the DMD gene or delete other 
neighboring genes, and mutations contained solely within the 3’ UTR have yet to be 
identified.  Although it has been shown that altered expression levels can impact disease 
severity (van Putten et al., 2012; van Putten et al., 2013) and evidence presented here 
supports a role for the DMD 3’ UTR in regulating expression, the identification of these 
mutations suggests that if pathogenic 3’ UTR mutations exist, they would most likely 
cause the milder BMD phenotype.  Another possibility is that mutations in these regions 
cause nonmuscular phenotypes and have been overlooked as disease causing.  For 
example, the dystrophin glycoprotein complex is involved in brain development and 
function (Waite et al., 2012; Waite et al., 2009) and approximately one third of DMD 
patients have cognitive impairments such as reduced intelligence quotient (IQ) scores 
(Cotton et al., 2005), autism spectrum disorder (ASD) and attention deficit hyperactivity 
disorder (ADHD) (Hendriksen and Vles, 2008; Wu et al., 2005).  Recently, a three base 
pair deletion in the coding region of the DMD gene was shown to cause intellectual 
disability, but causing no muscle phenotype (de Brouwer et al., 2014), showing that 
mutations which spare the muscle but have significant impacts in other tissues do exist in 
the DMD gene.  Mutations in either the DMD 5’ or 3’ UTR that alter expression of one or 
more dystrophin isoforms could similarly have tissue specific consequences that are not 
currently appreciated.  





Dp427p) isoforms of DMD revealed that these sequences reduced expression of a 
reporter construct 75-90% in both myoblasts and myotubes. Several factors may affect 
the efficiency of translation initiation, including the presence of upstream open reading 
frames or secondary structures that can limit the number of scanning ribosomes that 
access the initiation codon before initiation. Analysis of the DMD 5’ UTRs reveals 
several upstream AUGs in the 5’ UTRs of the Dp427c and Dp427p1 brain isoforms (11 
and 4 AUGs, respectively) that could alter translation initiation, although there are no 
AUG sequences contained in the muscle Dp427m 5’ UTR.  Once the ribosome engages 
the initiation codon, positions upstream and downstream of the initiation codon determine 
the efficiency of productive translation initiation. The consensus translation initiation 
context in mammals is GCCRCCaugG, originally identified by Marilyn Kozak, and often 
referred to as the Kozak consensus sequence (Kozak, 1986, 1987, 1997). Deviations from 
this consensus, in particular at the -3 or +4 position, have been shown to reduce the 
efficiency of translation initiation (Kozak, 1986, 1997).  The control pHRL-CMV vector 
matches the Kozak consensus sequence, whereas the DMD 5’ UTR and exon 1 isoforms 
alter several key positions (Table 1.1), an observation that likely explains, at least in part, 
the low levels of translation initiation observed when the isoform specific DMD 5’ UTRs, 
initiation codon, and exon 1 were placed upstream of the luciferase reporter gene.  
We show that the DMD 3’ UTR, which is common to all but one mRNA isoform, 
regulates expression during myogenesis.  Specifically, we show that the conserved 
Lemaire A regulates expression by increasing mRNA abundance and translation in 
differentiated myotubes, and that Lemaire D and the surrounding region primarily affects 





entire regions are necessary for the increase in expression observed during differentiation 
of myoblasts into myotubes.  This result is consistent with the high level of conservation 
that spans these regions.  The average sequence identity of 3’ UTRs between human and 
mouse sequences is 74.7% (Waterston et al., 2002).  Lemaire A has the largest effect on 
protein expression in C2C12 cells (the Aa, Ab, and Ac regions), and spans 429 base pairs 
with 97.4% sequence identity, and the Lemaire D region contains a 459 base pair 
sequence with 90.2% sequence identity. These regions are similar to previously described 
HCEs (Dassi et al., 2013; Siepel et al., 2005). HCEs are found across the genome in both 
coding and noncoding regions of genes (Dassi et al., 2013; Forest et al., 2007; 
Sathirapongsasuti et al., 2011; Siepel et al., 2005), are associated with the 3’ UTRs of 
regulatory genes, and may be involved in posttranscriptional gene regulation, alternative 
splicing, and polyadenylation (Dassi et al., 2013; Ho and Gunderson, 2011; 
Sathirapongsasuti et al., 2011; Siepel et al., 2005).  However, the mechanism of how 
HCEs regulate gene expression is still not understood, and the reason the extensive length 
and high conservation of these regions must remain intact is unknown.  The existence of 
multiple adjacent regulatory elements and secondary structure that act cooperatively to 
ensure proper expression could explain the conservation of a sequence larger than a 
single regulatory element.  One example of this is with the U1A gene that contains an 
approximately 53 nucleotide highly conserved region with ~91% sequence identity that 
binds to two U1A proteins and to the U1 snRNP splicing factor immediately upstream 
(Guan et al., 2007).  It is speculated that the existence of multiple binding sites in this 
region explains the conservation seen.  However, even in the presence of multiple protein 





shown for regions as large as HCEs that can span thousands of nucleotides.  The essential 
binding of long noncoding RNAs that spans these regions is another explanation, 
although unlikely as long noncoding RNAs are typically less conserved than protein 
coding genes (Johnsson et al., 2014).  Alternatively, some unknown function of the 
primary sequence yet to be discovered may exist. 
It was shown previously that miRNA-31 could inhibit dystrophin expression by 
binding to a predicted miRNA-31 binding site in the DMD 3’ UTR (Cacchiarelli et al., 
2011).  miRNA-31 is highly expressed in undifferentiated myoblasts where it inhibits 
expression of proteins involved in myogenesis, and is decreased in expression as the cells 
differentiate into myotubes (Cacchiarelli et al., 2011; Daubas et al., 2009). In our 
experiments, deleting the miRNA-31 binding site did not result in an increase in 
expression in C2C12 myotubes (Figure 1.8) suggesting that miRNA-31 does not repress 
dystrophin expression in C2C12 myotubes, and may only be repressing dystrophin 
expression in myoblasts and in disease tissue (Cacchiarelli et al., 2011) where miRNA-31 
is highly expressed.  This result does not necessarily conflict with the results of the 
previous study.  The authors of the previous study show that miRNA-31 is overexpressed 
in DMD cells and that miRNA-31 can alter dystrophin expression in cells expressing 
high levels of miRNA-31 (Cacchiarelli et al., 2011).  However, during differentiation of 
wild type muscle cells miRNA-31 levels decrease (Cacchiarelli et al., 2011) and our 
results suggest that miRNA-31 does not suppress dystrophin expression in differentiated 
cells where dystrophin expression is high.  Instead, other regulatory elements may exist 
in this region that increase dystrophin expression as the cells differentiate.  Our results do 





tissue types or in conditions where miRNA-31 is highly expressed.  A conflict does exist, 
however, in our results in C2C12 myoblasts.  The authors of the previous study show a 
~30% increase in expression of their reporter construct when the miRNA-31 site was 
deleted (Cacchiarelli et al., 2011), whereas we saw no significant change in expression 
(Figure 1.8).  Differences between the two experiments could account for the different 
results between the two studies, such as the different cell types or reporter constructs 
used.  For example, the C2 cells used by the previous authors show diminished 
differentiation, lower MyoD levels, and higher protein expression levels compared to the 
C2C12 cells used in our experiments (Sharples et al., 2010), and the effects we measured 
were highly dependent on the stage of differentiation with the greatest effects seen at later 
stages of differentiation.  The biological relevance of miRNA-31 in myoblasts is unclear 
because muscle dystrophin is not expressed in these cells.  Although miRNA-31 could be 
contributing to the suppression of the muscle isoform of dystrophin in undifferentiated 
cells or be acting on other dystrophin isoforms. 
In vitro experimental evidence has also been presented for binding of the protein 
vigilin to the Lemaire D region of the DMD 3’ UTR (Kanamori et al., 1998). However, in 
our experiments, we saw no difference in expression when we introduced mutations 
shown previously to prevent vigilin binding (Kanamori et al., 1998), suggesting that 
vigilin is not regulating dystrophin expression in cultured muscle cells.  While our 
experiments do not rule out the possibility that vigilin may be regulating dystrophin 
expression in other tissues or during other developmental stages, we find no evidence that 
vigilin is functioning through the 3’ UTR in differentiated C2C12 myotubes.   





they have in muscular dystrophies has become apparent in recent studies (Bovolenta et 
al., 2012; Cesana et al., 2011; Erriquez et al., 2013; Hube et al., 2011).  Several long 
noncoding RNAs transcribed from within the DMD gene and expressed during myogenic 
differentiation were shown to suppress endogenous dystrophin mRNA levels in 
Rhabdomyosarcoma and neuroblastoma cells when overexpressed (Bovolenta et al., 
2012).  In addition, several of these lncRNAs suppressed the expression of a luciferase 
reporter driven by the Dp427m promoter in C2C12 myoblasts (Bovolenta et al., 2012).  A 
1,872 bp lncRNA transcribed in the antisense orientation from the middle region of the 
DMD 3’ UTR was identified. While this lncRNA does not suppress dystrophin mRNA 
expression in these cell types (Bovolenta et al., 2012), we find that deleting the middle 
region of the DMD 3’ UTR increases mRNA and protein levels by ~40-50% in 
undifferentiated C2C12 myoblasts, consistent with the prediction that this lncRNA could 
inhibit dystrophin expression in myoblasts by annealing to the complementary region of 
the 3’ UTR. It should be noted that this effect is only observed in undifferentiated 
myoblasts, and that deletions within the middle region either had no effect or reduced 
expression in differentiated myotubes. 
DMD has been a model for developing genetic therapies to treat inherited genetic 
mutations, including approaches using antisense oligonucleotides to cause exon skipping 
of dystrophin to restore the reading frame of a mutant transcript, treating patients with 
drugs that promote readthrough to suppress premature stop codon mutations, and 
expression of minidystrophin gene constructs lacking nonessential DMD coding exons 
(Fairclough et al., 2013; Muir and Chamberlain, 2009; Pichavant et al., 2011).  Clinical 





mutations, have shown that these compounds can restore dystrophin expression in the 
majority of muscle fibers of treated muscle (Goemans et al., 2011; Kinali et al., 2009; 
Mendell et al., 2013; van Deutekom et al., 2007).  However, the total amount of 
dystrophin expressed in muscle tissue of these patients is highly variable between patients 
and typically results in less than 20% dystrophin levels compared to normal controls 
(Cirak et al., 2011; Goemans et al., 2011; Kinali et al., 2009; van Deutekom et al., 2007).  
Sequence variations in genomic regions regulating dystrophin expression, such as the 
DMD UTRs, could account for some of this variability.  It has also been shown that 
stability of the DMD transcript has a large impact on dystrophin protein levels in BMD 
patients and increasing stability could improve the outcome of therapies such as exon 
skipping (Spitali et al., 2013).  We have shown evidence that the DMD 3’ UTR has an 
effect on mRNA stability (Appendix A) and protein levels and could have an impact on 
these developing therapies.  In addition, restoring dystrophin expression by viral gene 
therapy has shown promise, but has been challenging because the 14 kb dystrophin 
transcript is too large to insert into viral vectors.  To overcome this, minidystrophin 
constructs (~3-8 kb) have been designed that contain the most essential domains of the 
DMD coding sequence that would express functional dystrophin (Fabb et al., 2002; 
Foster et al., 2012; Foster et al., 2008; Koo et al., 2011a; Koo et al., 2011b; Rodino-
Klapac et al., 2010; Wang et al., 2000; Wang et al., 2007; Wang et al., 2012).  Our results 
suggest that inclusion of the regulatory elements of the DMD 3’ UTR into these 
minidystrophin constructs could increase expression in differentiated muscle cells.  From 
our experiments, we estimate that the smallest DMD 3’ UTR that could be utilized 





the highly conserved Lemaire A and D regions of the 3’ UTR. 
In summary, we show the ability of the DMD 5’ and 3’ UTR to regulate gene 
expression during myogenesis. Patient specific variations in these regulatory elements 
may influence DMD expression and as a consequence explain some of the variation 
observed in disease phenotypes as well as the variable effectiveness of therapeutic 
approaches designed to restore endogenous dystrophin synthesis. Further, we propose 
that regulatory elements in the DMD 5’ and 3’ UTRs may be exploited for therapeutic 
purposes. For example, increasing the inherent low translation initiation efficiency 
imparted by the DMD 5’ UTRs or using the regulatory elements found within the 3’ UTR 
to increase expression in gene replacement therapy may be promising new approaches to 
increase dystrophin synthesis. 
 
Materials and methods 
Cell Culture 
Mouse C2C12 myoblast cells were purchased from ATCC (CRL-1772).  C2C12 
myoblasts were cultured in growth medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone).  Myogenic differentiation was induced by replacing the medium of the C2C12 
myoblasts with DMEM/F-12 media supplemented with 2% horse serum (Sigma).  In our 
studies, myoblasts were examined 2 days after being transfected, whereas myotubes were 
analyzed after 6 days in differentiation media unless otherwise stated.  HEK 293 cells 
were obtained from ATCC (CRL-1573), and cultured in growth medium consisting of 
Minimum Essential Medium (MEM, Life Technologies) supplemented with 10% FBS 





(NEAA, Gibco).  All cells were cultured at 37°C and 5% CO2. 
 
Generation of DMD 5’ and 3’ UTR reporter constructs  
and mutagenesis 
The full length DMD 3’ UTR was amplified from a European human genomic 
DNA sample using PCR and the following specific primers 
GCCGCTTCCTAGGAGGAAGTCTTTTCCACATGGC and 
GCTCATGGGATCCGCATGTATTACCTATTTAAAAAGTAAGTAAGTAAG that 
include an overhang containing the sequence of AvrII and BamH1 restriction sites, 
respectively.  The resulting 2,811 bp PCR product was digested with XbaI and AvrII and 
ligated into the XbaI and BamHI restriction sites of pHRL-CMV (Promega) immediately 
downstream of the Renilla Luciferase ORF. The resulting plasmid contains the human 
DMD 3’ UTR in place of the SV40 polyA region of the pHRL-CMV vector.  The DMD 
3’ UTR was inserted in the reverse orientation as described above except that the 3’ UTR 
from genomic DNA was amplified using a forward primer containing the BamH1 
restriction site and the reverse primer containing the AvrII restriction site.   
The Dp427m, Dp427c, and Dp427p1 5’ UTRs and surrounding regions were 
amplified from a human European genomic DNA sample using PCR and primers specific 
to each region (Table 1.2).  The resulting PCR products were used as a template for a 
second PCR that amplified the Dp427m, Dp427c, and Dp427p1 5 ‘UTRs using primers 
specific to each 5’ UTR and containing overhang sequences with the KpnI and XhoI cut 
sites in the forward and reverse primers, respectively (Table 1.2).  The pHRL-CMV 
vector containing the DMD 3’ UTR (3’ UTR construct) was amplified using primers that 





















KpnI cut site in the reverse primer, and an XhoI cut site and the Dp427m, Dp427c, or 
Dp427p exon 1 in the forward primer (Table 1.2).  The amplified 5’ UTR products were 
digested with KpnI and XhoI and ligated into the amplified 3’ UTR vectors containing 
the exon 1 isoforms.  The resulting XhoI cut site found between the DMD 5’ UTRs and 
the coding sequence was removed using the Phusion Site Directed Mutagenesis Kit 
(Thermo Scientific), as specified by the manufacturer using phosphorylated primers 
specific for each construct (Table 1.2).  Deletion constructs were made using the Phusion 
Site Directed Mutagenesis Kit (Thermo Scientific), as specified by the manufacturer 
using the DMD 3’ UTR construct as a template and phosphorylated primers specific for 
each deletion (Table 1.3).  For all subsequent experiments, plasmid DNA was prepared 
using QIAGEN kits. The miRNA-31 deletion construct was made using the Phusion Site 











full length DMD 3’ UTR construct as a template and the phosphorylated primers 
TTTCTTTATATGGAACGCATTTTG and 
TTTTACATGTAGTTTTCTTATAACTTTTTTGTA. C2C12 transfections and 
expression level measurements using the Renilla/Firefly dual luciferase assay were done 
as previously described. 
A DMD 3’ UTR construct containing six point mutations in the predicted vigilin 
binding site as previously described (Kanamori et al., 1998) was made by amplifying the 
3’ UTR construct using PCR and two sets of primers containing the desired nucleotide 
changes.  Specifically, the DMD 3’ UTR construct was first amplified using the primers 
CATACTTCACCAAGTATATGCCTTACTATTATATTATAGTACTG and 
ACTGAAGTTTACAAAAATAATTTGTAAATGTTACAGTGTTGG (desired 
mutations underlined), and the purified product was amplified a second time using the 
phosphorylated primers AACATATCATACTTCACCAAGTATATGCCTTACTATTA 
and  GCGAAAATGCAGTAAAACTGAAGTTTAC (desired mutations underlined).  





Biolabs) according to the manufacturer’s instructions.  All constructs described in the 
materials and methods were sequence verified. 
 
Dual luciferase reporter assay 
 C2C12 myoblasts (1x104 cells) or HEK 293 cells (4x104 cells) were transfected 
with 25 ng of the pHRL-CMV vector (Promega) containing either the full length DMD 3’ 
UTR or a mutant 3’ UTR construct using 0.3uL of Lipofectamine 2000 reagent (Life 
Technologies) in 96 well half area plates (Corning) with 0.16 cm2 growth area.  All 
reactions were co transfected with 6.25 ng of the pGL4.13 [luc2/SV40] Firefly Luciferase 
vector (Promega) as a transfection control.  To measure luciferase activity levels in 
myoblasts, cells were harvested 48 hours after transfection by adding 14 uL of a passive 
lysis buffer (Promega).  To measure luciferase activity levels in myotubes, the growth 
media for C2C12 myoblasts was replaced 48 hours after transfection with a low serum 
media to induce differentiation.  The differentiated myotubes were harvested after 6 days 
in differentiation media by adding 14 uL of a passive lysis buffer (Promega).  C2C12 
myoblasts and myotubes underwent one freeze-thaw cycle to aid in lysis.  The 
bioluminescence of Renilla and firefly luciferase was measured using the Dual Luciferase 
Reporter Assay System (Promega) in a Veritas Microplate Luminometer (Turner 
Biosystems) to determine luciferase levels, and the Renilla luciferase signal was 
normalized to the pGL4.13 firefly luciferase signal in each well to account for variation 
in transfection efficiency.  All transfections presented in the paper are expressed as the 
average +/- 1 standard deviation from a representative experiment with at least four 






Determining mRNA levels of 3’ UTR constructs 
 To determine the relative amounts of mRNA levels for the DMD 3’ UTR 
construct and deletion constructs, C2C12 myoblasts (6x105 cells) were transfected with 
750 ng of a 3’ UTR construct and 750 ng of the control pHRL construct using 18 uL of 
Lipofectamine 2000 in a 24 well tissue culture plate (Falcon) with 2 cm2 growth area.  
Total RNA was extracted from C2C12 cells 2 days after transfection (myoblasts) or after 
C2C12 cells had differentiated for 6 days in a low serum media (myotubes) using Trizol 
(Invitrogen) as described by the manufacturer.  Each RNA sample was treated with 
DNAse I (Thermo Scientific) to remove any DNA contamination, and cDNA was 
synthesized using the SuperScript III First Strand Synthesis Kit (Life Technologies) using 
random hexamers.  Real-time PCR was performed using the Applied Biosystems 7900HT 
Real time PCR system using Express SYBR GreenER qPCR SuperMix (Life 
Technologies) with primers optimized to amplify each construct according to the 
manufacturer’s protocols.  Results were analyzed using SDS 2.3 software and calculated 
using the comparative CT (ΔΔCT) method by normalizing the transfected construct levels 
to the control pHRL cotransfected construct value at 100%.  The forward and reverse 
primers used to amplify the cDNA of each construct are as follows:  
GCAACTACAACGCCTACCTT and TGGTTTGTCCAAACTCATCAA used to 
amplify the cotransfected pHRL vector; CTGAGGAGTTCGCTGCCTAC and 
GCCATGTGGAAAAGACTTCC to measure the full length 3’ UTR, dl-M, and dl-D 
constructs; CTGAGGAGTTCGCTGCCTAC and CCCCACTCAGCTGACAGTTC to 






Calculating percent sequence identity 
 To determine the percent sequence identity between human and mouse sequences 
in the DMD 3’ UTR, the human and mouse Lemaire A region, Lemaire D region, or the 
full length 3’ UTR were aligned in ClustalW.  The percent sequence identity was 
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ANALYSIS OF HUMAN 3’ UTR VARIANTS  
 




 Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) 
are both caused by mutations in the DMD gene.  Although a correlation between 
dystrophin protein or mRNA levels and disease severity is known, the posttranscriptional 
regulation of dystrophin has largely been unexplored.  We have shown in Chapter 1 that 
two highly conserved elements (HCEs) overlapping Lemaire A and D in the DMD 3’ 
UTR can regulate expression during differentiation in C2C12 cells.  The regions of the 3’ 
UTR affecting expression are consistent with the conservation of the 3’ UTR, but the 
mechanism of how these regions function and how it relates to human disease are 
unknown.  To date, no well defined human DMD 3’ UTR mutations have been identified, 
although a very small percent of human DMD and BMD patients have been identified 
that have no mutations in the coding region of the DMD gene, suggesting the possibility 
of mutations in noncoding regions of the gene.  Here, we characterize the variants in the 
DMD 3’UTR from a population of 1,222 humans that include DMD and BMD patients 
with no DMD coding mutations to determine if disease causing DMD 3’ UTR mutations 
exist.  We conclude that a disease causing mutation in the 3’ UTR in this population is 




when a second mutation is present or cause a disease phenotype in nonmuscular tissues.  
We also use a dual luciferase assay and an RNA protein hybridization assay to analyze 
the first 150 nucleotides of the HCE overlapping Lemaire A to better understand how 
these regions are functioning.  We found that this portion of Lemaire A is sufficient in 
itself to increase expression in C2C12 cells although with a different expression pattern 
than when the entire Lemaire A is present, suggesting that Lemaire A is composed of 
multiple regulatory elements that work cooperatively to regulate dystrophin expression.  
We also present evidence that this region binds to a ~36 kDa protein and an ~85 kDa 
protein.   
 
Introduction 
Duchenne muscular dystrophy (DMD) and the milder Becker muscular dystrophy 
(BMD) are both caused by mutations in the DMD gene (Koenig et al., 1987; Muntoni et 
al., 2003).  DMD patients experience progressive and severe muscle degeneration, and 
can die as early as the late teens or early 20s as the intercostal and cardiac muscles begin 
to be affected.  BMD patients experience muscle degeneration and weakness similar to 
Duchenne muscular dystrophy but at a much slower rate, and can typically survive into 
the fourth or fifth decades of life.  The severity of disease amongst BMD patients is 
highly variable.  Onset of clinical symptoms can begin around 12 years of age, but some 
patients do not show symptoms until late adulthood.  Likewise, human clinical trials 
using compounds to restore dystrophin expression in muscle tissue have shown success, 
but the restored dystrophin levels are highly variable between patients and typically result 
in less than 20% dystrophin levels compared to normal controls (Cirak et al., 2011; 
Goemans et al., 2011; Kinali et al., 2009; van Deutekom et al., 2007).  There is also a 
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correlation between dystrophin protein and mRNA levels and disease severity (Spitali et 
al., 2013; van Putten et al., 2012; van Putten et al., 2013).  These observations have 
important implications, not only for determining the prognosis of a patient, but also in the 
effectiveness of developing therapeutic treatments aimed at restoring dystrophin 
expression in DMD patients (Fairclough et al., 2013; Muir and Chamberlain, 2009; 
Pichavant et al., 2011).  Variation in regulatory factors involved in dystrophin expression 
could account for some of the variation in disease severity seen in human patients and 
impact the effectiveness of developing treatments. 
While tissue specific distribution and transcriptional regulation of DMD mRNA 
isoforms have been well characterized, the posttranscriptional regulation of dystrophin 
synthesis is not well understood.  3’ UTRs are known to regulate gene expression 
posttranscriptionally by altering mRNA stability, localizing mRNA, or directly affecting 
translation (Andreassi and Riccio, 2009; Gramolini et al., 2001; Matoulkova et al., 2012; 
Mazumder et al., 2003), and we were able to show that the DMD 3’UTR regulates 
expression during C2C12 cell differentiation (Chapter 1).  We identified two highly 
conserved regions that overlap and extend beyond the previously described Lemaire A 
and D regions of the 3’ UTR that increase translation and mRNA abundance in C2C12 
myotubes (Chapter 1).  Using deletion mutagenesis, we were unable to narrow down the 
regulatory sequences within these regions below ~400 base pairs because deleting any 
portion of the highly conserved Lemaire A or D regions resulted in decreased expression 
equal to or greater than the expression when the entire element was deleted.  Thus, the 
entire element must remain intact for proper function.  It is unclear from these 
experiments whether the entire sequence encompasses a single regulatory element that 
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must remain intact to increase expression or if these regions contain several regulatory 
elements acting cooperatively to regulate dystrophin expression. 
Regions of similar size and conservation as these highly conserved regions in the 
DMD 3’ UTR have been described in the literature, although the nomenclature of these 
regions has not been well defined.  These regions have been referred to as highly 
conserved elements (HCEs) (Siepel et al., 2005); hyper conserved elements (HCEs) 
(Dassi et al., 2013); conserved fragments (CFs) (Ho and Gunderson, 2011); and ultra 
conserved elements (UCEs) (Bejerano et al., 2004), but, in general, refer to sequences 
that are 100% or nearly 100% conserved between human and mouse sequences and span 
anywhere from 50 nucleotides to several thousand nucleotides.  Throughout this 
dissertation, I will refer to these elements as highly conserved elements (HCEs) defined 
as unusually large sequences in the genome that exceed the conservation seen in the 
protein coding regions of genes, which encompasses the range of definitions that have 
been used to describe these elements. 
A genome wide analysis that ranked HCEs based on conservation found that of 
the top 5000 elements, 42% overlapped protein coding exons, 9% overlapped 5’ UTRs, 
16% overlapped 3’ UTRs, 19% were contained within introns, and 32% were in 
unannotated regions (Siepel et al., 2005).  This analysis identified 10 HCEs in the DMD 
3’ UTR including two large HCEs that span the Lemaire A and Lemaire D regions 
(Siepel et al., 2005).  This study also showed that 3’ UTRs throughout the genome were 
enriched for HCEs.  3’ UTRs accounted for 5.6% of all conserved bases analyzed in this 
study, but 9.6% of bases in the top 5000 conserved elements, and 14.3% of bases in the 
top 100 elements were found in 3’ UTRs (Siepel et al., 2005).  Despite the enrichment of 
74 
 
HCEs in 3’ UTRs, they are still rarely seen.  Only 1.8% of all human 3’ UTRs contain at 
least one HCE, and collectively, HCEs account for 0.47% of total 3’ UTR sequence 
(Dassi et al., 2013).  3’ UTR HCEs have an average length of 100 bases, with 77% of all 
HCEs being shorter than 100 bases, and only 4.5% of them being larger than 500 bases 
(Dassi et al., 2013).  3’ UTR HCEs tend to localize into clusters when multiple HCEs are 
present in the same 3’ UTR, and are more enriched at the beginning of the 3’ UTR with 
25% of HCEs starting within the first 10% of the 3’ UTR (Dassi et al., 2013).  The HCE 
overlapping Lemaire A in the DMD 3’ UTR spans 429 base pairs with 97.4% sequence 
identity between human and mouse sequences with sections up to 124 base pairs with 
100% conservation, and begins immediately after the stop codon.  The HCE overlapping 
Lemaire D at the end of the 3’ UTR is less conserved with 90% sequence identity 
spanning a 459 base pair region with segments up to 49 base pairs with 100% 
conservation, although the sequence identity increases to 97.8% for the last 184 base 
pairs of this region. 
The mechanism of how 3’ UTR HCEs function is not well understood, but HCEs  
have been shown to be enriched in genes involved in the ubiquitin cycle, RNA binding, 
mRNA metabolism, and mRNA processing (Siepel et al., 2005), and functional evidence 
suggests that HCEs are involved in posttranscriptional gene regulation, alternative 
splicing, and polyadenlyation (Dassi et al., 2013; Ho and Gunderson, 2011; 
Sathirapongsasuti et al., 2011; Siepel et al., 2005).  It is not clear why such large 
noncoding regions remain conserved, but analysis of these regions suggests that 3’ UTR 
HCEs contain far more secondary structure than random 3’ UTR sequences (Dassi et al., 
2013; Siepel et al., 2005), and may contain biologically relevant structure.  These regions 
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may also function by interacting with miRNA or RNA binding proteins.  There is 
evidence that miRNAs regulate HCEs and genes containing HCEs (Calin et al., 2007; 
Sathirapongsasuti et al., 2011).  However, 3’ UTR sequences lying outside of HCEs are 
more enriched in predicted miRNA binding sites than 3’ UTR HCEs with only 1.6% of 
HCEs analyzed in one large study containing at least one predicted miRNA binding site 
(Dassi et al., 2013).  There is evidence that 3’ UTR HCEs bind to proteins.  There is 
enrichment for experimentally identified binding sites for RNA binding proteins in 3’ 
UTR HCEs, and at least one example where the RNA binding protein HuR regulates a 
network of genes by binding to 3’ UTR HCEs (Dassi et al., 2013).  The only 
experimental evidence of a miRNA or RNA binding protein binding to the DMD 3’ UTR 
HCEs is for miRNA-31 and RNA binding protein vigilin, but our results in Chapter 1 
suggest that these factors are not involved in the increased expression seen during C2C12 
differentiation.  However, there are several predicted RNA binding protein and miRNA 
binding sites in the conserved regions of the DMD 3’ UTR (Appendix B) that could 
potentially be functional in regulating dystrophin expression. 
Mutations in 3’ UTRs have been associated with several diseases in humans, 
including point mutations and small insertions/deletions that are disease causing, disease 
predisposing, or disease modifying (Chen et al., 2006a, b).  3’ UTR mutations have been 
shown to cause disease by altering the polyadenylation signal, predicted secondary 
structure, or predicted binding sites for miRNAs or RNA binding proteins (Chen et al., 
2006a, b).  Select examples in humans where even a small change in a 3’ UTR can cause 
disease include a T>C point mutation in the selenocysteine insertion sequence (SECIS) in 
the 3’ UTR of the SEPN1 gene that causes a mild form of rigid spine muscular dystrophy 
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(Allamand et al., 2006), a C>T polymorphism in an AU rich element in the TGFB3 gene 
shown to cause atypical arrhythmogenic right ventricular dysplasia (ARVD) and to 
increase reporter gene activity in C2C12 myoblasts (Beffagna et al., 2005), and, finally, a 
G>A transition in a predicted binding site for miRNA-189 in the 3’ UTR of the SLITRK1 
gene that was associated with Tourette’s Syndrome and shown to decrease expression of 
a reporter construct (Abelson et al., 2005).  For a comprehensive list of disease associated 
3’ UTR mutations, see the review (Chen et al., 2006a, b). 
The effect the DMD 3’ UTR has on human disease is unknown.  Thus far, no well 
defined disease causing mutations have been identified in the DMD 3’ UTR in human 
DMD or BMD patients.  There are two examples of BMD patients (Greener et al., 2002; 
McCabe et al., 1989) and two examples of DMD patients (Pillers et al., 1990; Todorova 
et al., 2008) with deletions that span the DMD 3’ UTR.  However, these deletions extend 
into the coding region of the DMD gene, delete other neighboring genes, or have not been 
fully analyzed to determine the extent of the deletion, and disease causing mutations 
shown to be contained solely within the 3’ UTR have yet to be identified.  However, 
there is a small group of human patients (0.2% in one large study) (Flanigan et al., 2009) 
where dystrophin expression is absent, but no DMD mutations exist in the coding region 
of the gene.  It is possible that a subset of these patients has disease causing mutations in 
noncoding regions of the gene that has been overlooked by standard mutation screens. 
Here, we analyzed DMD 3’ UTR sequences from a population of 1,222 humans 
that include several DMD and BMD patients with no DMD coding mutations, and 
characterize the variants found in this population and other publicly available databases 
to determine the likelihood of a disease causing 3’ UTR mutation existing in this group.  
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To better understand how the Lemaire A region regulates expression, we also conduct a 
more thorough analysis of the first 150 base pairs of the Lemaire A region (termed the Aa 
region).  We have shown in Chapter 1 that this Aa region is necessary for the increased 
expression of a reporter construct in C2C12 myotubes, and that the decrease in 
expression when this region is deleted is equal to the decrease when the entire Lemaire A 
region is deleted.  We investigate whether the Aa region alone is sufficient to regulate 
expression in C2C12 cells. We also attempt to narrow down the regulatory sequences 
contained in this region by subdividing the region into smaller portions, and investigate 
the potential of RNA binding proteins to bind to this region.   
We show that the first 150 base pairs of the Lemaire A region are sufficient to 
increase expression in C2C12 cells, and show evidence that a ~36 kDa protein and an 
~85 kDa protein can bind to the distal portion of the Aa region, suggesting that the 
Lemaire A region contains multiple regulatory elements and may be interacting with 
RNA binding proteins.  In our analysis of human 3’ UTR variants, we conclude that a 
disease causing mutation in the DMD 3’ UTR is unlikely to exist in the group of patients 
analyzed.  We show that the only human variant in this population found at a predicted 
protein binding site in the Aa region in our DMD population (where a T nucleotide is 
inserted at a predicted HuR binding site) does not alter expression in C2C12 cells.  
However, we could not rule out the possibility that variants contained within the highly 
conserved regions of the 3’ UTR could act as modifying mutations that alter the disease 
phenotype when other mutations are present or cause a disease phenotype in nonmuscular 






Characterization of DMD 3’ UTR variants in humans 
 To characterize the human variants in the DMD 3’ UTR and to determine if 
disease causing mutations exist in the DMD 3’ UTR, we obtained sequences from Dr. 
Robert Weiss (University of Utah, Human Genetics Department) of 1,222 human DMD 
3’ UTRs from three groups of patients that included DMD and BMD patients that had no 
DMD coding mutations (NODCM).  Sequences from 410 patients were obtained from 
patients enrolled in the United Dystrophinopathy Project (UDP), a registry of DMD and 
BMD patient information with identified DMD mutations that is managed by Dr. Kevin 
Flanigan (Nationwide Children’s Hospital, Columbus, OH).  This group contained 51 
NODCM patients.  Sequences from 569 patients were obtained from clinical referrals 
from doctors who had requested DMD mutation screening for individuals suspected to be 
dystrophic, and this group contained 189 NODCM patients.  Sequences from 243 patients 
were obtained from a newborn screening study that screened for DMD mutations in 
infants with high creatine kinase (CK) levels (Mendell et al., 2012).  Most of these infants 
were not dystrophic and had no DMD mutations (Mendell et al., 2012) with 228 of these 
patients identified as NODCM patients.  The sequences from all patients were analyzed 
and any discrepancy between a patient sequence and a reference sequence 
(NM_004006.2) was visually inspected to determine the quality of the trace.  All variants 
identified were named using the Human Genome Variation Society (HGVS) guidelines 
and recommendations for variant nomenclature (den Dunnen and Antonarakis, 2000).  
We verified 1,377 discrepancies that consisted of 84 unique variants in the DMD 3’ UTR 














Figure 2.1.  Human variation in the DMD 3’ UTR. 
Diagram of the DMD 3’ UTR SNPs and small insertions and deletions (Indels) found in 
444 human DMD patients is shown.  The cDNA DMD 3’ UTR position along with the 
PhastCons conservation scores along the length of the 3’ UTR is depicted on the X axis.  
Peak heights are equal to the number of 3’ UTRs found for each variant.  Variants found 







































variants reported in publicly available databases, and found a total of 83 variants in the 
current version of dbSNP (Sherry et al., 2001), 40 variants in the 1000 Genome database 
(Abecasis et al., 2012), and 38 variants reported in the Leiden Database (Aartsma-Rus et 
al., 2006) (Appendix B).  There were 56 additional variants found in these public 
databases that were not found in our patient population, and 40 variants found exclusively 
in the patients we analyzed.  In total, 140 unique 3’ UTR variants were identified in our 
patient population and all databases searched (Appendix B).  Although most of these 
variants are found in unconserved regions of the DMD 3’ UTR, several are found in 
conserved regions and predicted binding sites for RNA binding proteins or miRNAs 
(Figure 2.1, Appendix B). 
To determine which variants would most likely be disease causing mutations, we 
searched for unique variants found in patients described as having a disease phenotype, 
but that had no mutations found in the coding region of the DMD gene (NODCM 
patients) (Appendix B).  We identified 21 variants in the 3’ UTR that were found only in 
NODCM patients (Appendix B).  We filtered this list down to eight variants amongst 
nine NODCM patients where the variant was located in a conserved region of the 3’ UTR 
(Table 2.1).  Four of these patients were from the newborn screening study that collected 
bloodspots from infants with high creatine kinase (CK) levels (Mendell et al., 2012). 
All infants with confirmed DMD mutations in this study had CK levels over 2000 U/l 
(Mendell et al., 2012), whereas these four patients in our analysis had CK levels less than 
1000 U/l or had no known CK values (Table 2.2), and are likely not dystrophic.  The 
variants in these newborns are likely not disease causing mutations.  There is limited 









Note:  The DMD 3’ UTR variants identified in our patient population that were found 
only in patients with no DMD coding mutations and in a conserved region are shown.  
Patients containing these variants are shown.  Patients identifiers that start with “DOBS” 
were patients a newborn screening study (Mendell et al., 2012).  Patient identifiers that 
start with “DC” are patients from clinical referrals.  Both the 3’ UTR nucleotide position 















include an Asian Indian, an African American, two Hispanics, and a Caucasian (Table 
2.2).  Most 3’ UTR sequences we obtained were from Caucasians, and these variants 
could be common in other populations.  Testing for duplications using MLPA was not 
done on two of these patients, and one patient has a possible mutation near exon 32 that 
might create a cryptic splice acceptor (Table 2.2), evidence that a few of these patients 
could have disease causing mutations outside of the 3’ UTR.  We could not identify any 
clear disease causing mutations from our analysis of human DMD 3’ UTRs.  However, it 
is possible that variants in the DMD 3’ UTR could act as modifier mutations that affect 
disease severity when a second mutation is present.  Unfortunately, we could not obtain a 
big enough cohort of patients with 3’ UTR sequences and concise clinical information to 
investigate whether a human 3’ UTR variant is associated with disease severity in DMD 
and BMD patients.  Because of this, we took an experimental approach to better 
understand the mechanism of how the conserved regions in the 3’ UTR function, and to 
determine which variants or predicted binding sites of miRNAs or RNA binding proteins 
would most likely effect dystrophin expression and be associated with disease.  Due to 
the large size of conserved regions in the DMD 3’ UTR, we chose to focus our analysis 
on the first 150 base pairs of Lemaire A, (called the Aa region in Chapter 1).  Lemaire A 
contains several human variants and predicted binding sites for miRNAs and RNA 
binding proteins (Figure 2.2, Appendix B) that could potentially impact dystrophin 
expression when mutated.  
 
The Aa region is sufficient to increase expression in C2C12 cells 
Previously, we showed that protein expression decreased by ~70% in C2C12 





















Figure 2.2.  Variation and predicted binding sites in Lemaire A. 
 
The location of human variants and predicted binding sites for RNA binding proteins and 
miRNAs in Lemaire A of the DMD 3’ UTR is shown.  Lemaire A was broken down into 
three regions (Aa, Ab, and Ac), with the Aa region being subdivided into four parts (Aa1, 
Aa2, Aa3, and Aa4).  Human variants were identified in our patient population and in 
publicly available databases (see Appendix B).  Predicted RNA binding protein binding 
sites were obtained using the RNA Binding Protein DataBase (RBPDB) (Cook et al., 
2011).  Predicted miRNA binding sites were obtained using TargetScan (Lewis et al., 
2005).  Vertebrate conservation of Lemaire A was obtained from the Vertebrate 




































































same decrease was observed when only the first 150 nucleotides of Lemaire A was 
deleted (Aa region) (Chapter 1), showing that this region is necessary for the increase in 
expression seen during C2C12 differentiation.  However, deleting regions downstream 
had a similar effect on expression and it is unclear whether the Lemaire A region consists 
of one large regulatory element that must remain intact, or multiple regulatory elements 
cooperatively regulating expression.  To determine whether distinct regulatory elements 
exist within the sequence of the Aa region of the 3’ UTR, and whether it is sufficient to 
increase expression during differentiation, the Aa region was inserted into the SV40 3’ 
UTR in the pHRL construct (pHRL-Aa, Figure 2.3A), transfected into C2C12 myoblasts 
and myotubes, and analyzed using a Renilla/Firefly dual luciferase assay (Figure 2.3B 
and 2.3C, Materials and methods).  All transfections were cotransfected with a Firefly 
construct to normalize for transfection efficiency.  Inserting the Aa region into the pHRL 
construct (pHRL-Aa) increased expression of the construct by ~100% in C2C12 
myoblasts, whereas the full length DMD 3’ UTR (3’ UTR) decreased expression by 
~45% (Figure 2.3B).  In C2C12 myotubes, the Aa region increased expression to 150% 
compared to the control pHRL construct, whereas the full length 3’ UTR construct 
increased expression to ~250%, showing that the Aa region is sufficient to increase 
expression in both C2C12 myoblasts and myotubes, but other regions of the 3’ UTR 
suppress or enhance this effect in myoblasts and myotubes, respectively.  A pHRL 
construct containing only the Lemaire A region of the DMD 3’ UTR (A) only increased 
expression in C2C12 myotubes (Figure 2.3C).  Deleting the Aa region did not affect 
expression in C2C12 myoblasts (Chapter 1), showing that the increased expression due to 










Figure 2.3.  The Aa region increases expression in C2C12 myoblasts and myotubes. 
 
A.  Schematic of the control pHRL-CMV vector (pHRL), the full length DMD 3’UTR 
Renilla construct (3’ UTR), the pHRL-CMV vector with the Aa region inserted in the 3’ 
UTR (pHRL-Aa), and the pHRL vector with the Lemaire A region as a 3’ UTR (A) is 
shown.  The DMD 3’ UTR can be divided into three major regions containing the highly 
conserved Lemaire A and D regions (A and D, respectively) and the less conserved 
middle region (M).  The Aa region consists of the first 150 base pairs of Lemaire A.  The 
pHRL and pHRL-Aa constructs have an intact SV40 polyA region, whereas the 3’UTR 
and A constructs have an intact DMD 3’ UTR polyA region. 
B.  Relative expression of these constructs transfected into C2C12 myoblasts is shown.  
Expression levels were measured using a dual luciferase assay to measure the relative 
amounts of Renilla to Firefly protein levels.  The results of three biological replicates are 
shown and normalized to the amount of pHRL expression.  Error bars equal +/- 1 
standard deviation. 
C.  Relative expression of the constructs transfected into C2C12 myotubes is shown.  The 
results of three biological replicates are shown and normalized to the amount of pHRL 




































there are additional regions outside the Aa region in the 3’ UTR that suppress expression 
in C2C12 myoblasts but increase expression in myotubes. 
 
Size and location of deletions in the Aa region affect  
expression in C2C12 myotubes 
 To determine which sequences in the Aa region of the DMD 3’UTR were 
necessary for the increase in expression seen in C2C12 myotubes, the Aa region was 
subdivided into ~35-40 base pair sections (Aa1, Aa2, Aa3, and Aa4), and 3’ UTR 
deletion constructs were made deleting several variations of these regions (Figure 2.4A).  
These constructs were transfected into C2C12 myoblasts and myotubes, and expression 
levels were determined using a Renilla/Firefly dual luciferase assay as previously 
described.  Deleting the entire Aa region or any combination of Aa sections had little 
impact on expression in C2C12 myoblasts compared to the full length 3’ UTR construct 
(Figure 2.4B), but deleting portions of the Aa region in C2C12 myotubes had variable 
effects on protein expression (Figure 2.4C).  We made deletions of increasing size of the 
Aa region (Aa1, Aa1-2, and Aa1-3) and found that deleting the Aa1 region (dl-Aa1) had  
no significant effect on expression, deleting the Aa1 and Aa2 region (dl-Aa1-2) 
decreased expression by ~15%, and deleting Aa1-3 (dl-Aa1-3) decreased expression by 
~60% which was close to the expression levels seen when the entire Lemaire A region 
was deleted (Figure 2.4C).  Interestingly, when the Aa1-2 region or the Aa3 region were 
deleted separately (dl-Aa1-2 and dl-Aa3), there was very little impact on expression, but 
when both regions were deleted (dl-Aa1-3), expression decreased by ~60% similar to 
when the entire Lemaire A region was deleted (dl-A) (Figure 2.4C).  Constructs deleting 










Figure 2.4.  Expression of mini deletion constructs of the Aa region in C2C12 cells. 
 
A.  Schematic showing the regions deleted in the Aa region of the DMD 3’ UTR in 
several deletion constructs are shown.  The DMD 3’ UTR contains a highly conserved 
Lemaire A region that was split into ~150 base pair sections (Aa, Ab, Ac, and Ad).  The 
Aa region was further divided into ~35-40 base pair sections (Aa1, Aa2, Aa3, and Aa4).  
Each bar represents the region deleted in each construct and the numbers correspond to 
the nucleotide position in the DMD 3’ UTR. 
B.  The relative expression of the pHRL construct (pHRL), the full length DMD 3’ UTR 
construct (3’ UTR), and several deletion constructs transfected into C2C12 myoblasts are 
shown.  Deleting any portion of the Lemaire Aa region had little impact on expression 
compared to the full length 3’ UTR construct (3’UTR).  The result of at least three 
biological replicates is shown with expression levels normalized to pHRL-CMV 
expression (pHRL) using a Renilla/Firefly dual luciferase assay.  Error bars equal +/- 1 
standard deviation. 
C.  The relative expression of the pHRL construct (pHRL), the full length DMD 3’ UTR 
construct (3’ UTR), and several deletion constructs transfected in C2C12 myotubes are 
shown.  Larger deletions and deletions containing the Aa3 or Aa4 regions had the largest 
effect on expression.  The result of at least three biological replicates is shown with 
expression levels normalized to pHRL-CMV expression (pHRL) using a Renilla/Firefly 


































suggesting that these regions affect expression more than the Aa1 and Aa2 regions 
(Figure 2.4C). 
 
RNA binding proteins bind to the Aa3-4 region  
of the DMD 3’ UTR 
 Because deleting the Aa1-2 region had very little impact on expression, and 
because the Aa3-4 region had the largest impact on expression in the Aa region, we 
investigated whether RNA binding proteins were binding to the Aa3-4 region.  To do 
this, [α-32P]UTP labeled RNA of the Aa3-4 region was synthesized and hybridized with 
whole protein extracts from C2C12 myoblasts or myotubes.  Unlabeled tRNA and RNA 
from the kelch gene in Drosophila were used as competitors to bind to nonspecific RNA 
binding proteins where indicated.  The hybridized RNA/protein complexes were 
crosslinked using UV light and RNA was digested.  The resulting RNase resistant, 
covalently linked RNA/protein complexes were electrophoresed on an SDS Bis Tris 
polyacrylamide gel to determine the size of proteins that were binding to the Aa3-4 
region (Figure 2.5).  Several protein bands were detected with the Aa3-4 RNA when only 
tRNA was used as a competitor (Figure 2.5, tRNA only).  However, when tRNA and the 
additional competitor RNA were added, we found two strong protein bands that bound to 
the Aa3-4 region in myotubes (Figure 2.5, tRNA+ Comp. RNA).  The unknown binding 
proteins are ~35-37 kDa and ~80-90 kDa.  These bands were not present when a [α-
32P]UTP labeled control RNA (kelch RNA) was hybridized with C2C12 cell protein 






















Figure 2.5.  Proteins binding to the Aa3-4 region of the DMD 3’ UTR. 
Proteins bound to [α-32P]UTP labeled Aa3-4 RNA (Aa3-4 RNA) or a labeled control 
RNA (Control RNA) are shown.  Labeled RNA was hybridized in either C2C12 myoblast 
(MB) or myotube (MT) protein extracts.  Hybridized RNA protein complexes were 
crosslinked using UV and RNA was digested.  Unlabeled tRNA (tRNA) and RNA from 
the kelch gene (Comp. RNA) were used as competitor RNA during hybridization.  
Arrows indicate two strong protein bands at ~35-37 kDa and ~80-90 kDa found when the 
Aa3-4 RNA was hybridized with C2C12 myotube proteins in the presence of competitor 
RNA.  Proteins were electrophoresed on a precast SDS NuPAGE 4-12% Bis Tris Gel 
(Life Technologies) and MES running buffer.  Protein sizes were determined using the 





A human DMD 3’ UTR variant at a predicted HuR binding site  
does not alter expression in C2C12 cells 
 There is only one variant (c.*93_*94InsT) in the Aa region found in our human 
DMD population that is located at a predicted RNA binding protein binding site.  This 
variant, found in four human DMD patients, has a T inserted at a predicted HuR binding 
site in the Aa3 region of the DMD 3’ UTR (Appendix B).  To determine whether this 
variant could alter dystrophin expression in C2C12 cells, we made a full length DMD 3’ 
UTR construct containing this variant.  We transfected this construct into C2C12 
myoblasts and myotubes and measured the effect on expression using a Renilla/Firefly 
dual luciferase assay as previously described.  Inserting a T nucleotide at the predicted 
HuR binding site (c.*93InsT) had no effect on expression in C2C12 myoblasts or 
myotubes compared to the wild type 3’UTR construct (3’UTR) (Figure 2.6). 
 
Discussion 
Previously, we found that the conserved Lemaire A region of the DMD 3’ UTR 
regulates expression by increasing mRNA abundance and translation in differentiated 
myotubes (Chapter 1).  We had previously attempted to narrow down the regulatory 
sequence using mutagenesis but found that the entire region was necessary for function 
and deleting any large portion of Lemaire A resulted in loss of this regulation (Chapter 
1).  This result is consistent with the high level of conservation that spans this region, and 
is similar to previously described HCEs (Dassi et al., 2013; Siepel et al., 2005).  HCEs 
are enriched in 3’ UTRs and may be involved in posttranscriptional gene regulation, 
alternative splicing, and polyadenylation (Dassi et al., 2013; Ho and Gunderson, 2011; 

















Figure 2.6.  The human DMD variant c.*93_*94InsT has no effect on expression in 
C2C12 cells. 
 
A.  The relative protein expression of the control pHRL vector (pHRL), a pHRL vector 
containing the wild type DMD 3’UTR (3’UTR), and a mutated construct containing an 
inserted T nucleotide at a predicted HuR binding site (c.*93InsT) transfected into C2C12 
myoblasts are shown.  The results of three biological replicates are shown.  Error bars 
equal +/- 1 standard deviation. 
B.  The relative protein expression in C2C12 myotubes is shown.  The results of three 









interact with RNA binding proteins and miRNAs, the mechanism of how HCEs regulate 
gene expression is still not understood, and why the extensive length and high 
conservation of these regions must remain intact is unknown.   
Here, we show that the first 150 base pairs of Lemaire A (the Aa region) alone are 
sufficient to increase expression in both C2C12 myoblasts and myotubes.  However, the 
expression pattern is different than when the entire Lemaire A region is present.  The Aa 
region itself increases expression in both myoblasts and myotubes, whereas the entire 
DMD 3’ UTR or a 3’ UTR consisting of the Lemaire A region alone decreases expression 
in myoblasts and only increases expression as the cells differentiate into myotubes.  This 
suggests that the Lemaire A region is not comprised of a single functional regulatory 
element, but of several functional regulatory elements that may be acting cooperatively to 
regulate dystrophin expression, and elements contained within the Lemaire A region that 
lie outside the Aa region suppress increased expression in myoblasts.  There is evidence 
that miRNA-31 binds to the Ac region of Lemaire A and suppresses dystrophin 
expression (Cacchiarelli et al., 2011).  However, our own analysis suggests that there are 
additional regions that suppress expression in myoblasts (See Chapter 1). 
We used deletion mutagenesis to further break down the Aa region into four 
sections of ~35-40 base pairs (Aa1, Aa2, Aa3, and Aa4) to determine which regions 
contained regulatory elements.  We made deletions of increasing size of the Aa region 
(Aa1, Aa1-2, and Aa1-3) and found that deleting the Aa1 region (dl-Aa1) had no effect 
on expression, deleting the Aa1 and Aa2 region (dl-Aa1-2) decreased expression by 
~15%, and deleting Aa1-3 (dl-Aa1-3) decreased expression by ~60% and was close to the 
expression levels seen when the entire Lemaire A region was deleted.  We first 
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hypothesized that the Aa3 region must contain the regulatory element functioning in this 
region.  Unexpectedly, when we deleted only the Aa3 region (dl-Aa3) we did not see this 
large decrease in expression.  This result could be explained by the existence of two 
redundant regulatory elements contained within the Aa1-2 region and the Aa3 region.  
Under this scenario, when the Aa1-2 or Aa3 region is deleted separately, the region still 
retains the ability to increase expression as the second element is present, whereas when 
both the Aa1-2 and Aa3 regions are deleted, function is lost and expression does not go 
up.  Alternatively, the size of the deletion may be the determining factor on how well this 
region functions.  Perhaps, there is a size threshold for deletions in the Lemaire A region, 
and once the deleted size hits a certain point, function of the entire region is abolished.  
This is consistent with our previous attempts to narrow down the functional sequences of 
the Lemaire A region and found that deleting any portion of Lemaire A (~150 base pairs 
each) decreased expression to the same degree as deleting the entire region.  Although 
size of deletion does not fully explain our results and some regions appear more 
important than others.  For example, the Aa4 region seems to be more important than the 
other regions in Aa.  When only the Aa4 region is deleted expression decreases by ~45%, 
and when the Aa3 and Aa4 regions are deleted expression decreases by ~50%.  This 
decrease is larger than the decrease seen when deletions of the same size are made in the 
Aa1-2 regions.   
Using an RNA protein binding assay, we found that two proteins of ~36 kDa and 
~80-90 kDa were binding to the Aa3-4 region.  There are several predicted RNA protein 
binding sites in the Aa3-4 region (Figure 2.2, Table 2.3).  Of the predicted RNA protein 









Note:  Predicted RNA protein binding sites in the Aa3-4 region of the DMD 3’ UTR 
using RBPDB (Cook et al., 2011) are shown.  RBPDB predicts binding sites by scoring 
potential binding sites in the sequence using position weight matrices and assigns a score 
that is calculated as the sum of the scores of each nucleotide at each position in the 
position weight matrix.  A relative score is also given as a percent of the score to the 
maximum possible score of the predicted site.  Only predicted sites with a relative score 




range of 80-90 kDa (Table 2.3).  Little is known about this RNA binding protein other 
than that it interacts with the protein emerin (Wilkinson et al., 2003).  Mutations in the 
emerin gene cause Emery Dreifuss muscular dystrophy in humans, and emerin has been 
shown to function in both muscle and heart tissue (Fairley et al., 1999; Helbling-Leclerc 
et al., 2002).  However, further investigation would be needed to determine if YTHDC1 
is interacting with the DMD 3’ UTR.  Of the predicted RNA protein binding sites, there 
are three proteins (KHDRBS3, SFRS13A, and ELAVL1 (HuR)) that best match the size 
of the ~36 kDa protein (Table 2.3).  KHDRBS3 (a.k.a. T-STAR) is a KH containing 
RNA binding protein that has been shown to regulate processes in cancer cells (Lei et al., 
2011; Lu et al., 2009; Zhang et al., 2006) and may be involved in spermatogenesis 
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(Venables et al., 1999).  The RNA binding protein SFRS13A (a.k.a. SRSF10 and SRp38) 
has been shown to be involved in sequence specific alternative splicing (Feng et al., 
2009; Ling and Estus, 2010; Zhou et al., 2014). However, there is not strong evidence 
that KHDRBS3 or SFRS13A is functioning in muscle cells.  The best candidate protein 
in the 35-37 kDa range is the protein ELAVL1 (a.k.a. HuR).  Two groups using PAR-
CLIP, a genome wide method to examine the interaction between RNA binding proteins 
and mRNA, identified DMD as a target for HuR in HeLa and HEK 293 cells (Hafner et 
al., 2010; Lebedeva et al., 2011; Mukherjee et al., 2011).  Although muscle cells were not 
used in these experiments, HuR has been shown to regulate myogenesis by binding to the 
3’ UTR of important myogenic factors such as myogenin and MyoD (Deschenes-Furry et 
al., 2005; Figueroa et al., 2003; van der Giessen et al., 2003; von Roretz et al., 2011).   
HuR has also been shown to regulate other proteins that increase in expression during 
differentiating muscle cells (Deschenes-Furry et al., 2005).  HuR was shown to directly 
interact with and regulate acetylcholinesterase, a protein that dramatically increases in 
expression during differentiation, by binding to an AU rich sequence in the 3’ UTR of the 
acetylcholinesterase transcript (Deschenes-Furry et al., 2005).  The regulatory pattern of 
acetylcholinesterase is very similar to the regulatory pattern of dystrophin.  However, 
further investigation is required to determine whether the unknown 35-35 kDa protein is 
HuR. 
There are several predicted binding sites for RNA binding proteins and miRNAs 
in the conserved regions of the DMD 3’ UTR (Figure 2.2, Appendix B), and several of 
the variants found in human patients lie within or adjacent to these predicted sites.  In the 
Aa region, there is only one variant found in our human DMD population with a variant 
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at a predicted RNA protein binding site.  This variant, c.*93_*94InsT, inserts a T 
nucleotide at a predicted HuR binding site in the Aa3 region of the DMD 3’ UTR.  This 
changes the predicted HuR binding site from a GUUU to a GUUUU.  When we 
transfected C2C12 cells with a DMD 3’ UTR construct containing this mutation, we saw 
no effect on expression in either myoblasts or myotubes compared to the full length 3’ 
UTR construct.  This mutation may not be significant enough to alter HuR binding at this 
site, or HuR may not be binding to this region of the 3’ UTR. 
 The DMD 3’ UTR sequences analyzed were from patients enrolled in the United 
Dystrophinopathy Project (UDP) (Flanigan et al., 2009), a newborn screening study 
(Mendell et al., 2012), or from clinical referrals.  The group with the most clinical 
certainty of a DMD or BMD diagnosis was the patients included in the UDP study.  The 
patients from clinical referrals were from cases where a doctor diagnosed a 
dystrophinopathy or suspected dystrophinopathy enough to order DMD mutation 
screenings.  Although it is possible that a subset of these patients were misdiagnosed, it is 
likely that most of these patients were DMD or BMD patients.  The majority of the 
patients from the newborn screening study are not dystrophic patients.  We found no 
candidate disease causing mutations in the DMD 3’ UTR amongst the patients included 
in the UDP study where the clinical diagnosis is the most certain.  Our top candidate 
disease causing variants were found only in patients from the newborn screening study 
and older clinical referrals with limited patient information.  Our search for disease 
causing variants pulled out the patients with incomplete screening with the possibility of 
mutations in other regions of the gene.  We conclude that it is unlikely that a disease 
causing 3’ UTR mutation exists in these patients.  However, it is possible that variants 
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found in the 3’ UTR could affect the disease phenotype by acting as modifier mutations 
when a second mutation is present.  Such mutations have been found in other genes and 
shown to modify disease severity in DMD and BMD patients (Chandrasekharan et al., 
2010; Flanigan et al., 2013; Heydemann et al., 2007).  It is been shown that stability of 
the DMD transcript has a large impact on dystrophin protein levels in BMD patients 
(Spitali et al., 2013), and we have shown evidence that the DMD 3’ UTR can effect 
mRNA stability and protein expression (Chapter 1, Appendix A).  Variants in the 3’ UTR 
could affect dystrophin expression and act as modifier mutations that alter disease 
severity.  Unfortunately, we were unable to obtain a big enough cohort of DMD 3’ UTR 
sequences from human patients accompanied with detailed phenotypic data to test this 
hypothesis. 
One aspect that has been underappreciated in clinical DMD studies is the effect of 
dystrophin expression levels in the brain.  The dystrophin glycoprotein complex is 
involved in several cellular processes in brain development and function (Waite et al., 
2012; Waite et al., 2009), and several DMD and BMD patients exhibit neurological 
disorders.  One third of DMD patients have cognitive impairments with the DMD 
population having a mean full scale intelligence quotient (IQ) score one standard 
deviation lower than the population average (Cotton et al., 2005).  DMD and BMD is also 
associated with an increased incidence of neurological disorders, such as autism spectrum 
disorder (ASD) and attention deficit hyperactivity disorder (ADHD) (Hendriksen and 
Vles, 2008; Wu et al., 2005).  Although mutations in DMD or BMD patients with 
cognitive defects have been identified in all regions of the DMD gene, there is a higher 
correlation with mutations found in the distal end of the DMD gene and cognitive 
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impairments (Taylor et al., 2010).  It is speculated that this is due to mutations that 
disrupt the dystrophin isoforms Dp140 and Dp71; short dystrophin isoforms transcribed 
only from the 3’ end of the dystrophin gene that are highly expressed in brain tissue 
(Blake et al., 1992; Lidov et al., 1995; Moizard et al., 1998).  It is possible that disease 
causing mutations exist in the DMD 3’ UTR but have been overlooked because they 
cause a nonmuscular phenotype or affect dystrophin isoforms expressed in nonmuscular 
tissues such as the brain.  One such mutation was recently discovered in a patient with a 3 
base pair deletion in the coding region of the DMD gene that causes intellectual 
disability, but no muscle phenotype (de Brouwer et al., 2014).  Clinical screens for DMD 
mutations have primarily focused on the muscle phenotype of the disease, and, in fact, 
classification of DMD and BMD patients is determined by the severity of the muscle 
phenotype (defined by age of ambulatory loss).  Although it is very well documented that 
DMD and BMD patients exhibit cognitive defects, DMD mutation screenings have 
focused primarily on mutations that disrupt the muscle isoform of dystrophin and 
phenotypic data on cognitive deficits are not as standardized and often not reported in 
clinical studies, making it difficult to identify these types of mutations in current DMD 
mutation databases. 
In summary, we found no mutations in the human DMD 3’ UTRs that are likely to 
be disease causing.  However, we could not rule out the possibility that variants in the 3’ 
UTR could also act as modifier mutations when a second mutation is present or cause a 
disease phenotype in nonmuscular tissues such as the brain.  We show evidence that the 
Lemaire A region is composed of multiple regulatory elements that work cooperatively to 
downregulate dystrophin expression in myoblasts and upregulate expression in myotubes, 
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and that the Aa region of Lemaire A binds to RNA binding proteins.  The entire region is 
necessary for the increased expression during differentiation, although certain small 
deletions and minor alterations can be made to the region without affecting expression in 
C2C12 cells.  The high level of conservation that spans this region remains a mystery, 
and is higher than what would be required to retain individual RNA protein binding sites.  
I conclude that there must be some unknown component in the function of these regions 
that lies within the primary sequence that is yet to be discovered. 
 
Materials and methods 
Generation of the 3’ UTR reporter constructs and mutagenesis 
The full length DMD 3’ UTR was inserted into the pHRL-CMV Renilla vector 
(Promega) as previously described (Chapter 1) to make the DMD 3’ UTR reporter 
construct.  The Aa region of the DMD 3’ UTR (base pair positions 1 through 150), was 
inserted into the pHRL-CMV Renilla vector (Promega) by first amplifying the Aa region 
from the DMD 3’ UTR construct using the primers 
GCCGCTTTCTAGAAGGAAGTCTTTTCCACATGGC and 
GCCGCTTTCTAGACTAATCCTCTTTGTTGTATGAATATTATAAAAA that include 
an overhang sequence containing the XbaI cut site.  The resulting PCR product was 
digested with XbaI (New England Biolabs) and ligated using T4 DNA Ligase (New 
England Biolabs) as specified by the manufacturer into the XbaI restriction site of the 
pHRL-CMV vector (Promega) immediately upstream of the SV40 polyadenylation 
region. 
The pHRL construct containing only the Lemaire A region of the DMD 3’ UTR 
downstream of the coding sequence was made using the Phusion Site Directed 
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Mutagenesis Kit (Thermo Scientific) as specified by the manufacturer using the DMD  
3’ UTR construct as a template and the phosphorylated primers 
GTGTATCTCAATAAAGCACGCAGTTATGTTAC and 
CCACTCAGCTGACAGTTCTCAAATG to delete the middle region and Lemaire D 
region of the 3’ UTR.  The resulting construct contained only the Lemaire A region and 
an intact DMD polyadenylation signal immediately downstream of the Renilla coding 
sequence. 
The construct containing an insertion in a predicted HuR binding site of the DMD 
3’ UTR (c.*93_*94InsT) and the constructs with deletions in the Aa region of the DMD 
3’ UTR were made using the Phusion Site Directed Mutagenesis Kit (Thermo Scientific), 
as specified by the manufacturer using the DMD 3’ UTR construct as a template and 
phosphorylated primers specific for each deletion or the insertion (Table 2.4).  All 
constructs made were sequence verified and QIAGEN kits were used to prepare plasmid 
DNA. 
 
Cell culture and protein extraction 
Mouse C2C12 myoblast cells were purchased from ATCC (CRL-1772).  C2C12 
myoblasts were cultured in growth medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone) at 37°C and 5% CO2.  Myogenic differentiation was induced by replacing the 
medium of the C2C12 myoblasts with DMEM/F-12 media supplemented with 2% horse 
serum (Sigma) for 6 days.  Protein extracts for RNA hybridization experiments were 
obtained by growing C2C12 myoblasts or myotubes in CytoOne T25 Tissue Culture 









collecting the cells in twice the volume of the cell pellet in a homogenization buffer (0.3 
M Sucrose, 60 mM NaCl, 15 mM Tris, pH 8.0, and 10 mM EDTA).  Cells underwent 
five cycles of freeze thaw to aid in lysis, and centrifuged at 15000 g for 15 minutes at 4°C 
to remove cell debris.  Protein levels were quantified using the Nanodrop ND-1000 
Spectrophotometer (Thermo Scientific), and protein extracts were stored at -80°C.  
 
Transfections and dual luciferase reporter assay 
C2C12 myoblasts (1x104 cells) were transfected with 25 ng of the pHRL-CMV 
vector (Promega) or a DMD 3’ UTR construct using 0.3 uL of Lipofectamine 2000 
reagent (Life Technologies) in 96 well half area plates (Corning) with 0.16 cm2 growth 
areas.  All reactions were cotransfected with 6.25 ng of the pGL4.13 [luc2/SV40] Firefly 
Luciferase vector (Promega) as a transfection control.  To measure protein expression in 
myoblasts, cells were harvested 48 hours after transfection by adding 14 uL of a passive 
lysis buffer (Promega).  To measure protein levels in myotubes, the growth media for 
C2C12 myoblasts was replaced 48 hours after transfection with a low serum media to 
induce differentiation.  The differentiated myotubes were harvested after 6 days in 
differentiation media by adding 14 uL of a passive lysis buffer (Promega).  C2C12 
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myoblasts and myotubes underwent one freeze thaw cycle to aid in lysis.  The 
bioluminescence of Renilla and firefly luciferase was measured using the Dual Luciferase 
Reporter Assay System (Promega) in a Veritas Microplate Luminometer (Turner 
Biosystems) to determine luciferase levels, and the Renilla luciferase signal was 
normalized to the pGL4.13 firefly luciferase signal in each well to account for variation 
in transfection efficiency.  At least three biological replicates were done for each 
transfection. 
 
Preparation of labeled RNA transcripts 
 The Aa3-4 region of the DMD 3’ UTR was amplified using the primers 
TAATACGACTCACTATAGGGAGGAGCAGAATAAATGTTTTACAACTC and 
CATGGTTTTTATAATATTCATACAACAAAGAGGATTAG with a T7 promoter 
contained within the overhang of the forward primer using Taq DNA Polymerase (Sigma 
Aldrich) and purified using the QIAquick Gel Extraction Kit (Qiagen) using the 
manufacturer’s recommended protocol.  Labeled RNA transcripts were synthesized using 
T7 RNA polymerase and [α-32P]UTP (Perkin Elmer).  The in vitro transcription reaction 
had a final concentration of 1 mM of dATP, dCTP, and dGTP, 5 µM dUTP, 40 µCi [α-
32P]UTP (Perkin Elmer), 200 ng of DNA, 100 µg/mL Bovine Serum Albumin (BSA) 
(New England Biolabs), 5 mM DTT, 40 U RNasin® Plus RNase Inhibitor (Promega), 
and 1 Unit T7 RNA Polymerase in a transcription buffer (60 mM Tris pH 8.0, 50 mM 
MgCl2, 4 mM spermadine, 0.02% Triton X-100 (Sigma Aldrich)).  The reaction was 
incubated for 45 minutes at 37°C before 2 U RNase free DNAse (Thermo Scientific) was 
added and incubated for an additional 10 minutes.  The labeled RNA was purified using 
NucAway Spin Columns (Ambion) as specified by the manufacturer.  Labeled and 
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unlabeled RNA from the kelch gene in Drosophila was obtained from Norma Wells 
(University of Utah, Human Genetics Department), and used as control RNA and 
competitor RNA in the RNA protein hybridizations. 
 
RNA protein binding 
 Labeled RNA from the Aa3-4 region of the DMD 3’ UTR or a control RNA from 
the kelch gene in drosophila was hybridized with C2C12 protein extracts by adding 1.5 x 
105 CPM of labeled RNA with 30 µg of protein from either C2C12 myoblasts or 
myotubes.  Four µg of tRNA was added to each reaction to compete with nonspecific 
RNA binding proteins, and 600 ng of unlabeled kelch RNA was added as competitor 
RNA when specified.  Each reaction contained 40 units RNasin® Plus RNase Inhibitor 
(Promega) and a homogenization buffer (0.3 M Sucrose, 60 mM NaCl, 15 mM Tris, pH 
8.0, and 10 mM EDTA).  Reactions were incubated for 20 minutes at room temperature.  
The reactions underwent UV crosslinking for 15 minutes at 254 nm UV light using the 
UV Stratalinker™ 2400 (Stratagene) as specified by the manufacturer.  The reaction was 
digested using 20 ug of RNase A (Life Technologies) and incubating at 37°C for 10 
minutes.  Electrophoresis was done on an SDS gel using the precast NuPAGE 4-12% Bis 
Tris Gel (Life Technologies) and MES running buffer as specified by the manufacturer.  
Protein sizes were determined using the Precision Plus Protein Kaleidoscope™ Standards 
(Bio Rad).  The gel was dried on Whatman paper for 1.5 hours at 80°C using the Model 
583 Gel Dryer (Bio Rad), and analyzed using the Typhoon Trio+ Imager (GE Healthcare 






Analysis of human DMD variants 
 DMD 3’ UTR sequences and clinical information for human DMD patients were 
obtained from Dr. Robert Weiss (University of Utah, Department of human genetics).  
Any sequence with a discrepancy that varied from the reference DMD sequence was 
visually inspected using Consed (Gordon and Green, 2013) to determine the validity of 
each discrepancy.  Identified variants were named using the HGVS guidelines and 
recommendations for variant nomenclature (den Dunnen and Antonarakis, 2000).   
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Dogs affected by canine X linked muscular dystrophy (cxmd) are important 
animal models of Duchenne muscular dystrophy (DMD), in large part because they 
recapitulate skeletal muscle pathology to a greater degree than the standard mdx mouse 
model.  We studied four dystrophic dog lines that were identified in clinical veterinary 
practice due to variable weakness and either altered or absent dystrophin expression and 
we identified novel DMD mutations in three of them.  These include a Labrador retriever, 
in which we identified a disease associated LINE-1 insertion resulting in the inclusion of 
a pseudoexon within the mRNA; a Cocker spaniel, in which we identified a 4 nucleotide 
frameshifting deletion in exon 65; and a Tibetan terrier, in which we identified a large 
deletion of exons 8-29.  To aid in establishing and maintaining research colonies, 
genotyping assays were developed for each dog model along with a genotyping assay for 
a Yorkshire terrier with a known exon 3-7 deletion of the DMD gene.  Developing 
therapeutic approaches to treat human DMD patients target specific types of mutations, 
and the identification of these novel mutations adds to the catalog of available dog lines 







The dystrophinopathies Duchenne muscular dystrophy (DMD) and the milder 
disorder Becker muscular dystrophy (BMD) are both caused by mutations in the DMD 
gene.  The DMD gene is the largest known human gene, spanning 2.2 megabases on the 
X chromosome, and consisting of 79 exons.  DMD codes for several isoforms of the 
protein dystrophin derived from tissue specific promoters found within the gene 
(Hoffman et al., 1987; Muntoni et al., 2003).  The predominant muscle isoform, Dp427m, 
codes for a 427 kilodalton protein that connects the cytoskeleton of muscle to the 
extracellular matrix via the dystrophin associated glycoprotein complex (DAG), and 
mediates signal transduction cascades through the C terminal domain of dystrophin 
(Blake et al., 2002; Cohn and Campbell, 2000).  Patients with DMD exhibit severe 
muscle degeneration, development of cardiac hypertrophy, an association with 
neurological disorders, and a life expectancy into the second decade of life.  BMD 
patients, on the other hand, exhibit muscle degeneration that occurs at a much slower rate 
and typically survive into late adulthood. The molecular pathogenesis of DMD is not 
completely understood, but, in the absence of dystrophin, the integrity of the muscle 
membrane is compromised during muscle contraction, and degeneration of myofibers 
follows (Deconinck and Dan, 2007).   
DMD homologues have been identified in several mammalian and 
nonmammalian species such as the dog (Cooper et al., 1988; Valentine et al., 1988), cat 
(Carpenter et al., 1989), mouse (Bulfield et al., 1984), zebrafish (Bassett and Currie, 
2004), and C. elegans (Bessou et al., 1998), and animal models with mutations in the 
DMD homologue have been used to study Duchenne muscular dystrophy.  The most 
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commonly used animal model is the mdx mouse (C57BL/10ScSn-Dmdmdx/J), a strain that 
contains a nonsense mutation in exon 23 of the DMD gene and has no dystrophin 
expression (Bulfield et al., 1984; Sicinski et al., 1989).  It is not a perfect model of human 
DMD.  This is in part because the severe muscle degeneration and early death observed 
in human DMD patients is not seen in the mdx mouse despite the absence of dystrophin 
expression, and, instead, a relatively mild skeletal muscle phenotype is seen (Collins and 
Morgan, 2003; Dangain and Vrbova, 1984).  Likewise, nonmammalian models of DMD, 
such as the zebrafish and C. elegans, have the advantage of being easier to genetically 
manipulate and maintain in large numbers, but have different musculature and pathology 
compared to human patients (Baumeister and Ge, 2002; Bessou et al., 1998; Chambers et 
al., 2001; Guyon et al., 2003).   
Canine X linked muscular dystrophy (cxmd) dogs with mutations in the DMD 
gene have been identified that have an  absence of dystrophin expression, and similar 
clinical features and disease progression as human DMD patients (Valentine et al., 1988).  
The best characterized dog model to date is the Golden Retriever Muscular Dystrophy 
(GRMD) dog (Cooper et al., 1988; Kornegay et al., 1988; Valentine et al., 1988).  The 
GRMD dog has a point mutation in the splice acceptor site of intron 6, and, as a result, 
exon 7 is skipped during splicing of the premRNA, resulting in an out-of-frame transcript 
and a premature stop codon (Sharp et al., 1992).  Other known sporadic canine models of 
DMD have been found in other breeds.  For example, a German short hair pointer with a 
complete deletion of the DMD gene (Schatzberg et al., 1999), a Cavalier King Charles 
Spaniel with a missense mutation in the 5’ donor splice site of exon 50 that results in the 
deletion of exon 50 in the DMD mRNA (Walmsley et al., 2010), and a Pembroke Welsh 
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corgi with a long interspersed repetitive element-1 (LINE-1) insertion in intron 13 that 
introduces a pseudoexon in the DMD mRNA (Smith et al., 2011) have been found.  
Several other dystrophin deficient dog lines have been identified, but specific mutations 
have not been reported (Baltzer et al., 2007; Baroncelli et al., 2013; Barthelemy et al., 
2007; Bergman et al., 2002; Blot et al., 2002; Jones et al., 2004; Klarenbeek et al., 2007; 
Wetterman et al., 2000; Wieczorek et al., 2006). 
Several therapeutic approaches are being developed to treat DMD patients 
(Fairclough et al., 2013; Muir and Chamberlain, 2009; Pichavant et al., 2011), including 
exon skipping using antisense molecules (Cirak et al., 2011; Goemans et al., 2011; 
Gurvich et al., 2008; Kinali et al., 2009; Lu et al., 2005; Mendell et al., 2013; van 
Deutekom et al., 2007), premature stop codon suppression therapies (Barton-Davis et al., 
1999; Finkel, 2010; Howard et al., 2004; Malik et al., 2010) and the delivery and 
expression of mini dystrophin gene constructs lacking nonessential DMD coding exons 
(Fabb et al., 2002; Foster et al., 2012; Foster et al., 2008; Koo et al., 2011a; Koo et al., 
2011b; Rodino-Klapac et al., 2010; Wang et al., 2000; Wang et al., 2007; Wang et al., 
2012).  Animal models have proven to be important tools in testing these developing 
treatments for human use.  Although animal models, such as the mdx mouse and 
nonmammalian models, have been useful in understanding DMD pathogenesis, 
differences in the musculature and pathological expression of the disease in these animals 
prevent them from being perfect animal models of DMD when testing these treatments in 
human DMD patients (Collins and Morgan, 2003; Willmann et al., 2009).  Large animal 
models that more faithfully recapitulate human DMD are particularly useful for 
preclinical development of potential therapies to better study the effectiveness and side 
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effects in human patients. 
We set out to identify DMD mutations in dogs who presented in clinical 
veterinary practice with symptoms of weakness along with altered or absent dystrophin 
expression on muscle biopsy.  We identified the mutations responsible in three such dogs.  
These include a Labrador retriever with a LINE-1 insertion in intron 19 of the DMD gene 
that results in the inclusion of a pseudoexon in the  mRNA; a Tibetan terrier with a 
deletion of exons 8-29 of the DMD gene; and a Cocker Spaniel with a small 
frameshifting deletion of 4 nucleotides in exon 65 of the DMD gene.  We developed 
genotyping assays for each mutation found to aid in establishing research colonies of 
these dogs, including a genotyping assay for a Yorkshire terrier with a known exon 3 
through 7 deletion of the DMD gene where no rapid assay previously existed.  
Identification of these novel mutations adds to the catalog of available dog models, and 




Immunofluorescence/immunoblot analysis of dystrophic dogs 
To determine dystrophin expression levels in each dog, muscle sections were 
obtained from a biopsy of a dystrophic Springer spaniel, Labrador retriever, Tibetan 
terrier, and Cocker spaniel dogs that had not been screened for DMD mutations.  Sections 
of each muscle sample were stained for dystrophin using immunofluorescence and 
antibodies directed against the N terminus (Manex1A) or rod domains (Dys1) of 
dystrophin (Figure 3.1).  Immunofluorescence showed no dystrophin staining in all four 
dystrophic dogs (Figure 3.1).  To confirm membrane integrity, an antilaminin antibody 










Figure 3.1.   Immunofluorescent analysis of muscle tissue from dystrophic dogs. 
 
Skeletal muscle sections were stained with monoclonal antibodies against Laminin, the N 
terminus of dystrophin (Manex1a), or the rod domain of dystrophin (Dys1).  Sections are 
shown from a wild type dog (W) as well as the following dystrophic dog lines with 
previously undefined mutations: Springer Spaniel (S), Labrador Retriever (L), Tibetan 
Terrier (T), and Cocker Spaniel (C).  Sections from a GRMD dog (G) (exon 6 splice site 
mutation) and the German short hair pointer (R) (deletion of the entire DMD gene) were 
































Tibetan terrier, which was accidentally thawed and refrozen during shipping, resulting in 
damaged tissue) (Figure 3.1).  As a positive control, a muscle biopsy was obtained from a 
wild type dog and stained for dystrophin using the Manex1A and Dys1 antibodies 
showing normal staining of dystrophin (Figure 3.1).  Disease control muscles were 
obtained from a GRMD dog, known to contain a point mutation in the splice acceptor site 
of intron 6 (Sharp et al., 1992) resulting in a premature stop codon, as well as a German 
Short Hair Pointer that was shown to have the entire DMD gene deleted (Schatzberg et 
al., 1999) and both showed no dystrophin staining (Figure 3.1).  Immunoblot analysis of 
proteins isolated from each muscle biopsy showed the presence of full length dystrophin 
(ca. 400 kDa) in the wild type dog sample, but no dystrophin staining in any of the 
dystrophic dog samples (Figure 3.2A).  Antibodies against myosin heavy chain were used 
as a loading control during immunoblot analysis (Figure 3.2B) 
 
Mutation analysis of dystrophic dogs 
 
Labrador retriever 
To determine the causative mutation in the Labrador retriever, RNA was isolated 
from the muscle biopsy and cDNA of the DMD mRNA was synthesized.  Sequencing of 
the entire DMD cDNA revealed a 184 nucleotide (nt) pseudoexon insertion between exon 
19 and exon 20 (Figure 3.3A) which results in a premature stop codon immediately 
downstream of the insertion (p.Gly796X).  Using BLAST, the first 19 nt of the insertion 
were identified as a portion of intron 19 beginning 2,947 nt into the intron with the 
remainder of the insertion as a Long Interspersed Element (LINE) sequence (Figure 3.3A, 
Appendix D).  A set of intronic primers surrounding the insertion point was used to 
















Figure 3.2. Immunoblot analysis of dystrophic dogs.   
A.  Immunoblotting results using antibodies against the rod domain of dystrophin (Dys1) 
in dystrophic dog lines are shown.  Full length dystrophin (ca. 400 kDa) was detected in 
the protein extract of the wild type muscle (W).  No dystrophin was seen for the 
dystrophic Springer spaniel (S), Labrador retriever (L), Tibetan terrier (T), or Cocker 
spaniel (C) or the GRMD dog (G) and German short hair pointer (R) disease controls.  
Size markers are measured in kDa. 
B.  Immunoblotting results using antibodies against myosin heavy chain are shown for 











Figure 3.3.  Mutations found in the dystrophic dog lines.   
 
A.  LINE-1 insertion in the Labrador retriever.  Schematic of the 6,363 nucleotide LINE-
1 insertion found in intron 19 of the DMD gene and the resulting 184 nt pseudoexon 
insertion in the DMD mRNA.    
B.  An exon 8 through 29 deletion was found in the Tibetan terrier.  Absence of PCR 
products from exons 8 and 29 of the DMD gene in the Tibetan terrier (T), with products 
of expected size in the wild type dog (W) is shown.   
C.  Chromatograph of the four nucleotide deletion in exon 65 in the Cocker spaniel is 
shown.  A four nucleotide deletion in exon 65 of the DMD gene (lower chromatogram) 
was found in the Cocker spaniel, compared to the sequencing results from a wild type 



































sequence the insertion and surrounding intronic sequence, and we identified the insertion 
as a 6,363 nt Canis familiaris Long Interspersed Element-1 (L1_Cf) transposable 
element.  The LINE is essentially full length; the inserted sequence starts from position 9 
of the L1-Cf consensus sequence and is less than 1% divergent from the consensus.  An 
11 nucleotide sequence from the intron is repeated on both sides of the insertion and 
matches a target site duplication (TSD) associated with canonical L1 insertions.  A “GT” 
at the 166-167 nt of the L1 insertion serves as a cryptic splice donor site and an “AG” 
present at position 2945-2946 nt into intron 19 serves as a splice acceptor site for the 
pseudoexon insertion (Figure 3.3A, Appendix D).  The nomenclature of the mutation at 
the RNA level is thus r.2383_2384ins2383+2949_2383+2967ins165. 
 
Tibetan terrier 
Sequencing the entire DMD cDNA derived from skeletal muscle mRNA from a 
dystrophic Tibetan terrier revealed several alternatively spliced products containing 
deletions of varying numbers of exons found at the 5’ end of the gene.  The smallest 
deletion detected among these products encompassed exons 8 through 29; no products 
were seen that included any exons between exons 8 through 29.  Primers were designed 
to amplify exons 3 through 50 from genomic template DNA obtained from muscle 
samples of the Tibetan terrier and a wild type control (Appendix D).  Products were not 
obtained for exons 8 through 29 in the Tibetan terrier (Figure 3.3B), whereas all products 
were amplified successfully from the wild type control.  PCR was repeated using an 
alternate, nonoverlapping set of primers for both exons 8 and 29 in order to exclude the 
possibility that the absence of amplification was due to a polymorphism at the site of 
hybridization of one of the original primers (see Materials and methods).  
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Cocker spaniel   
To determine the causative mutation in a dystrophic Cocker spaniel, the entire 
DMD cDNA derived from skeletal muscle mRNA was sequenced and a four nucleotide 
deletion in exon 65 (c.9444_9447delTCTG) was identified (Figure 3.3C), corresponding 
to positions c. 9459_9462 in the human DMD cDNA.  The resulting shift in the reading 
frame results in a premature stop codon at the site of the deletion (p.Cys3148X). 
 
Springer spaniel  
To determine the causative mutation in the dystrophic Springer spaniel, the 
complete DMD cDNA derived from skeletal muscle mRNA was sequenced.  However, 
no mutations were found.  Genomic DNA was extracted from muscle tissue and the 
DMD 5’ UTR, Dp427m muscle promoter, and 3’ UTR were sequenced.  No mutations 
were found in these regions. 
 
Genotyping canine models of DMD 
 Rapid genotyping assays using extracted genomic DNA were developed for each 
mutation identified.  To assay the presence of the LINE-1 insertion in intron 19 of the 
DMD gene identified in the dystrophic Labrador retrievers, primer pairs were designed to 
differentiate between the wild type intron 19 or to amplify a portion of the LINE-1 
insertion from a colony of dogs (Figure 3.4A) with the wild type allele expected to yield 
a 460 bp product and the mutant allele expected to yield a 531 bp product in our assay 
(Figure 3.4A).  The assay was successfully used to genotype Labrador retrievers 
containing the LINE-1 insertion (Figure 3.4B).  To detect the presence of the 4 bp 









Figure 3.4.  Genotyping dog models of DMD. 
 
A.  Schematic of the LINE-1 insertion PCR assay for the Labrador retriever.  Primers 
were designed to amplify either the mutant allele containing the LINE-1 insertion in 
intron 19 of the DMD gene (Primers L1 and L2) or the wild type allele (Primers L1 and 
L3) from genomic DNA.  Primer pair L1/L2 amplifies a 531 bp product if the LINE-1 
insertion is present, and primer pair L1/L3 amplifies a 460 bp product with no LINE-1 
insertion. 
B.  Samples genotyped using the LINE-1 insertion PCR assay is shown.  A wild type dog 
sample contains only the wild type allele (L3).  The dystrophic male Labrador retriever 
contains only the mutant allele (L2).  A female carrier for the LINE-1 insertion contains 
both the mutant (L2) and wild type (L3) alleles. 
C.  Schematic of the qPCR assays used for the deletions found in the Tibetan terrier and 
Yorkshire terrier.  qPCR using genomic DNA was used to calculate the ratio of exon 8 to 
exon 49 (Tibetan terrier) or exon 3 to exon 49 (Yorkshire terrier) in the DMD gene to 
determine the carrier status of dog samples for the described deletions. 
D.  A Yorkshire terrier is genotyped.  qPCR was used to calculate the ratio of exon 3 to 
exon 49 in a line of Yorkshire terriers containing an exon 3 through 7 deletion of the 
DMD gene.  A female carrier for the deletion contains 57% (+/- 8%) the amount of exon 
3 compared to exon 49.  A female Yorkshire terrier of unknown status was genotyped 
and had 106% (+/- 12%) the ratio of exon 3 to exon 49.  The unknown sample was 
determined to be wild type.  Levels were normalized to the ratio of exon 3 to exon 49 in a 




































and sequenced using specific primers (see Materials and methods).  
To determine the carrier status of a line of Yorkshire terriers previously known to 
carry a deletion of exon 3 through exon 7 and the line of Tibetan terriers with a deletion 
of exon 8 through exon 29 in the DMD gene, quantitative real time PCR using SYBR 
green was performed.  Primers were designed to amplify exon 49 of the DMD gene as a 
reference and exon 3 of the DMD gene in the Yorkshire terrier or exon 8 in the DMD 
gene in the Tibetan terrier as a test exon (Figure 3.4C).  The relative levels of exon 3 or 
exon 8 compared to exon 49 were used to determine whether the sample was a carrier for 
the exon 3-7 deletion or for the exon 8-29 deletion (Figure 3.4C).  The relative levels of 
exon 3 or exon 8 to exon 49 were normalized to a wild type sample.  For the Yorkshire 
terrier, a known carrier for the exon 3-7 deletion had 57% the levels of exon 3 compared 
to exon 49 (Figure 3.4D).  An example of a Yorkshire terrier from a dog colony was 
genotyped and had 106% levels of exon 3 compared to exon 49, which we determined to 




 We have identified the DMD mutations responsible for three new dog models of 
Duchenne muscular dystrophy.  These mutations represent three different mutation 
classes found in human dystrophinopathies, including a pseudoexon insertion into 
mRNA; a small 4 nucleotide frameshifting deletion; and a large out-of-frame deletion 
spanning 22 exons. These dogs add to the catalog of available models that can be used to 
study human Duchenne muscular dystrophy. 
 The L1_Cf insertion we describe in the Labrador retriever appears to be a new 
insertion belonging to the Long Interspersed Element-1 (LINE-1 or L1) lineage of 
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transposable elements.  L1s are retrotransposons that are transcribed as an RNA 
intermediate, and then reverse transcribed back into a different position of the genome.  
Insertions of other repeat elements, such as ALUs and other SINEs, require the L1 
reverse transcriptase to initiate mobilization (Chen et al., 2007; Dewannieux et al., 2003).  
In dogs, L1s comprise more than 14% of the genome and are believed to be more active 
than human L1s (Wang and Kirkness, 2005).  L1 and L1 mediated insertions can impact 
the gene expression of surrounding genes, and have been shown to cause both canine and 
human disease (Babushok and Kazazian, 2007).  Recently, an L1 insertion in intron 13 of 
the DMD gene was shown to cause muscular dystrophy in a Pembroke Welsh corgi dog 
(Smith et al., 2011).  Other examples of disease causing retrotransposon insertions in 
dogs include a LINE insertion in the Factor IX gene associated with mild form of 
hemophilia B (Brooks et al., 2003); a short interspersed element (SINE) insertion in the 
SILV gene responsible for merle patterning (Clark et al., 2006); and a SINE insertion in 
the PTPLA associated with centronuclear myopathy in Labradors (Pele et al., 2005).  In 
humans, retrotransposon insertions have been associated with diseases (Babatz and 
Burns, 2013; Kazazian et al., 1988; Mine et al., 2007), and several insertions have been 
found within the DMD gene (Ferlini et al., 1998; Ferlini and Muntoni, 1998; Holmes et 
al., 1994; McNaughton et al., 1993; Muntoni et al., 1993; Musova et al., 2006; Narita et 
al., 1993; Pizzuti et al., 1992), most of which are disease causing.  Examples include a 
chimeric L1 insertion into exon 48 in a patient with disease intermediate in severity 
between DMD and BMD (Holmes et al., 1994).  Insertions of rearranged (Musova et al., 
2006) and truncated L1 (Narita et al., 1993) elements into exon 44 lead to exon 44 
skipping and to DMD.  In contrast, in the Labrador retriever, insertion of the full length 
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L1 element into intron 19 results in the inclusion of an out-of-frame pseudoexon within 
the mRNA.  This is an increasingly recognized category of human mutation (Gurvich et 
al., 2008), and the Labrador may prove to be a useful model for preclinical trials directed 
toward mRNA splicing therapies. 
The Tibetan terrier with an out-of-frame deletion spanning 22 exons (exons 8-29) 
represents one of the only dog models affected by the most common mutation class found 
in human dystrophinopathy, where deletions of one or more exons account for around 60-
65% of mutations (Flanigan et al., 2009).  Typically, out-of-frame deletions result in 
DMD (Monaco et al., 1988), whereas deletions in frame resulting in a modified 
dystrophin protein with an intact C terminal domain can lead to the less severe BMD, 
even in the setting of very large deletions (England et al., 1990).  Only one patient with 
an out-of-frame exon 8-29 deletion has been identified and reported to the Leiden 
Muscular Dystrophy Database (White and den Dunnen, 2006), although the phenotype is 
not described.    
Small out-of-frame deletions similar to the 4 nt deletion in exon 65 found in the 
Cocker spaniel represent another class of mutations in DMD patients that account for 
7.3% of DMD mutations in human patients (Flanigan et al., 2009).  The Leiden Muscular 
Dystrophy database includes three 4 nt deletions in exon 65, all of which have been 
reported as associated with DMD:  c.9454_9457del, c.9459_9462del, and 
c.9471_9474del(Aartsma-Rus et al., 2006) (also reported elsewhere (Gardner et al., 
1995)).  The canine mutation c.9444_9447delTCTG deletes the same homologous 
nucleotides as one of these (c.9459_9462del).  
The absence of a detectable mutation in the Springer spaniel also has a correlate 
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in human disease.  Sequencing of cDNA derived from muscle mRNA should detect all 
categories of coding region mutations, but rare patients (0.2% in one large series) 
(Flanigan et al., 2009) have been reported with absence of dystrophin expression but no 
DMD mutation detectable by mRNA analysis.  These include cases where the 5’UTR, 
including the known promoter, has been sequenced, as was the case in the Springer 
spaniel.  Expression and variation of other genes have been shown to modify the disease 
phenotype in DMD patients (Flanigan et al., 2012; Heller et al., 2013; Martin et al., 2014; 
Pegoraro et al., 2011).  Perhaps unidentified mutations in other genes necessary for 
dystrophin expression explain the result in these patients.  Alternatively, unidentified 
mutations could exist in the noncoding regions of the DMD gene that alter expression of 
dystrophin and lead to a DMD phenotype.  Mutations in the DMD gene that alter splicing 
signals have been shown to affect disease severity in human patients (Juan-Mateu et al., 
2013).  Further investigation of the dystrophic Springer spaniel could help determine the 
cause of this unusual observation as seen in this small subset of patients. 
These new models offer new tools for the preclinical development of therapeutic 
strategies.  A current strategy that uses antisense oligonucleotides (AONs) to mediate 
exon skipping in order to restore the open reading frame and lead to a milder BMD 
phenotype  (Aartsma-Rus and van Ommen, 2007; Gurvich et al., 2008).  The Tibetan 
terrier we describe could be used as a model for AON mediated exon skipping; the open 
reading frame of the dystrophin mRNA could be restored by skipping either exons 6 and 
7 or exons 30-50.  Similarly, in the Cocker spaniel, skipping of exons 65 and 66 would 
restore the open reading frame.  These dogs may serve as improved models of 
nonmutation class specific therapies, as they appear to more faithfully recapitulate human 
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DMD at the histopathologic level, with more consistent absence of dystrophin expression 
than is found in the more common GRMD model. 
 
Materials and methods 
Immunofluorescence 
 Frozen muscle biopsies were obtained from Joe Kornegay, Dan Bogen, and Janet 
Bogen (University of North Carolina).  Frozen muscle was cut in 10 micron sections and 
fixed using 1% paraformaldehyde for 1 minute. Sections were then blocked in 10% fetal 
calf serum and permeabilized in 0.1% Triton for 30 minutes.  Next, the sections were 
incubated for one hour at room temperature with either an antidystrophin antibody 
specific to the rod domain (1:10, Dys1, Novocastra, produced in mouse) or to exon 1 
(1:10, Manex1a, Clone No. 4C7, a gift of Dr. G.E. Morris, produced in mouse) of 
dystrophin and washed with phosphate buffer saline (PBS).  To evaluate membrane 
integrity of each sample, all sections were stained with an antilaminin antibody (1:50, 
Sigma, produced in rabbit).  Goat antimouse AlexaFluor 488 (Molecular Probes) and 
Goat antirabbit AlexaFluor 568 (Molecular Probes) were used as a secondary antibodies 
for all sections at a 1:500 dilution.  Images were obtained on the Olympus IX71 
microscope under 20X magnification.  
 
Western blot analyses 
Frozen muscle was cut into 10 micron sections and solubilized in 4.6 mM Tris, 
pH 7.4, 9% SDS, 4% glycerol, 5% B-mercaptoethanol using the TissueLyser (Qiagen) 
and protein levels were quantified using the Nanodrop ND-1000 Spectrophotometer 
(Thermo Scientific).  Protein (20 ug per lane) was separated using a Nupage 3-8% Tris-
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Acetate precast gel (Invitrogen) and transferred to nitrocellulose.  Blots were blocked in 
Tris-buffered saline pH 7.4 with 0.1% Tween-20 and 5% nonfat milk.  Blots were 
incubated for one hour at room temperature with monoclonal antibodies against 
dystrophin rod domain (1:100, DYS1, Novocastra) or myosin heavy chain (1:500, MHC 
H-300, Santa Cruz Biotechnology, Inc.).  After washing in Tris buffered saline pH 7.4 
with 0.1% Tween-20, secondary antibodies (antimouse IgG at 1:300000 for DYS1 and 
antirabbit IgG at 1:15000 for antimyosin heavy chain) conjugated to horseradish 
peroxidase were added for 45 minutes.  Blots were washed again and developed by 
incubating the membrane in Luminol/Enhancer Solution and stable peroxide buffer 
(Supersignal® West Femto Maximum Sensitivity Substrate kit, Pierce) for 5 minutes and 
exposing to autoradiography film (Kodak) for one minute. 
 
Genetic analysis of DMD mRNA 
Frozen muscle was cut into 30-50 sections of 10 microns each and total RNA was 
extracted using Trizol (Invitrogen, La Jolla, CA) according to the manufacturer’s 
recommended protocol.  RNA levels were quantified using the Nanodrop ND-1000 
Spectrophotometer (Thermo Scientific).  Complementary DNA (cDNA) was synthesized 
using random hexamers and SuperScript III reverse transcriptase (Invitrogen) according 
to the manufacturer’s recommended protocol.  Primer sets were designed to amplify the 
coding region of the DMD cDNA in 10 amplicons (i.e., sections) (Table 3.1).  Due to the 
relatively low concentration of DMD mRNA in RNA extracts, each amplicon was 
amplified in two PCR steps using external and internal primer sets using Expand High 
Fidelity Taq polymerase (Roche) according to the manufacturer’s recommended protocol 
























Note:  The primers used to amplify and sequence the DMD mRNA in dogs are shown.  
Due to the relatively low concentration of DMD mRNA, each amplicon was amplified 
twice using an external and internal primer set.  Internal forward and reverse sequencing 





 (Table 3.1) using BigDye v3.1 sequencing reagent (Applied Biosystems) on the ABI 
3700 DNA analyzer (Applied Biosystems, Foster City, CA) prepared with POP-5 
capillary gel matrix.  The entire coding region of the DMD cDNA was sequenced for 
each dog and sequence files were analyzed using Sequencher (Gene Codes, Ann Arbor, 
MI) and compared against the wild type canine dystrophin cDNA sequence (NM 
001003343). 
 
Genetic analysis of genomic DNA 
 Where appropriate, genomic DNA was analyzed to verify mutations identified 
from mRNA.  DNA was isolated from 30 ten micron sections of frozen muscle using the 
Puregene Genomic DNA Purification Kit (Qiagen) according to the manufacturer’s 
recommended protocol.  DNA levels were quantified using the Nanodrop ND-1000 
Spectrophotometer (Thermo Scientific).  PCR amplification was conducted using Taq 
DNA Polymerase (Roche) according to the manufacturer’s protocol for short products 
(100-500 nts).  PCR products were sequenced using internal sequencing primers and the 
BigDye v3.1 sequencing reagent (Applied Biosystems) on the ABI 3700 DNA analyzer 
(Applied Biosystems, Foster City, CA) prepared with POP-5 capillary gel matrix.  
Sequence files were analyzed using Sequencher (Gene Codes, Ann Arbor, MI). 
The entire LINE-1 insertion in the Labrador retriever was amplified using the flanking 
intronic primers TGAAAGTAAGAGCTGAGTCATGG and 
TCGCCAAAAGTGAATTGAAA with the Expand Long Range DNA polymerase 
(Roche) according to the manufacturer’s recommended protocol.  The entire LINE-1 
insertion was sequenced using internal sequencing primers as described above. 
To determine the boundaries of the deletion in the Tibetan terrier, primers were 
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designed to amplify exons 3 through 32 and exons 44 through 50 of the DMD gene from 
genomic DNA (Appendix D).  An alternate set of primers for exons 8 and 29 were made 
to verify the deletion extended to exons 8 and 29 (Appendix D).  PCR amplification was 
done using Taq DNA Polymerase (Roche) according to the manufacturer’s protocol and 
electrophoresed on a 1% agarose gel stained with ethidium bromide. 
The muscle promoter region, DMD 5’ UTR and DMD 3’ UTR was sequenced 
from genomic DNA obtained from the Springer spaniel.  The 5’ region of the muscle 
isoform of dystrophin including the promoter and 5’ UTR (from 1,285 nucleotides 
upstream of the start codon) was amplified using the primers 
TTCTGTGCCAAGCAATTGAA and GGGCATGAACTCTTGTGGAT using Taq DNA 
Polymerase (Roche) according the manufacturer’s protocol and sequenced using internal 
primers as described above.  The DMD 3’ UTR was amplified in four sections using the 
following primers:  Section 1 – primers TGGTACAACGGTGTCTTCTCC and 
CAGCCAGTTCCAATCAGTCA; Section 2 – primers TATGGAACGCTTTTGGGTTG 
and TTACCAGGAGCACACCATGA; Section 3 – primers 
TCCCAGACAGTGAGGAGGAC and TGCACGCTATTTACCTCTGC; and Section 4 – 
primers ACATCCAACATGGCTTCTCA and TGCGTGCTTTATTGAGATACAC.  
Each section of the 3’ UTR was sequenced using internal primers as described above. 
 
Genotyping mutations in dogs 
 Genomic DNA was isolated from either 30 ten micron sections of frozen muscle 
using the Puregene Genomic DNA Purification Kit (Qiagen) according to the 
manufacturer’s recommended protocol or from whole blood using the DNeasy Blood and 
Tissue Kit (Qiagen) according to the manufacturer’s recommended protocol for all 
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genotyping assays described.  DNA levels were quantified using the Nanodrop ND-1000 
Spectrophotometer (Thermo Scientific).  To determine the carrier status of the LINE-1 
insertion in intron 19 of the DMD gene found in the Labrador retriever, a PCR assay was 
used to differentially amplify the wild type or mutant allele.  The primers  
L1 (TGAAAGTAAGAGCTGAGTCATGG) and L2 (GAAGCGCGAACTCTTCTCAC) 
were designed to amplify a 531 bp product if the LINE-1 insertion was present, and the 
primers L1 (TGAAAGTAAGAGCTGAGTCATGG ) and L3 
(TCGCCAAAAGTGAATTGAAA ) were designed to amplify a 460 bp product if the 
LINE-1 insertion was absent.  PCR amplification was conducted using Taq DNA 
Polymerase (Roche) according to the manufacturer’s recommended protocol, and 
products were electrophoresed on a 1% agarose gel. 
 To determine the presence of the 4 bp deletion in exon 65 of the DMD gene found 
in the Cocker spaniel, the primers TGGATCTCTTGAGCCTATCG and 
ATTCAGCAGCCAATTGAGAC were used to amplify the region of interest from 
genomic DNA.  PCR amplification was conducted using Taq DNA Polymerase (Roche) 
according to the manufacturer’s recommended protocol, and PCR products were 
sequenced as described above.   
Quantitative PCR (qPCR) was used to detect the carrier status of the deletion of 
exons 3 through 7 of the DMD gene found in the Yorkshire terrier or the deletion of 
exons 8 through 29 found in the Tibetan terrier by comparing the relative levels of a test 
DMD exon deleted in each mutation compared to a reference exon in the same gene.  The 
primers TGCCCTTCCTAGAATCAACA and GTCTCCCATCCTGTAGGTCA were 
used to amplify DMD exon 3 in the Yorkshire terrier and primers 
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TTGTTCATTCGCCTTTCAGA and TGTGTATGATGGCTAAAAATGC were used to 
amplify DMD exon 8 in the Tibetan terrier.  The reference DMD exon 49 was amplified 
using the primers CCCAGGAAATTGAAGTAGCA and 
AGCACACCAGGACAGAATTG in both dogs.  qPCR reaction mixtures contained a 
final concentration of 1x Platinum SYBR Green Mix (Invitrogen), 20 ng of genomic 
DNA, and 0.5 µM of forward and reverse primers and done in replicates of four.  After 
an initial denaturation of 95°C for 2 minutes, amplification was performed using the 
following cycle conditions:  40 cycles of 95°C for 15 seconds, 58°C for 30 seconds, and 
72°C for 30 seconds.  Fluorescence intensity was monitored once per cycle after the 
elongation phase using the 7900HT (Applied Biosystems).  A melting curve was 
produced after each run starting from 60°C to 95°C at a ramp rate of 2% on the 7900 HT 
(Applied Biosystems).  A standard curve was produced for each primer pair by diluting 
the control DNA to concentrations of 40 ng, 20 ng, 10 ng, and 5 ng of DNA and running 
four duplicates for each concentration.  Results were analyzed using SDS 2.3 software 
(Applied Biosystems) and calculated using the comparative CT (ΔΔCT) method. 
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 3’ UTRs have been shown to regulate gene expression posttranscriptionally by 
altering mRNA stability, localizing mRNA, or directly affecting translation (Andreassi 
and Riccio, 2009; Gramolini et al., 2001; Matoulkova et al., 2012; Mazumder et al., 
2003). We have shown that the highly conserved elements (HCEs) spanning the Lemaire 
A and Lemaire D regions of DMD 3’ UTR regulate translation and mRNA abundance in 
differentiated C2C12 cells (Chapter 1).  It has been shown previously that mRNA 
stability of the DMD transcript has a larger impact on dystrophin protein levels than 
transcription rate in BMD patients (Spitali et al., 2013) and could impact the 
effectiveness of developing therapies.  Here, we use the transcription inhibitor 
Actinomycin D to directly measure changes in mRNA stability and show that the HCEs 
spanning the Lemaire A and D regions increases mRNA stability in C2C12 myotubes. 
 
Results 
 Having shown that the DMD 3’ UTR increases translation and mRNA abundance 
in C2C12 myotubes, we were interested in determining what effect the DMD 3’ UTR has 
on mRNA stability during differentiation.  To do this, we first transfected C2C12 




(3’ UTR) we had previously made by replacing the SV40 poly A region of the pHRL 
vector with the entire DMD 3’ UTR.  After 2 days, we measured Renilla mRNA stability 
by replacing the growth media of the C2C12 cells with media containing the transcription 
inhibitor, Actinomycin D, and used qPCR to measure mRNA levels of the transfected 
constructs compared to total RNA at various time points after Actinomycin D addition 
(Figure A.1A and A.1C, Myoblasts).  To measure mRNA stability of the pHRL and 
DMD 3’ UTR constructs in C2C12 myotubes, transfected myoblasts were placed in a low 
serum media for 5 days to induce differentiation before Actinomycin D was added and 
mRNA levels were measured using qPCR at various time points (Figure A.1B and A.1D, 
Myotubes).   Because the half life of the Renilla constructs was unknown, we duplicated 
the experiment in at least four independent experiments for each transfected construct and 
measured mRNA levels at time points between 0 and 17 hours after Actinomycin D 
exposure.  The results of all independent experiments were combined and the half life 
was estimated using a nonlinear regression analysis to plot the best fit line (Figure A.1).  
The estimated half life of the control pHRL construct (pHRL) and the DMD 3’UTR 
construct (3’ UTR) was similar in C2C12 myoblasts (T1/2 = 3.05 hours and 3.76 hours, 
respectively) (Figure A.1A and A.1C).  In C2C12 myotubes, the estimated half life of the 
control pHRL vector (pHRL) increased slightly from 3.05 hours to 3.78 hours (Figure 
A.1B).  However, the construct containing the DMD 3’ UTR was more stable in 
myotubes with an estimated half life of 8.72 hours (Figure A.1D, Myotubes).  We found 
that we had a high well to well variation when transfecting C2C12 cells due to 
differences in differentiation, cell survival, and transfection efficiency (see Appendix C), 








Figure A.1.  Half life of the DMD 3’ UTR construct. 
 
A.  RNA levels of the pHRL Renilla construct in transfected C2C12 myoblasts are 
shown.  Data points represent individual transfections of C2C12 cells across at least four 
independent experiments, and nonlinear regression analysis was used to estimate the half 
life of the transfected construct. 
B.  RNA levels of the pHRL Renilla construct in transfected C2C12 myotubes are shown.  
Data points represent individual transfections of C2C12 cells across at least four 
independent experiments, and nonlinear regression analysis was used to estimate the half 
life of the transfected construct.  The estimated half life (T1/2) of pHRL Renilla mRNA 
was similar in both myoblasts and myotubes (3.05 hours and 3.78 hours, respectively). 
C.  RNA levels of the DMD 3’ UTR construct in transfected C2C12 myoblasts are 
shown.  Data points represent individual transfections of C2C12 cells across at least four 
independent experiments, and nonlinear regression analysis was used to estimate the half 
life of the transfected construct. 
D.  RNA levels of the DMD 3’ UTR construct in transfected C2C12 myotubes are shown. 
Data points represent individual transfections of C2C12 cells across at least four 
independent experiments, and nonlinear regression analysis was used to estimate the half 
life of the transfected construct.  The DMD 3’UTR construct was more stable in C2C12 
myotubes compared to myoblasts (T1/2 = 8.72 hours and 3.76 hours, respectively).  RNA 
levels were measured using qPCR and plotted as the percent of RNA remaining 
normalized to the average amount of RNA measured before Actinomycin D treatment (0 



































to total RNA.  To overcome this, we designed a more accurate method for detecting 
changes in mRNA stability that would take into account any well to well variation in 
transfecting C2C12 cells.  Specifically, we designed a 3’ UTR tagged construct (3’UTR-
tag) that was identical to our original Renilla DMD 3’ UTR construct (3’UTR) except 
with the addition of a random 18 bp sequence inserted between the Renilla coding 
sequence and the DMD 3’ UTR.  This allowed us to design qPCR primers that could 
selectively amplify the 3’UTR-tag construct containing the full length DMD 3’ UTR and 
any 3’ UTR deletion construct cotransfected with this construct.  To determine what 
effect the conserved regions of the DMD 3’ UTR has on mRNA stability, we transfected 
C2C12 myoblasts with either the full length DMD 3’ UTR Renilla construct (3’UTR) or 
the deletion constructs we had previously made spanning the Lemaire A region (dl-A), 
the middle region of the 3’ UTR (dl-M), or the Lemaire D region (dl-D) (See Chapter 1 
for deletion boundaries).  All cells were cotransfected with the 3’UTR tagged construct 
(3’UTR-tag) containing the full length 3’UTR.  After 2 days in growth media for 
myoblasts or an additional 5 days in differentiation media for myotubes, Actinomycin D 
was added and mRNA levels were measured for the 3’ UTR construct and the 
cotransfected 3’UTR tagged construct using qPCR after 0 hours, 4 hours, or 8 hours after 
Actinomycin D exposure (Figure A.2, Figure A.3).  In myoblasts, the mRNA levels of 
the full length 3’UTR construct and the deletion constructs with the Lemaire A region 
(dl-A), the middle region (dl-M), or the Lemaire D region (dl-D) deleted remained the 
same as the cotransfected 3’UTR tagged construct (3’UTR-tag) after 8 hours in 
Actinomycin D, showing the mRNA decay rate remains the same when any of these 









Figure A.2.  Relative half life of DMD 3’ UTR constructs in C2C12 myoblasts. 
 
A.  Relative RNA levels of the dl-A construct transfected in C2C12 myoblasts treated 
with Actinomycin D are shown.  The construct was cotransfected with the control 
3’UTR-tag construct and RNA levels were normalized to the amount of the 3’UTR-tag 
mRNA at each time point.  There was no significant difference between the deletion 
construct and the cotransfected 3’UTR-tag construct. 
B.  Relative RNA levels of the dl-M construct transfected in C2C12 myoblasts treated 
with Actinomycin D are shown.  The construct was cotransfected with the control 
3’UTR-tag construct and RNA levels were normalized to the amount of the 3’UTR-tag 
mRNA at each time point.  There was no significant difference between the deletion 
construct and the cotransfected 3’UTR-tag construct. 
C.  Relative RNA levels of the dl-D construct transfected in C2C12 myoblasts treated 
with Actinomycin D are shown.  The construct was cotransfected with the control 
3’UTR-tag construct and RNA levels were normalized to the amount of the 3’UTR-tag 
mRNA at each time point.  There was no significant difference between the deletion 
construct and the cotransfected 3’UTR-tag construct. There was no significant difference 
between the mRNA levels of the DMD 3’ UTR construct (3’UTR) and the cotransfected 
3’UTR-tag construct after 8 hours of Actinomycin D treatment showing that the decay 
rate is the same for both constructs.  The average of four biological transfection replicates 










































Figure A.3.  Relative half life of DMD 3’ UTR constructs in C2C12 myotubes. 
 
A.  Relative RNA levels of the dl-A construct transfected in C2C12 myotubes treated 
with Actinomycin D are shown.  The construct was cotransfected with the control 
3’UTR-tag construct and RNA levels were normalized to the amount of the 3’UTR-tag 
mRNA at each time point.  There was ~20% less dl-A RNA after 8 hours in Actinomycin 
D compared to the full length 3’ UTR construct. 
B.  Relative RNA levels of the dl-M construct transfected in C2C12 myotubes treated 
with Actinomycin D are shown.  The construct was cotransfected with the control 
3’UTR-tag construct and RNA levels were normalized to the amount of the 3’UTR-tag 
mRNA at each time point.  There was no significant difference between the deletion 
construct and the cotransfected 3’UTR-tag construct. 
C.  Relative RNA levels of the dl-D construct transfected in C2C12 myotubes treated 
with Actinomycin D are shown.  The construct was cotransfected with the control 
3’UTR-tag construct and RNA levels were normalized to the amount of the 3’UTR-tag 
mRNA at each time point.  There was ~20% less dl-D RNA after 8 hours in Actinomycin 
D compared to the full length 3’ UTR construct.  The average of four biological 




































decrease in mRNA levels when the Lemaire A or D regions were deleted (dl-A and dl-D) 
compared to the cotransfected 3’UTR tagged construct after 8 hours of Actinomycin D 
exposure showing that the mRNA decay rate was faster when these conserved regions 
were deleted relative to the full length 3’ UTR (Figure A.3). 
 To measure the actual change in mRNA half life when the conserved Lemaire A 
region is deleted from the DMD 3’ UTR in myotubes, we transfected C2C12 myoblasts 
with the 3’ UTR deletion construct with the Lemaire A region removed (dl-A) and 
differentiated the cells in a low serum media for five days.  After differentiation, we 
added Actinomycin D to the cell media and estimated the mRNA half life of the dl-A 
construct as previously described (Figure A.4).  The estimated half life for the dl-A 
construct in myotubes is 7.03 hours (Figure A.4) compared to 8.72 hours of the full 
length 3’UTR construct in C2C12 myotubes (Figure A.1, Myotubes). 
 
Discussion 
 We had shown previously that the highly conserved elements spanning the 
Lemaire A and D regions affect mRNA abundance in C2C12 myotubes.  Here, we 
directly measure the effect the DMD 3’ UTR and these conserved regions have on mRNA 
stability.  Adding the DMD 3’ UTR to the Renilla pHRL construct increased mRNA half 
life slightly in C2C12 myoblasts with the 3’ UTR construct being 3.76 hours versus 3.05 
hours for the pHRL construct, but more than doubled the mRNA half life in C2C12 
myotubes with the 3’ UTR construct being 8.72 hours versus 3.78 hours for the pHRL 
construct, showing that the DMD 3’ UTR stabilizes the mRNA transcript during 
differentiation.  It was difficult to obtain accurate half life measurements of transfected 

















Figure A.4.  Half life of the dl-A construct. 
 
RNA levels of the DMD 3’ UTR Renilla construct with the Lemaire A region deleted (dl-
A) in transfected C2C12 myotubes treated with Actinomycin D is shown.  Data points 
represent individual transfections of C2C12 cells across two independent experiments.  
Nonlinear regression analysis was used to estimate the half life of the dl-A construct in 
C2C12 myotubes.  The estimated half life (T1/2) of the dl-A construct is 7.03 hours.  RNA 
levels were measured using qPCR and plotted as the percent of RNA remaining 
normalized to the average amount of RNA measured before Actinomycin D treatment (0 








differentiation and transfection efficiency (see Appendix C).  A cotransfected control that 
would account for this variation would degrade when the cells were exposed to 
Actinomycin D and could not be used.  To overcome this, we cotransfected our deletion 
constructs with a modified 3’ UTR construct (3’UTR-tag).  Although we could not 
directly measure mRNA half life of each deletion construct, we could more accurately 
determine whether deleting a region of the 3’ UTR had an effect on mRNA stability 
compared to the full length 3’ UTR because all measurements could be normalized to the 
cotransfected control to account for any well to well variation.  When we deleted the 
Lemaire A region (dl-A), the middle portion of the 3’ UTR (dl-M), or the Lemaire D 
region (dl-D), we did not see a change in mRNA stability in myoblasts (Figure A.2).  
However, in myotubes, we saw a decrease in mRNA stability when the conserved 
Lemaire A or D regions were deleted (dl-A and dl-D) (Figure A.3), with 20% less RNA 
measured for these deletion constructs compared to the full length 3’ UTR construct after 
8 hours in Actinomycin D.  Assuming the half life of the full length 3’ UTR construct is 
8.72 hours in myotubes, the calculated half life of the dl-A construct would be 7.11 +/- 
0.59 hours (Elkon et al., 2010; Perez-Ortin et al., 2007).  In a separate experiment, we 
measured the half life of the dl-A construct in C2C12 myotubes at 7.03 hours (Figure 
A.4).  According to mRNA kinetics calculations (Perez-Ortin et al., 2007), this 19% 
decrease in half life would result in a 19% decrease in steady state mRNA levels as long 
as transcription rate remains constant.  Indeed, we measured a 20% decrease in steady 
state RNA levels in C2C12 myotubes when the Lemaire A region was deleted (dl-A) in 
the cells that were used in these experiments.  It should be noted that this decrease of 
20% in mRNA levels is smaller than the decrease we showed previously where deleting 
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the Lemaire A region of the 3’ UTR decreased mRNA levels by ~50% in C2C12 
myotubes (Chapter 1).  This is likely due to differences in C2C12 differentiation states 
between the two experiments and is discussed more fully in Appendix C.  Although we 
did get a large amount of variation using no transfection control when measuring the half 
life of these constructs, the separate experiments measuring the estimated half life, the 
relative half life using the cotransfected 3’UTR-tag construct, and measuring steady state 
mRNA levels all agree.  We conclude that these regions do affect mRNA stability, but 






Mouse C2C12 myoblast cells were purchased from ATCC (CRL-1772).  C2C12 
myoblasts were cultured in growth medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone).  Myogenic differentiation was induced by replacing the medium of the C2C12 
myoblasts with DMEM/F-12 media supplemented with 2% horse serum (Sigma) for 5 
days.  Cells were cultured at 37°C and 5% CO2. 
 
Transfecting C2C12 cells 
 When mRNA levels of transfected constructs were analyzed, C2C12 myoblasts 
(6x105 cells) were transfected with 275 ng of the construct (137.5 ng of each construct if 
two constructs were cotransfected) using 3.3 uL of Lipofectamine 2000 in a 24 well 





Measuring mRNA stability 
Half lives of transfected constructs were determined by culturing transfected 
C2C12 cells in Actinomycin D (5µg/mL) at 37°C to inhibit transcription.  No cell death 
or changes in morphology were observed when the cells were exposed to Actinomycin D 
for up to 8 hours.  Total RNA was extracted from C2C12 cells at the times indicated in 
each figure using Trizol (Invitrogen) as described by the manufacturer.  Each RNA 
sample was treated with DNAse I (Thermo Scientific) to remove any DNA 
contamination, and cDNA was synthesized using the SuperScript III First Strand 
Synthesis Kit (Life Technologies) using random hexamers.  Real time PCR was 
performed using the Applied Biosystems 7900HT Real time PCR system using Express 
SYBR GreenER qPCR SuperMix (Life Technologies) with primers optimized to amplify 
each construct according to the manufacturer’s protocols.   
When a single Renilla construct was transfected into C2C12 cells, 500 ng of total 
RNA was added to each qPCR reaction and the primers GGCTTGTCTGGCCTTTCACT 
and CCCTTCACCTTCACGAACTC were used to amplify all Renilla constructs used as 
described above.  Results were analyzed using SDS 2.3 software and calculated using the 
comparative CT (ΔΔCT) method by normalizing the transfected construct levels at each 
time point to the average amount of RNA measured for that construct before 
Actinomycin D treatment (t=0) set at 100%.  The percent mRNA remaining was plotted 
versus time of Actinomycin D addition by combining the data of at least four independent 
experiments, and nonlinear regression analysis was done using Excel (Microsoft, 




To measure the relative stability of a deletion construct, a full length DMD 3’ 
UTR construct modified to include an 18 bp insertion between the Renilla coding 
sequence and the DMD 3’ UTR (3’UTR-tag) was cotransfected with a deletion construct.  
This 3’UTR tagged construct was made using the Phusion Site Directed Mutagenesis Kit 
(Thermo Scientific), as specified by the manufacturer using the DMD 3’ UTR construct 
we had previously made as a template and the phosphorylated primers 
CGGTAAGAAGGAGGAAGTCTTTTCCACATG and 
GTCCAAGTCCAGAATTACTGCTCGTTCTTCAGC.  This resulted in the inclusion of 
the sequence GGACTTGGACCGGTAAGA in the construct.  The primers 
CTGAGGAGTTCGCTGCCTAC and CTCTTACCGGTCCAAGTCC were used during 
qPCR to selectively amplify the 3’UTR tagged construct.  When the 3’UTR tagged 
construct was cotransfected with other Renilla constructs, the primers 
CTGAGGAGTTCGCTGCCTAC and TGTGGAAAAGACTTCCTCCTAGAA were 
used to selectively amplify the 3’UTR, dl-M, and dl-D constructs.  The primers 
CTGAGGAGTTCGCTGCCTAC and CTGACAGTTCTCAAATGCCTAGAA were 
used to selectively amplify the dl-A construct.  Results were analyzed using SDS 2.3 
software and calculated using the comparative CT (ΔΔCT) method by normalizing each 




Andreassi, C., and Riccio, A. (2009). To localize or not to localize: mRNA fate is in 
3'UTR ends. Trends Cell Biol 19, 465-474. 
 
Elkon, R., Zlotorynski, E., Zeller, K.I., and Agami, R. (2010). Major role for mRNA 
stability in shaping the kinetics of gene induction. BMC Genomics 11, 259. 
165 
 
Gramolini, A.O., Belanger, G., and Jasmin, B.J. (2001). Distinct regions in the 3' 
untranslated region are responsible for targeting and stabilizing utrophin transcripts in 
skeletal muscle cells. J Cell Biol 154, 1173-1183. 
 
Matoulkova, E., Michalova, E., Vojtesek, B., and Hrstka, R. (2012). The role of the 3' 
untranslated region in post-transcriptional regulation of protein expression in mammalian 
cells. RNA Biol 9, 563-576. 
 
Mazumder, B., Seshadri, V., and Fox, P.L. (2003). Translational control by the 3'-UTR: 
the ends specify the means. Trends Biochem Sci 28, 91-98. 
 
Perez-Ortin, J.E., Alepuz, P.M., and Moreno, J. (2007). Genomics and gene transcription 
kinetics in yeast. Trends Genet 23, 250-257. 
 
Spitali, P., van den Bergen, J.C., Verhaart, I.E., Wokke, B., Janson, A.A., van den Eijnde, 
R., den Dunnen, J.T., Laros, J.F., Verschuuren, J.J., t Hoen, P.A., et al. (2013). DMD 














CHARACTERIZATION OF HUMAN DMD 3’ UTR  
VARIANTS AND PREDICTED BINDING SITES 
 
3’ UTR variants in human DMD patients 
 
 The sequence of human DMD 3’ UTRs from a population of 1,222 patients was 
obtained from Dr. Robert Weiss (Department of Human Genetics, University of Utah). 
This group of patients included 410 patients enrolled in the United Dystrophinopathy 
Project (UDP), 569 patients from clinical referrals of doctors who had requested DMD 
mutation screening for individuals suspected to be dystrophic, and 243 patients from a 
newborn screening study that screened for DMD mutations in infants with high creatine 
kinase (CK) levels.  There were a total of 1,843 discrepancies compared to a reference 
sequence identified amongst 626 3’ UTR sequences using Consed.  Each discrepancy 
was visually inspected to determine whether the change was due to a sequencing error or 
represented a true variant.  There were 1,377 discrepancies amongst 435 3’ UTRs that 
were verified as true variants.  Identified variants were named using the HGVS guidelines 
and recommendations for variant nomenclature (den Dunnen and Antonarakis, 2000) 
(Table B.1).  There were 787 3’ UTRs that matched the reference sequence and contained 
no variants.  Twenty-three variants in the DMD 3’ UTR were found only in patients 
labeled as having no mutations in the coding region of the DMD gene (NODCM) (Table 





















Table B.1 continued 
 
 
Note:  Variants found in human DMD 3’ UTRs are shown.  ‘# of Hits’ equals the number 
of 3’ UTRs each variant was found in.  The 3’ UTR position for each variant was 
determined where nucleotide #1 is the nucleotide immediately after the stop codon.  If the 
variant affected more than one nucleotide, the position of the first nucleotide is given.  A 
‘Variant Code’ was assigned for each variant as a shorthand way of referring to each 
variant.  Any variant found in less than 5 3’ UTRs was assigned a code starting with ‘M’ 
and followed by a number.  Any variant found in 5 or more 3’ UTRs was assigned all 
other letters.   Conservation of each variant was determined by the PhastCons score of 
that position of the 3’ UTR extracted from the UCSC genome browser.  The PhastCons 
score is a measurement of conservation indicated by a score between 0 (not conserved) 
and 1 (conserved).  PhastCons scores above 0.85 are highlighted. One hundred and one 
unique variants were identified.  “Sequencing Error” and “No Trace Information 
Available” represent the number of times a discrepancy between the sequence and a 
reference sequence was miscalled by Consed or where the sequence trace was 
















each variant was determined (Table B.1).  The conservation of each variant was 
determined by the measured PhastCons score extracted from the UCSC Genome Browser 
(Table B.1).  One hundred and one total variants were identified in the DMD 3’ UTR and 
surrounding regions of our patient population and given a variant code; where rare 
variants (found in less than five patients) were given a label M followed by a #, and more 
common variants (found in five or more patients) were coded with all other letters (Table 
B.1).  The haplotype of all patients containing at least one variant is shown (Table B.2).  
In addition, we searched for DMD 3’ UTR variants in publicly available databases, and 
found 83 variants in the current version of dbSNP (Sherry et al., 2001), 40 variants in the 
1000 Genome database (Abecasis et al., 2012), and 38 variants reported in the Leiden 
Database (Aartsma-Rus et al., 2006) (Table B.3).  One hundred and forty total variants in 
the DMD 3’ UTR were identified in our patient population and all databases searched 
(Table B.3).  Predicted miRNA binding sites in the DMD 3’ UTR were identified using 
TargetScan (Lewis et al., 2005) (Table B.4).  Predicted RNA protein binding sites in the 
Lemaire A region (Table B.5), a conserved AU rich sequence from the middle region 
(Table B.6), and the Lemaire D region (Table B.7) of the DMD 3’ UTR were identified 



















































Table B.2 continued 
 
 
Note:  *Each variant in each patient is depicted in this graph using the ‘Variant Code’ 
assigned to each variant in Table B.1.  The variants for each patient are sorted from left to 
right by 3’ UTR position, where the leftmost variants are found earlier in the 3’ UTR.  
Patients described as having no mutations in the coding region of the DMD gene 









































Table B.3 continued 
 
 
Note:  DMD variants found in all databases searched are shown.  Variant codes were 
assigned for all variants found in the DMD patient population (See Table B.1).  The 
number of patients found in the Leiden Database (Aartsma-Rus et al., 2006) is shown (# 
of Hits Leiden Database).  dbSNP numbers are shown for any variant found in the current 
version of dbSNP (Sherry et al., 2001).  In some cases, multiple dbSNP numbers describe 
the same mutation.  For example, a four base pair duplication may be described as a 
duplication or insertion and given two separate dbSNP numbers.  For any variant reported 
in the 1000 genomes project (Abecasis et al., 2012), the Minor Allele Frequency (MAF) 


























Note:  Predicted miRNA binding sites in the DMD 3’ UTR using TargetScan (Lewis et 
al., 2005) are shown.  The 3’ UTR regions deleted that contain each predicted binding 
site are shown (see Chapter 1 for details of deleted regions).  References:  [1] - 
(Eisenberg et al., 2007); [2] - (Roberts et al., 2012); [3] - (Ketley et al., 2013); [4] - 

























Table B.5 continued 
 
 
Note:  Predicted RNA protein binding sites in the Lemaire A region of the DMD 3’ UTR 
using RBPDB (Cook et al., 2011) are shown.  RBPDB predicts binding sites by scoring 
potential binding sites in the sequence using position weight matrices and assigns a score 
that is calculated as the sum of the scores of each nucleotide at each position in the 
position weight matrix.  A relative score is also given as a percent of the score to the 
maximum possible score of the calculated matrix.  Only predicted sites with a relative 
score above 80% are shown.  The 3’ UTR start and end positions if each predicted 
binding site are shown.  Human variants found within or directly adjacent to a predicted 




















Note:  Predicted RNA protein binding sites contained within a conserved AU rich 
sequence found in the middle region of the DMD 3’ UTR using RBPDB (Cook et al., 
2011) are shown.  RBPDB predicts binding sites by scoring potential binding sites in the 
sequence using position weight matrices and assigns a score that is calculated as the sum 
of the scores of each nucleotide at each position in the position weight matrix.  A relative 
score is also given as a percent of the score to the maximum possible score of the 
calculated matrix.  Only predicted sites with a relative score above 80% are shown.  The 
3’ UTR start and end positions of each predicted binding site are shown.  Human variants 

















Table B.7 continued 
 
 
Note:  Predicted RNA protein binding sites in the Lemaire D region of the DMD 3’ UTR 
using RBPDB (Cook et al., 2011) are shown.  RBPDB predicts binding sites by scoring 
potential binding sites in the sequence using position weight matrices and assigns a score 
that is calculated as the sum of the scores of each nucleotide at each position in the 
position weight matrix.  A relative score is also given as a percent of the score to the 
maximum possible score of the calculated matrix.  Only predicted sites with a relative 
score above 80% are shown.  The 3’ UTR start and end positions if each predicted 
binding site are shown.  Human variants found within or directly adjacent to a predicted 
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CONTROLS FOR THE DMD 3’ UTR EXPERIMENTS 
 
 
Expression of the pHRL and 3’ UTR constructs  
 
during C2C12 differentiation 
 
Previously, we showed that a Renilla construct containing the DMD 3’ UTR 
increased in expression during C2C12 differentiation relative to the control pHRL vector 
(Chapter 1).  To determine whether the relative increase was due to an increase in the 
DMD 3’ UTR construct or a decrease in the control pHRL construct during 
differentiation, we transfected C2C12 cells with these constructs and monitored changes 
in expression of the pHRL-CMV (pHRL) control construct and the DMD 3’ UTR (3’ 
UTR) construct every 24 hours for 7 days as the cells differentiated (Figure C.1).  The 
observed increase in expression of the 3’ UTR construct (3’ UTR) began 2 days after 
C2C12 cells were grown in differentiation media and continued to increase until the 5th 
day of differentiation (Figure C.1).  This increase in expression of the 3’ UTR construct 
correlates with the morphology of the differentiating C2C12 cells with elongation of the 
myoblasts first being observed at Day 2 and large, mature myotubes being formed by 
Day 5.  Expression of the control pHRL construct (pHRL) remained consistent during 
differentiation (Figure C.1).  Construct synthesis, C2C12 transfections, and 
measurements of expression using a Renilla/Firefly dual luciferase assay were done as 




















Figure C.1.  Expression of the control pHRL construct remains consistent during C2C12 
myogenesis.   
 
Relative expression levels for the control pHRL reporter construct (pHRL) and the DMD 
3’UTR construct (3’UTR) are shown during the course of differentiation.  C2C12 cells 
transfected with the DMD 3’ UTR construct (3’ UTR) had an increase in Renilla 
expression as the cells differentiated, whereas cells transfected with the control pHRL-
CMV construct (pHRL) did not show an increase during differentiation.  The average of 
four biological transfection replicates is shown for each construct at each time point.  







Size control constructs for deletions of the DMD 3’ UTR 
There is evidence that length of a 3’ UTR can affect translational efficiency and 
mRNA stability (Hogg and Goff, 2010; Tanguay and Gallie, 1996).  To determine if the 
effect of deleting regions of the 3’ UTR was due to changing the size of the 3’ UTR 
rather than deleting regulatory elements, we made DMD 3’ UTR Renilla constructs 
containing the full length 3’ UTR except with the Lemaire A or middle region inserted in 
the reverse orientation (A-rev and M-Rev, respectively), and transfected these constructs 
into C2C12 cells.  Reversing the sequence would disrupt any regulatory elements 
contained within this region without changing the length of the 3’ UTR.  In C2C12 
myoblasts and myotubes, deleting the Lemaire A region (dl-A) had the same effect on 
expression as reversing the Lemaire A region (A-Rev) (Figure C.2), showing that the 
decrease in expression in myotubes when this region is deleted is not due to changing the 
length of the 3’UTR.  Likewise, deleting the middle region (dl-M) compared to reversing 
the middle region (M-Rev) resulted in the same level of expression in C2C12 myotubes 
(Figure C.2, Myotubes).  However, deleting the middle region (dl-M) increased 
expression ~80% whereas reversing the middle region (M-Rev) did not increase 
expression compared to the full length 3’ UTR construct in C2C12 myoblasts (Figure 
C.2, Myoblasts).  The change in size of the 3’ UTR when the middle region of the 3’ 
UTR is deleted could account for the increase in expression seen in myoblasts.  
Alternatively, the previously described antisense lncRNA that spans the entire middle 
region of the DMD 3’ UTR (Bovolenta et al., 2012) could still be functional when the 
middle region is reversed.  The beginning and end portions of the lncRNA are found in 











Figure C.2.  Size control constructs for the dl-A and dl-M constructs in C2C12 cells. 
 
A.  Relative protein expression of the control Renilla vector (pHRL), the full length DMD 
3’ UTR construct (3’UTR), the 3’ UTR constructs with the Lemaire A region or middle 
region deleted (dl-A and dl-M), and the 3’ UTR constructs with the Lemaire A region or 
middle region reversed (A-Rev and M-Rev) in transfected C2C12 myoblasts are shown. 
B.  Relative protein expression of the pHRL, 3’ UTR and size control constructs 
transfected into C2C12 myotubes are shown.  The result of three biological replicates is 
shown with expression levels normalized to pHRL-CMV expression (pHRL) using a 






































lncRNA is still expressed and needs only to complement the 3’ UTR sequence to alter 
expression.  In this case, reversing the sequence could still allow for the complementary 
binding of the resulting antisense lncRNA with the DMD 3’ UTR.  However, further 




 Size control constructs were made by amplifying the Lemaire A region or middle 
region of the DMD 3’ UTR using the specific primers 
CGTTTAGGTACCAGGAAGTCTTTTCCACATGGC and 
CGTTTACTCGAGCCACTCAGCTGACAGTTCTCAAATG for the Lemaire A region, 
and the primers CGTTTAGGTACCCATTTGAGAACTGTCAGCTGAGTGG and 
CGTTTACTCGAGCTTAAACTTCTTAGTAGGATGTAAAGTAACCCCTTG to 
amplify the middle region of the 3’ UTR.  The full length DMD 3’ UTR Renilla construct 
that we had previously made was used as a template to amplify the vector for the size 
control constructs using the primers 
CGTTTAGGTACCCATTTGAGAACTGTCAGCTGAGTGG and 
CGTTTACTCGAGCCTAGAATTACTGCTCGTTCTTCAGCAC for the Lemaire A 
insert and the primers 
CGTTTAGGTACCCAAGGGGTTACTTTACATCCTACTAAGAAGTTTAAG and 
CGTTTACTCGAGCCACTCAGCTGACAGTTCTCAAATG for the middle region 
insert.  Overhang sequences in insert and vector primers contain the cut sites for the KpnI 
and XhoI restriction enzymes so that the inserted Lemaire A or middle region inserts in 
the reverse orientation in the DMD 3’ UTR.  The vector and insert PCR product was 
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digested with XhoI (New England Biolabs) and KpnI (New England Biolabs) and ligated 
using T4 DNA Ligase (New England Biolabs) as specified by the manufacturer.  
Transfections of C2C12 cells and the dual luciferase assay to measure relative expression 
levels of the reporter constructs were done as previously described (Chapter 1). 
 
Mouse 3’ UTR constructs 
 In our experiments, we analyzed the effects of a human DMD 3’ UTR in the 
mouse C2C12 cell line.  To determine if constructs containing the mouse DMD 3’ UTR 
would give rise to different patterns of expression than the human DMD 3’ UTR in 
C2C12 cells, we designed a Renilla reporter construct containing the mouse DMD 3’ 
UTR downstream of the Renilla coding sequence in pHRL-CMV (3’ UTR).  This 
reporter construct (Mouse 3’ UTR) along with the control Renilla construct (pHRL) and 
the original DMD 3’ UTR construct (Human 3’UTR) was transfected into C2C12 cells, 
and protein expression levels were measured in myoblasts and myotubes using a dual 
luciferase assay (Figure C.3).  Expression of the human DMD 3’ UTR construct had a 
similar expression pattern as before (Chapter 1).  We did not see a significant difference 
in expression levels with the pHRL construct containing the human or mouse DMD 3’ 
UTR in C2C12 myoblasts or myotubes (Figure C.3), which is consistent with the high 
degree of conservation between the two 3’ UTRs. 
 
Methods 
The full length mouse DMD 3’ UTR was amplified from DNA extracted from 
C2C12 myoblasts using PCR and the following specific primers 














Figure C.3.  Expression of the pHRL vector containing either the human or mouse DMD 
3’ UTR in C2C12 cells. 
 
A.  Relative protein expression of the control Renilla vector (pHRL), a construct 
containing the human DMD 3’ UTR (Human 3’UTR), and a construct containing the 
mouse DMD 3’ UTR (Mouse 3’UTR) in transfected C2C12 myoblasts are shown.   
B.  Relative protein expression of the control pHRL construct, the human 3’ UTR 
construct and the mouse 3’ UTR construct in transfected C2C12 myotubes are shown.  
The result of three biological replicates is shown with expression levels normalized to 
pHRL-CMV expression (pHRL) in myoblasts or myotubes using a Renilla/Firefly dual 
luciferase assay.  Error bars equal +/- 1 standard deviation. 
 
GTCTCATGCCTAGGGGATCCGGCTAAGGCAGGATGGAACACT that include an 
 
overhang containing the XbaI and BamH1 restriction sites, respectively.  The resulting 
PCR product was digested with XbaI and AvrII and ligated into the XbaI and BamHI 
restriction sites of pHRL-CMV (Promega) immediately downstream of the Renilla 
Luciferase ORF. The resulting plasmid contains the mouse DMD 3’ UTR in place of the 
SV40 polyA region of the pHRL-CMV vector.  Transfections of C2C12 cells and the 
dual luciferase assay to measure relative expression levels of the reporter constructs were 
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done as previously described (Chapter 1). 
 
Optimization of C2C12 transfections 
 For our transfections in C2C12 cells, we optimized our transfection conditions by 
serially transfecting cells using differing amounts of transfected DNA, Lipofectamine 
2000 (Life Technologies), and cell concentrations.  We determined the optimal 
transfection contained 1x104 C2C12 myoblasts with 25 ng of total transfected DNA 
0.3uL of Lipofectamine 2000 reagent in a 96 well half area plate (Corning) with 0.16 cm2 
growth area.  We saw no decrease in transfection efficiency when these amounts were 
scaled up for larger transfections.  After incubating overnight at 37°C, the media was 
removed and replaced with growth medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone).  Two days after transfection, the cells were harvested or placed in a low serum 
media (DMEM/F-12 (Life Technologies) supplemented with 2% horse serum (Sigma)) 
for 6 days to differentiate the cells before harvesting.   
Cell death and variation decreased when the cells were spun down and 
resuspended in growth media after trypsinization and before transfection.  We found a 
significant decrease in measured Firefly levels between wells that had a small amount of 
DMEM left in during lysis versus wells that were free of DMEM media which affected 
Renilla/Firefly ratios.  Care should be taken to ensure that the DMEM media is 
completely removed from the cells prior to lysis and analysis. We found that freezing the 
cells for 30 minutes at -70°C and thawing helped in lysing myotubes, but did not see any 
benefit in multiple freeze thaw cycles.  While measuring Renilla and Firefly luciferase 
levels, we found that light emitted from a well can bleed over into adjacent wells and 
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increase the measured luciferase levels in adjacent wells.  For all transfections measuring 
protein levels in this dissertation, cells were transfected in every other well so that each 
well was surrounded by empty wells. 
C2C12 cells comprise a heterogeneous group of cells, and not all cells 
differentiate into myotubes.  We observed variability in different batches of C2C12 cells 
on how well they differentiated even from aliquots taken from the same stock.  We also 
found that transfection conditions, such as amount of DNA and cell concentration, had an 
effect on how well the cells differentiated.  Care should be taken when optimizing 
transfection conditions to not only optimize for increased expression of transfected 
constructs, but to also optimize differentiation, and every transfection should be 
monitored to ensure they are differentiating.  In our attempt to increase expression of our 
transfected constructs in C2C12 myotubes, we transfected cells using the optimized 
conditions described in a previous publication comparing transfection methods in C2C12 
cells (Dodds et al., 1998).  Expression of our transfected constructs increased by ~10 fold 
using this described method, but our cells failed to differentiate even after 7 days in 
differentiation media.  Low cell concentrations and high DNA amounts inhibited 
differentiation of C2C12 cells. 
Despite the variability in C2C12 cells, we observed the same pattern of 
expression of our DMD 3’ UTR deletion constructs under many different conditions.  The 
transfections results presented in this dissertation are from the same batch of C2C12 cells 
transfected at the same time to ensure that we were accurately measuring changes in 
expression.  However, the transfections were repeated several times in consecutive 
transfections of different batches of cells, in serial transfections of the same batch of 
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cells, under varying transfection conditions, and we obtained the same results except in 
cases where the cells visually did not form myotubes.  All results presented in this 
dissertation were from C2C12 cells between passages 3 and 9.  However, we transfected 
our deletion constructs in cells at passage 20 and obtained the same results.  We also 
found that the increase in expression due to the DMD 3’ UTR was dependent on the 
differentiation state of the C2C12 cells.  3’ UTR reporter constructs still had an increase 
in expression in cells that were partially differentiated, but not to the degree seen when 
the cells were fully differentiated.  In our hands, the cells were fully differentiated at Day 
5 or 6 in differentiation media.    
The experiments described in Appendix A were performed before we had 
optimized the conditions to maximize the differentiation of C2C12 cells.  The protein 
expression of the cells described in Appendix A was at the levels of the C2C12 cells 
differentiated for 3 days described in Chapter 1, suggesting that the cells in Appendix A 
were not fully differentiated.  However, the expression pattern was the same with an 
increase in expression during differentiation when the DMD 3’ UTR was present and a 
large decrease when the Lemaire A and D regions were deleted, but the increased 
expression is greater when the cells are more differentiated.  We conclude that the effect 
on stability shown in Appendix A is the effect in C2C12 cells differentiated for 3 days, 
but that we would have seen a larger effect on stability if these cells were more 
differentiated.  All experiments in this dissertation besides the experiments described in 
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CXMD DOG SEQUENCES AND PRIMERS 
 
 
 The entire sequence of the LINE-1 insertion in intron 19 of the dystrophic 
Labrador retriever was determined using long range PCR (Figure D.1).  The resulting 
pseudoexon insertion in the DMD mRNA along with the primers used to amplify the 
sequence is shown (Figure D.1).  PCR primers were designed to amplify exons 3 through 

























Figure D.1.  DNA sequence of the LINE-1 insertion found in a dystrophic Labrador 
retriever.   
 
The numbered uppercase sequence indicates the 6,363 nucleotide insertion found in 
intron 19.  The lowercase sequence before and after the insertion indicate the surrounding 
intron 19 sequence at the insertion point.  The underlined sequence indicates the resulting 
pseudoexon that is inserted into the DMD mRNA which includes 19 nucleotides of intron 
19 and 165 nucleotides of the LINE-1 insertion.  The boxed sequence shows the target 
site duplication at the beginning and end of the LINE-1 insertion.  The forward and 
reverse primers used to amplify the insertion are shown in bold at the beginning and end 






























    1 AGATGTGGAG CAAGATGGCG GAAGAGTAGG GTCCCCAAAT CACCTGTCTC 
   51 CACCAAACTA CCTAGAAAAC CTTCAAATTA TCCTGAAAAT CTATGAATTC 
  101 GGCCTGAGAT TTAAAGAGAG ACCAGCTGGA ATGCAACAGT GAGAAGAGTT 
  151 CGCGCTTCTA TCAAGGTAGG AAGACGGGGA AAAAGAAGTA AAGGAACAAA 
  201 GGCCTCCAAG GGGGAGGGGC CCCGCGAGGA CCCGGGCTGA GGCCGGGGCG 
  251 AGTGTCCCCA GGACAGGAGA GCCCCGTCCC GGAGGAGCAG GAGCTGCACC 
  301 GACCTTCCCG GGGGAAAGGG GCTCGCAGGG AGTTGGAGCA GGACCCAGGA 
  351 GGGCGGGGAT GCCCTCGGGC TCCCTGGGAC AGTAACAGAG CAACTGCGCG 
  401 CCCAGGAGAG TGCGCCGAGC TCCCTAAGGG CTGCAGCAGG CACGGCGGGA 
  451 CCCGGCGGGA CCGGAGCAGC CAGGAGGGGC TCGGGCGGCG GCTCCGCGGA 
  501 GGGGGCTGCG CGGCCCCGGG AGCAGCTCGG AGGGGCTCGG GCAGAGGAAG 
  551 AGGCTCCGTG CGGAGGGGGC TGCGCGGTTC CAGGAGCAGC TCGCAGGGGC 
  601 TCGGGCGGCG GCTCCGCGGA GGGGGCTGCG CGGCCCGGGA GCGCGAATCC 
  651 ACCAGCGCAG GCTCCGGAGC ACAGGGCGCC GGGACACAGC CCAGGATCCC 
  701 GCCTCCCCCG GGACAGGCAG AGGCCGGGAG GGCCCAGGAC AGCGAGGACG 
  751 CTCCTGCCCC AGCTGAGCAG AGCAGCGGCC CCGCCCCGGA GCCTCCAGGC 
  801 CCTGCAGACG GAGTTCCTGC CGGAGCTGAA TCCAGGTTTC CAGAGCTGCC 
  851 CCGCCACTGG GGCTGTTCCT CCTGCGGCCT CACGGGGTAA ACAACCCCCA 
  901 CTGAGCCCTG CACCAGGCAG GGGCACAGCA GCTCCCCCAA CTGCTAACAC 
  951 CTGAAAATCA GCACAACAGG CCCCTCCCCC AGAAGATCAG CTAGACTGAC 
 1001 AACTTCCAGG AGAAGCCAAG GGACTTAAAG AACACAGAAT CAGAAGATAC 
 1051 TCCCCTGTGG TTCTTTTTTT TGTTTTGTTT TGTTTTTTTT TGTTTTTGTT 
 1101 TTTGTTTTGT TTTGCTTTTT GATTTGTTTC CTTCCCCCAC CCCCTTTTTT 
 1151 TCTCCTTTCT TTTTCTCTTT TTCTTCCTTT TTTTTTTTCT CTCGTTTTTC 
 1201 TTTTCTTTTC TTCCCTTTTT TTTCTCTTTC TCTTTTCTTT CCTTCTTTCT 
 1251 CTCCTCTCTT TTTCTCTTTT TCCCAATACA ATTTGCTTTT GGCCACTCTG 
 1301 CACTGAGCAA AATGACTAGA AGGAAAACCT CACCTCAAAA GAAAGAATCA 
 1351 GAAACAGTCC TCTCTCCCAC AGAGTTACAA AATCTGGATT ACAATTCAAT 
 1401 GTCAGAAAGC CAATTCAGAA GCACTATTAT ACAGCTACTG GTGGCTCTAG 
 1451 AAAAAAGTAT AAAGGACTCA AGAGACTTCA TGACTGCAGA ATTTAGAGCT 
 1501 AATCAGGCAG AAATTAAAAA TCAATTGAAT GAGATGCAAT CCAAACTAGA 
 1551 AGTCCTAACG ACGAGGGTTA ACGAGGTGGA AGAACGAGTG AGTGACCTAG 
 1601 AAGACAAGTT GATAGCAAAG AGGGAAACTG AGGAAAAAAG AGACAAACAA 
 1651 TTAAAAGACC ATGAAGATAG ATTAAGGGAA ATAAACGACA GCCTGAGGAA 
 1701 GAAAAACCTA CGTTTAATTG GGGTTCCCGA GGGCGCCGAA AGGGACAGAG 
 1751 GGCCAGAATA TGTATTTGAA CAAATTCTAG CTGAAAACTT TCCCAATCTG 
 1801 GGAAGGGAAA CAGGCATTCA GATCCAGGAA ATAGAGAGAT CCCCCCCTAA 
 1851 AATCAATAAA AACCGTTCAA CACCTCGACA TTTAATTGTG AAGCTTGCAA 
 1901 ATTCCAAAGA TAAGGAGAAG ATCCTTAAAG CAGCAAGAGA CAAGAAATCC 
 1951 CTGACTTTTA TGGGGAGGAG TATTAGGGTA ACAGCAGACC TCTCCACAGA 
 2001 GACCTGGCAG GCCAGAAAGG GCTGGCAGGA TATATTCAGG GTCCTAAATG 
 2051 AGAAGAACAT GCAACCAAGA ATACTTTATC CAGCAAGGCT CTCATTCAAA 
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 2101 ATGGAAGGAG AGATAAAGAG CTTCCAAGAC AGGCAGCAAC TAAAAGAATA 
 2151 TGTGACCTCC AAACCAGCTC TGCAAGAAAT TTTAAGGGGG CCTCTTAAAA 
 2201 TTCCCCTTTA AGAAGAAGTT CAGTGGAACA GTCCACAAAA ACAAAGACTG 
 2251 AATAGATATC ATGATGACAC TAAACTCATA TCTCTCAATA GTAACTCTGA 
 2301 ATGTGAACGG GCTTAATGAC CCCATCAAAA GGCGCAGGGT GTCTGACTGG 
 2351 ATAAAAAAGC AGGACCCATC TATTTGCTGT CTACAAGAGA CTCATTTTAG 
 2401 ACAGAAGGAC ACCTACAGCC TGAAAATAAA AGGTTGGAGA ACCATTTACC 
 2451 ATTCGAATGG TCCTCAAAAG AAAGCAGGGG TAGCCATCCT TATATCAGAT 
 2501 AAACTAAAAT TTACCCCAAA GACTGTAGTG AGAGATGAAG AGGGACACTA 
 2551 TATCATACTT AAAGGATCTA TTCAACAAGA GGACTTAACA ATCCTCAATA 
 2601 TATATGCTCC GAATGTGGGA GCTGCCAAAT ATATAAATCA ATTATTAACC 
 2651 AAAGTGAAGA AATACTTAGA TAATAATACA CTTATACTTG GTGACTTCAA 
 2701 TCTAGCTCTT TCTATACTCG ACAGGTCTTC TAAGCAAAAC ATCTCCAAAG 
 2751 AAACGAGAGC TTTAAATGAT ACACTGGACC AGATGGATTT CACAGATATC 
 2801 TACAGAACTT TACATCCAAA CTCAACCGAA TACACATTCT TCTCAAGCGC 
 2851 ACATGGAACT TTCTCCAGAA TAGACCACAT ATTGGGTCAC AAATCGGGTC 
 2901 TGAACCGATA CCAAAAGATT GGGATTGTCC CCTGCATATT CTCGGACCAT 
 2951 AATGCCTTGA AATTAGAACT AAATCACAAC AAGAAGTTTG GAAGGACCTC 
 3001 AAACACATGG AGGTTAAGGA CCATCCTGCT AAAAGATAAA AGGGTCAACC 
 3051 AGGAAATTAA GGAAGAATTA AAAAGATTCA TGGAAACTAA TGAGAATGAA 
 3101 GATACAACCG TTCAAAATCT TTGGGATGCA GCAAAAGCAG TCCTAAGGGG 
 3151 GAAATACATC GCAATACAAG CATCCATTCA AAAACTGGAA AGAACTCAAA 
 3201 TACAAAAGCT AACCTTACAC ATAAAGGAGC TAGAGAAAAA ACAGCAAATA 
 3251 GATCCTACAC CCAAGAGAAG AAGGGAGTTA ATAAAGATTC GAGCAGAACT 
 3301 CAATGAAATC GAGACCAGAA GAACTGTGGA ACAGATCAAC AGAACCAGGA 
 3351 GTTGGTTCTT TGAAAGAATT AATAAGATAG ATAAACCATT AGCCAGCCTT 
 3401 ATTAAAAAGA AGAGAGAGAA GACTCAAATT AATAAAATCA TGAATGAGAA 
 3451 AGGAGAGATC ACTACCAACA CCAAGGAAAT ACAAACGATT TTAAAAACAT 
 3501 ATTATGAACA GCTATACGCC AATAAATTAG GCAATCTAGA AGAAATGGAC 
 3551 GCATTCCTGG AAAGCCACAA ACTACCAAAA CTGGAACAGG AAGAAATAGA 
 3601 AAACCTGAAC AGGCCAATAA CCAGGGAGGA AATTGAAGCA GTCATCAAAA 
 3651 ACCTCCCAAG ACACAAGAGT CCAGGGCCAG ATGGCTTCCC AGGAGAATTT 
 3701 TATCAAACGT TTAAAGAAGA AATCATACCT ATTCTCCTAA AGCTGTTTGG 
 3751 AAAGATAGAA AGAGATGGAG TACTTCCAAA TTCGTTCTAT GAAGCCAGCA 
 3801 TCACCTTAAT TCCAAAGCCA GACAAAGACC CCGCCAAAAA GGAGAATTAC 
 3851 AGACCAATAT CCCTGATGAA CATGGATGCA AAAATTCTCA ACAAGATACT 
 3901 GGCCAATAGG ATCCAACAGT ACATTAAGAA AATTATTCAC CATGACCAAG 
 3951 TAGGATTTAT CCCTGGGACA CAAGGCTGGT TCAACACCCG TAAAACAATC 
 4001 AATGTGATTC ATCATATCAG CAAGAGAAAA ACCAAGAACC ATATGATCCT 
 4051 CTCATTGGAT GCAGAGAAAG CATTTGACAA AATACAGCAT CCATTCCTGA 
 4101 TCAAAACTCT TCAGAGTGTA GGGATAGAGG GAACATTCCT CGACATCTTA 
 4151 AAAGCCATCT ACGAAAAGCC CACAGCAAAT ATCATTCTCA ATGGGGAAGC 
 4201 ACTGGGAGCC TTTCCCCTAA GATCAGGAAC AAGACAGGGA TGTCCACTCT 
 4251 CACCACTGCT ATTCAACATA GTACTGGAAG TCCTAGCCTC AGCAATCAGA 
 4301 CAACAAAAAG ACATTAAAGG CATTCAAATT GGCAAAGAAG AAGTCAAACT 
 4351 CTCCCTCTTC GCCGATGACA TGATACTCTA CATAGAAAAC CCAAAAGTCT 
 4401 CCACCCCAAG ATTGCTAGAA CTCATACAGC AATTCGGTAG CGTGGCAGGA 
 4451 TACAAAATCA ATGCCCAGAA GTCAGTGGCA TTTCTATACA CTAACAATGA 
 4501 GACTGAAGAA AGAGAAATTA AGGAGTCAAT CCCATTTACA ATTGCACCCA 
 4551 AAAGCATAAG ATACCTAGGA ATAAACCTCA CCAAAGATGT AAAGGATCTA 
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 4601 TACCCTCAAA ACTATAGAAC ACTTCTGAAA GAAATTGAGG AAGACACAAA 
 4651 GAGATGGAAA AATATTCCAT GCTCATGGAT TGGCAGAATT AATATTGTGA 
 4701 AAATGTCAAT GTTACCCAGG GCAATATACA CGTTTAATGC AATCCCTATC 
 4751 AAAATACCAT GGACTTTCTT CAGAGAGTTA GAACAAATTA TTTTAAGATT 
 4801 TGTGTGGAAT CAGAAAAGAC CCCGAATAGC CAGGGGAATT TTAAAAAAGA 
 4851 AAACCATATC TGGGGGCATC ACAATGCCAG ATTTCAGGTT GTACTACAAA 
 4901 GCTGTGGTCA TCAAGACAGT GTGGTACTGG CACAAAAACA GACACATAGA 
 4951 TCAGTGGAAC AGAATAGAGA ATCCAGAAGT GGACCCTGAA CTTTATGGGC 
 5001 AACTAATATT CGATAAAGGA GGAAAGACTA TCCATTGGAA GAAAGACAGT 
 5051 CTCTTCAATA AATGGTGCTG GGAAAATTGG ACATCCACAT GCAGAAGAAT 
 5101 GAAACTAGAC CACTCTCTTT CACCATACAC AAAGATAAAC TCAAAATGGA 
 5151 TGAAAGATCT AAATGTGAGA CAAGATTCCA TCAAAATCCT AGAGAAGAAC 
 5201 ACAGGCAACA CCCTTTTTGA ACTCGGCCAT AGTAACTTCT TGCAAGATAC 
 5251 ATCCACAAAG GCAAAAGAAA CAAAAGCAAA AATGAACTAT TGGGACTTCA 
 5301 TCAAGATAAG AAGCTTTTGC ACAGCAAAGG ATACAGTCAA CAAAACTCAA 
 5351 AGACAACCTA CAGAATGGGA GAAGATATTT GCAAATGACA TATCAGATAA 
 5401 AGGGCTAGTT TCCAAGATCT ATAAAGAACT TATTAAACTC AACACCAAAG 
 5451 AAACAAACAA TCCAATCATG AAATGGGCAA AAGACATGAA CAGAAATCTC 
 5501 ACAGAGGAAG ACATAGACAT GGCCAACATG CATATGAGAA AATGCTCTGC 
 5551 ATCACTTGCC ATCAGGGAAA TACAAATGAA AACTACAATG AGATACCACC 
 5601 TCACACCAGT GAGAATGGGG AAAATTAACA AGGCAGGAAA CAACAAATGT 
 5651 TGGAGAGGAT GCGGAGAAAA GGGAACCCTC TTACACTGTT GGTGGGAATG 
 5701 TGAACTGGTG CAGCCACTCT GGAAAACTGT GTGGAGGTTC CTCAAACAGT 
 5751 TAAAAATATA CCTGCCCTAC GACCCAGCAA TTGCACTGTT GGGGATTTAC 
 5801 CCCAAAGATA CAAATGCAAT GAAACGCCGG GACACCTGCA CCCCGATGTT 
 5851 TCTAGCAGCA ATGGCCACGA TAGCCAAACT GTGGAAGGAG CCTCGGTGTC 
 5901 CAACGAAAGA TGAATGGATA AAGAAGATGT GGTTTATGTA TACAATGGAA 
 5951 TATTACTCAG CTATTAGAAA TGACAAATAC CCACCATTTG CTTCAACGTG 
 6001 GATGGAACTG GAGGGTATTA TGCTGAGTGA AGTAAGTCAG TCAGAGAAGG 
 6051 ACAAACATTA TATGTTCTCA TTCATTTGGG GAATATAAAT AATAGTGAAA 
 6101 GGGAAAATAA GGGAAGGGAG AAGAAATGTG TGGGAAATAT CAGAAAGGGA 
 6151 GACAGAACAT AAAGACTGCT AACTCTGGGA AACGAACTAG GGGTGGTAGA 
 6201 AGGGGAGGAG GGCGGGGGGT GGGAGTGAAT GGGTGACGGG CACTGGGGGT 
 6251 TATTCTGTAT GTTAGTAAAT TGAACACCAA TAAAAAAATA AATTAAAAAA 
 6301 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 






















































*Alternate nonoverlapping primer sets were designed for exons 8 and 29 to verify the 
deletion boundary in the Tibetan terrier containing a deletion of exons 8 through 29 of the 
DMD gene. 
